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"...the key to every biological problem must finally be sought in the cell, for 
every living organism is, or at sometime has been, a cell.” 
 
 
Edmund B. Wilson 
The Cell in Development and Heredity 
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ABSTRACT 
Cell-extracellular matrix (ECM) detachment triggers a cell survival mechanism known as 
autophagy. A link between attachment and autophagy suggests a form of adhesion-based 
regulation, involving mechanotransduction of extracellular-originating signals to the cellular 
machinery controlling autophagy induction. This implies a role for integrin-linked kinase 
(ILK), which transmits mechanical stimuli to the mammalian target of rapamycin (mTOR) 
signalling pathway. Cells with a propensity for metastasis may negate these adhesive signals, 
inducing autophagy inappropriately. Metastasis is a hallmark of transformation frequently 
associated with human oesophageal squamous cell carcinoma (HOSCC). Additionally, 
hyperactive mTOR/mTORC1 signalling correlates increasingly with HOSCC. Therefore, the 
protein expression of significant signal transduction pathway intermediates was investigated 
in response to both soluble and ECM-originating stimuli. Measurements by SDS-PAGE and 
western-blotting coupled to semi-quantitative densitometry, during standard tissue culture 
conditions, revealed that HOSCC’s expressed moderate-to-high levels of mTOR, p-RPS6(Ser 
235/236)
 and mATG-13; indicating elevated levels of autophagy induction despite aberrant 
signalling through mTOR/mTORC1. Additionally, an 80 kDa mTORβ isoform was identified 
in HOSCC cells with lower mTOR abundance, presumably to maintain aberrant mTORC1 
signalling. A canonical role for the PI3K/PKB pathway was also identified; where autophagy 
induction accompanied diminished mTORC1 signalling in response to specific PI3K 
inhibition with LY294002 and serum withdrawal. However, autophagy induction varied in 
response to a dose-dependent decrease in mTORC1 signalling after exposure of HOSCC cells 
to rapamycin. Moreover, specific inhibition of p90RSK with BI-D1870, suggests that 
mTORC1 phosphorylates RPS6(Ser 235/236) in the absence of MAPK signals. Furthermore, 
ectopic ILK expression indicated an enhanced potential for adhesion-based signalling. 
Correspondingly, HOSCC cells commonly increased mTOR and p-RPS6(Ser 235/236) expression 
following growth on fibronectin or collagen. However, co-immunoprecipitation analysis 
revealed that signals transduction to mTOR precludes a direct interaction with ILK or FAK. 
Rather, ECM-modulation of mTOR occurs in a integrin-triggered, but PI3K-depedant 
manner; since specific inhibition of PI3K negated fibronectin-induced increases of mTOR 
concentration and RPS6(Ser 235/236) phosphorylation. Thus, these data strongly suggest mTOR 
is a target for adhesion-based signal transduction, where the ECM influences cell survival 
through mTORC1. Moreover, exploitation of autophagy induction post cell-ECM detachment 
in HOSCC may promote the survival of metastases during dissemination.   
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CHAPTER 1 
 
1. GENERAL INTRODUCTION AND LITERATURE REVIEW 
 
1.1. Regulation of intracellular communication at the cell-ECM interface 
 
During development, highly coordinated signalling events guide the formation of coherent 
epithelial sheets into a functional, adult epithelium (Gumbiner, 1996). When the adult 
epithelium is formed properly, developmental signals are ‘switched off’ and morphogenetic 
information is no longer supplied (Gumbiner, 1996). The adult epithelium now conforms to a 
biologically-relevant structure that experiences different types of extracellular signalling 
events within all cell layers (Mammoto and Ingber, 2010). These new signals directly 
contribute towards the maintenance of tissue integrity, and therefore homeostasis.  
 
Currently, extracellular-originating signals may influence tissue homeostasis through two 
known mechanisms (Asthagiri and Lauffenbburger, 2000; Mammoto and Ingber, 2010). The 
first mode is biochemical in origin; where signals are elicited in response to specialised cell 
membrane receptors that associate with soluble, cognate ligands; such as amino-acids, 
hormones and growth factors (Brunton et al., 2004; Groves and Kuriyan, 2010). The second 
mode is mechanically-derived and rather involves signals elicited in response to a cell 
encountering a solid, matrix-like environment (Gao et al., 2006; Mammoto and Ingber, 
2010). Although these stimuli originate from different sources, the appropriate regulation of 
both types of signals is essential for the maintenance of healthy epithelial tissue. 
 
A popular approach to addressing the basis to tumour development is to view it as a change 
in the molecular mechanisms regulating cell proliferation and survival signalling (Gray et al., 
2010; Hanahan and Weinberg, 2011). These mechanisms are seen to involve a corruption in 
sensing and transmitting the above stimuli. Since these signals are both numerous and varied, 
of particular interest to us is the influence of the immediate cellular environment on these 
signals, i.e. signals elicited from mechanical sources in response to cell-extracellular matrix 
(ECM) attachment. Adhesion-based signalling in this manner has been found to support 
inappropriate proliferative events; for example the aberrant activation of cell adhesion 
molecules (such as those forming part of the integrin adhesion system) are reported to delay 
2 
 
apoptotic cell death in squamous cell carcinoma (SCC) of the human oesophagus, allowing 
tumours to evade tissue-dependant survival restraints (Fanucchi and Veale, 2011). However, 
what remains to be understood in this regard is the influence of adhesion-based stimuli on a 
cellular process closely related to proliferation; such as the evolutionary conserved cell 
survival pathway known as autophagy (Meijer and Codogno, 2004). 
 
In response to extensive biochemical and mechanical stimuli, epithelial cells may often 
utilize autophagy as a rehabilitation strategy (Cecconi and Levine, 2008; Eisenberg-Lerner et 
al., 2009; Erol, 2011). Under conditions where autophagy is initiated, stressed cells are 
extended an opportunity for restoration before pro-death signals fully activate programmed 
cell death cascades, such as anoikis (Edinger and Thompson, 2004; Cecconi and Levine, 
2008; Fung et al., 2008; Lock and Debnath, 2008). In light of the above, we have identified 
major players that may contribute to epithelial transformation by dissecting the most likely 
route triggered by adhesion-based stimuli to the autophagy induction machinery. These 
include essential components of the integrin cell-extracellular matrix (ECM) adhesion 
system; namely integrin-linked kinase (ILK) - which is a major conduit for the transduction 
of adhesion-based signals (Clarke and Brugge, 1995); as well as the mammalian target of 
rapamycin (mTOR) signalling pathway - which is the main signal transduction pathway 
controlling extracellular-originating signals triggering autophagy induction (Schmelzle and 
Hall, 2000; Foster and Fingar, 2010). Therefore, in order to equip the reader with the relevant 
background and the current understanding of these cellular events, we begin with a brief 
discussion of the major players. 
 
1.2. Integrin-mediated Cell-ECM Adhesion 
 
Biochemical signal transduction is controlled by receptor tyrosine kinases (RTK’s), which 
activate an array of intracellular protein kinase-mediated cascades. This type of signal 
transduction brings about a change in cell behaviour by influencing transcriptional events in 
the nucleus (Brunton et al., 2004; Groves and Kuriyan, 2010). In contrast, mechanical signals 
are controlled by specialised biochemical entities forming part of the cell adhesion system 
(Gao et al., 2006; Mammoto and Ingber, 2010). These are notably the integrins; 
transmembrane glycoproteins that adhere to an array of extracellular matrix (ECM) support 
structures and regulate cell-ECM interactions (Harburger and Calderwood, 2009). Integrins 
directly couple mechanical stimuli to biochemical signals through interactions with integrin-
triggered protein kinases, thus influencing cell behaviour (Aplin et al., 1998; Shwartz, 2001).  
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Clearly, both RTK’s and integrin-mediated adhesion play an important role during the 
maintenance of homeostasis in epithelial tissue. However, while much is known concerning 
RTK-dependant biochemical signalling, comparatively less is known concerning the 
transduction of mechanical stimuli through integrins and the downstream effects on important 
cellular processes; such as proliferation or cell survival signalling. Moreover, understanding 
the impact of adhesion-based signalling schemes becomes complicated, as cells commonly 
integrate biochemical and mechanical signals to emphasise a particular behavioural response 
(Aplin et al., 1998).  
 
The integrin adhesion system is responsible for facilitating physical connections between a 
cell and ECM, as well as mediating the intracellular propagation of ECM-originating signals 
(Clark and Brugge, 1995). Structurally, integrins are heterodimeric, transmembrane 
glycoproteins composed of α and β subunits (Hynes, 1992; Rosales et al., 1992); where each 
subunit possesses a protruding extracellular domain, a membrane spanning domain and a 
short cytoplasmic domain (Hynes, 1992; Rosales et al., 1992). Integrins are capable of 
binding a variety of ECM proteins; for example fibronectin, collagen, laminin and vitronectin 
(Aplin et al., 1998). This is a consequence of their immense ligand-binding ability, resulting 
from the numerous permutations possible between α and β integrin pairs (Aplin et al., 1998).  
 
The short cytoplasmic domains of α and β integrins do not possess any innate enzymatic 
activity (Harburger and Calderwood, 2009). Rather, they associate with a vast array of 
intracellular proteins that include both cytoskeletal and structurally-related components, and 
catalytic signalling proteins (Clark and Brugge, 1995). Structural proteins, such as α-catenin, 
talin, vinculin and tensin, commonly congregate to these sites, thereby linking integrin 
systems to the cytoskeleton. Additionally, co-localisation of specific protein kinases occurs; 
such as integrin-linked kinase (ILK), focal adhesion kinase (FAK) and phosphoinositol-3-
kinase (PI3K) (Harburger and Calderwood, 2009), which are involved in signal transmission 
and will be discussed in more detail later in this chapter. Therefore, cytoplasmic regions of 
integrins are sites of multi-protein assemblies where structurally-related proteins play 
important roles in the stabilisation of cell adhesion, regulation of cell shape, morphology and 
mobility (Shwartz, 2001). The current model for integrin activation and focal adhesion 
formation was proposed by Legate et al. (2006). Figure 1.1 on the next page visually 
demonstrates these important integrin structure-function relationships. 
4 
 
 
Figure 1.1: Model of integrin activation and focal adhesion formation. This schematic 
representation by Legate et al. (2006) demonstrates the molecular 
mechanisms pertaining to focal adhesion biogenesis upon contact with an 
ECM-like substrate. (a) When inactive, naturally occurring integrins within the 
cell membrane may be found in a ‘bent’ conformation. However, when 
structurally-related proteins, such as talin, are recruited to the plasma 
membrane, binding to cytoplasmic integrin tails occurs whereupon integrins 
adopt a ‘primed’ conformation (b). Integrin extracellular domains extend and 
become unmasked, exposing sites with ligand-binding potential (c). Depending 
on the integrin pair, these sites subsequently bind ECM components, inducing 
talin to act as a molecular platform for other focal-adhesion proteins; such as 
ILK, FAK, paxillin and PINCH. In this way, a fully mature focal adhesion develops 
and ultimately involves the clustering of numerous, ligand-interacting integrin 
α and β subunit pairs, which both tethers the actin cytoskeleton to the ECM 
and facilitates communication with related intracellular signalling pathways.  
 
1.3. Sensing mechanical signals is necessary for the perception of the physical 
environment 
 
Now that the role of integrin-mediated adhesion and signalling has been clarified, the purpose 
of mechanically-derived stimuli may be explored in context of the functional, adult 
epithelium. Under ‘normal’ physiological conditions, epithelial tissue functions as a 
biological interface protecting the internal milieus from environmental stresses (Junqueira 
and Carneiro, 2007; Young et al., 2007). As a result, the cell layers comprising the epithelium 
of the gut and skin, for example, are constantly exposed to various types of physical and 
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chemical stimuli that may cause damage to the epithelium. Considering that physical and 
chemical damage elicit specific forms of mechanical signalling (Erol, 2011), the integrin 
adhesion system is primarily involved in sensing these stimuli (Jaalouk and Lammerding, 
2009; Shwartz, 2010; Erol, 2011). Therefore, integrin-mediated cell adhesion allows for the 
intracellular propagation of these mechanical signals, which then bring about the appropriate 
biological response; such as the initiation of pro-death signals to destroy irreparably damaged 
cells, the initiation of pro-survival pathways to rehabilitate cells with reparable damage, or 
increase cell growth or proliferation to replace dying cells (Erol, 2011). However, a specific 
scheme of adhesion-based signal transduction must occur in order to trigger the correct 
cellular response. 
 
1.3.1. Intracellular signal transduction of extracellular-originating stimuli 
 
A relatively novel and exciting aspect of cell adhesion-related research is the concept of 
adhesion-based signalling, where conventional cell surface receptors function to intercept and 
relay extracellular-originating stimuli. Thus, external stimuli that are mechanical in nature 
may be sensed by the integrin adhesion system, and subsequently transmitted intracellularly 
by means of conformational changes to these receptors. These changes initiate a series of 
integrated signal transduction cascades that result in a change in gene expression, allowing 
for a regulated behavioural response (Aplin et al., 1998; Shwartz, 2001). 
 
In the past decade, an increasing amount of research has focussed on this aspect of integrin-
mediated mechanotransduction. Integrins were shown to transmit biochemical signals into the 
cell (termed outside-in signalling), thus providing spatial information concerning the external 
environment, location and relative adhesive state (Harburger and Calderwood, 2009). In 
addition, it was discovered that integrins possess the ability to self-regulate affinity for 
extracellular ligands. This occurs by means of conformational changes in their extracellular 
domains in response to signals that impinge on the cytoplasmic tail (termed inside-out 
signalling) (Harburger and Calderwood, 2009). However, both outside-in and inside-out 
signalling requires spatially and temporally regulated multi-protein assemblies that form 
around the cytoplasmic tail of integrins (Aplin et al., 1998; Shwartz, 2001). Therefore, these 
coordinated signalling processes function to determine cellular responses; such as migration, 
survival and differentiation, placing inputs received from growth factors and G-protein 
coupled receptors into context (Harburger and Calderwood, 2009).    
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Analysis of the biochemical events triggered by integrin engagement, as well as by the 
characterisation of proteins associated with focal adhesion complexes, has allowed the 
identification of a plethora of signalling events activated by the integrin adhesion system 
(Clark and Brugge, 1995). Protein phosphorylation was one of the earliest events detected in 
response to integrin stimulation; where focal adhesion kinase, or FAK (Figure 1.2, A), was 
identified as a phosphorylation-regulated signalling scaffold important for adhesion turnover, 
Rho-family GTPase activation, cell migration and cross-talk between growth-factor 
signalling and integrin adhesions (Mitra et al., 2005). 
 
Following this pattern of phosphorylation, a similar protein kinase was discovered, however, 
one pivotal in regulating cell adhesion, as well as anchorage-dependant growth (Persad and 
Dedhar, 2003). This key node vital to integrin signalling was termed integrin-linked kinase, 
or ILK. ILK is a 59 kDa, ubiquitously expressed serine/threonine protein kinase implicated in 
numerous signalling pathways; such as integrin-, growth factor- and Wnt signalling (Li et al., 
1999). Through a yeast two-hybrid screen, ILK was found to associate with the cytoplasmic 
domain of the integrin β1 subunit (Hannigan et al., 1996). From this position, ILK primarily 
functions as a signalling scaffold at sites of integrin adhesion (Harburger and Calderwood, 
2009), and ILK may therefore mediate a variety of downstream signal transduction cascades.  
 
Structurally, ILK possesses three distinct regions, as seen in Figure 1.2, B. Four ankyrin 
(ANK) repeats lie at the N-terminal, a plekstrin homology (PH)-like motif and C-terminal 
that exhibits significant homology to other protein kinase catalytic domains (Wu and Dedhar, 
2001). The ANK repeat domain of ILK allows for a variety of protein-protein interactions, 
where over nine binding partners have been established (Persad and Dedhar, 2003). This 
region also mediates interactions with Nck-2, a Src homology SH2 and SH3 domain-
containing adapter protein. Nck-2 binds to a LIM domain-only adapter protein called PINCH 
(a cystein-rich motif first identified in C. elegans, Lin-11, ISL-1 and mec-3), bridging the 
interaction between ILK and receptor tyrosine kinases (RTK’s) (Wu and Dedhar, 2001; 
Persad and Dedhar, 2003). 
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Figure 1.2: Comparative domain organization of focal adhesion kinase (FAK) and integrin-
linked kinase (ILK). This schematic representation, adapted from Wu (2005) 
and Cox et al. (2006), demonstrates the relative position of functional domains 
in the commonly activated integrin-triggered protein kinases. FAK comprises a 
FERM and kinase domains towards the N-terminal as well as a FAT (or focal 
adhesion targeting) domain towards the C-terminus. ILK comprises an N-
terminal ankyrin repeat domain, a PH-like motif and a C-terminal kinase 
domain. Both FAK and ILK are recruited to focal adhesions for the purposes of 
mechanotransduction, as well as a molecular scaffold for protein-protein 
interactions.   
 
Since the functional plasticity of ILK involves both a molecular scaffold, as well as a protein 
kinase, ILK is capable of coupling signals captured by integrins and RTK’s to downstream 
signalling pathways (Grashoff et al., 2004). As such, ILK has been acknowledged as a 
component of numerous signalling pathways that control cell survival, differentiation, 
proliferation and gene expression in mammalian cells (Wu and Dedhar, 2001; Attwell et al., 
2003). A complete analysis of ILK’s influence would require in depth discussion and vast 
detail. Therefore, to be as succinct as possible, we highlight the major roles of ILK during 
adhesion-based and intracellular signalling events.   
 
1.3.2. ILK functions as a molecular conduit for adhesion-based signal transduction 
 
ILK activity is regulated negatively by two protein phosphatases: namely PTEN and PP2C 
(Leung-Hagesteijn et al., 2001). As a critical regulator of signal transduction, PTEN, a lipid 
phosphatase that dephosphorylates phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3) into 
a  phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2) form (Morimoto et al., 2000; Persad et 
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al., 2001). Interestingly, both PI(3,4,5)P3 binding and ILK auto-phosphorylation are crucial 
for complete ILK activation, since mutations in the PH domain (Arg 211) or in the activation 
loop (Ser 343) render ILK inactive and unable to phosphorylate PKB; an important 
intracellular protein kinase (Persad et al., 2001).  
 
ILK may also associate with Raf, inducing MAPK activity in a FAK- and Ras-independant 
manner (Aplin et al., 1998), depicted in Figure 1.3. In this way, ILK suppresses transcription 
factors required for myogenic differentiation (Huang et al., 2000). Moreover, ILK interacts 
with members of the PI3K/PKB signalling pathway, where ILK phosphorylates PKB(Ser 473) 
consequently influencing cell growth and proliferation events (Wu and Dedhar, 2001).  
Furthermore, ILK may impinge on the Wnt signalling pathway by phosphorylating and 
inhibiting GSK-3β(Ser 9) by a similar mechanism (Persad and Dedhar, 2003). In this way, ILK 
may influence gene transcription (Figure 1.3) by stabilising the β-catenin-Tcf/Lef-1 
transcription complex (Seidensticker and Behrens, 2000; Reya and Clevers, 2005). Also, a 
consequence of constitutive ILK activation or over-expression is the suppression of apoptosis 
and anoikis in mammalian cells (Attwell et al., 2000; Persad et al., 2000). Both of these 
effects involve ILK-mediated PKB activation and suppression of activated caspase-3 (Persad 
et al., 2000). Consequently, ILK is major components of cell adhesion that facilitates 
mechanotransduction of extracellular-originating signals. 
 
It is evident that signalling through integrin-triggered protein kinases, such as ILK, impacts 
cell behaviour. Therefore, one may gain an appreciation for the role mechanotransduction of 
extracellular-originating signals has on essential biological processes; such as anchorage-
dependent growth, proliferation and pro-survival signalling. In light of this, it is conceivable 
that other important pro-survival pathways linked to the state of cell adhesion, such as 
autophagy (Fung et al., 2008; Lock and Debnath, 2008; Chen and Debnath, 2010), may also 
contain an understated mechanotransduction component that has not, as of yet, been fully 
deciphered. Hence, a discussion concerning the mechanical regulation of pro-survival 
signalling and related pathways extends this idea further.   
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Figure 1.3: Mechanotransduction of extracellular-originating stimuli through integrin-
mediated cell adhesion complexes. This model for mechanotransduction by 
Legate et al. (2006) demonstrates how extracellular-originating stimuli, derived 
from cell-ECM interactions, elicit intracellular signal transduction cascades that 
ultimately bring about a change in cell behaviour. Central to 
mechanotransduction is the influence of ILK; a focal adhesion-associated 
protein kinases that acts as a molecular conduit linking RTK and integrin 
receptor systems to downstream pro-survival pathways. The involvement of 
soluble factors eliciting biochemical signals, through RTK’s, is also shown – 
since pathway integration is a common occurrence presumably to enhance a 
particular biological response.  
 
1.4. Mechanical regulation of pro-survival signalling pathways 
 
Autophagy serves as a catabolic strategy to recycle nutrients and provide energy for essential 
cellular processes during stressful environmental conditions (Cecconi and Levine, 2008; 
Eisenberg-Lerner et al., 2009; Erol, 2011). Briefly, pro-survival signals induce the assembly 
of autophagosomes that sequester cytoplasmic constituents (Edinger and Thompson, 2004). 
However, if autophagy is allowed to continue unabated, total cell disassembly may occur (a 
‘so called’ programmed cell death type II) (Edinger and Thompson, 2004). Consequently, if 
anoikis (the subset of apoptosis triggered upon loss of cell-ECM adhesion (Frisch and 
Francis, 1994), as well as autophagy are initiated in response to mechanically-derived stimuli, 
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the integrin adhesion system would be involved in sensing and relaying these signals (as 
discussed previously). Therefore, it follows that a molecular connection may exist between 
adhesion-based signalling events and the signalling machinery responsible for autophagy 
induction. By extension then, it is also conceivable that this relationship is somehow 
exploited in the transformed state to enhance tumour progression, since autophagy essentially 
functions as a cellular survival strategy and may be upregulated in solid tumours (Lock and 
Debnath, 2008). 
 
In support of the above, seminal observations by Fung et al. (2008) and Lock and Debnath 
(2008) report that cell-ECM detachment (which usually triggers anoikis) may also trigger a 
concurrent anti-apoptotic signalling cascade inducing cellular autophagy. The activation of 
autophagy presumably delays the onset of anoikis and allows an opportunity for cell-ECM 
contacts to be re-established, promoting cell longevity and cell survival. Therefore, it is 
conceivable that a link exists between extracellular-originating signals and pro-survival 
signalling machinery which induces autophagy, allowing for cell survival during cell 
migration, necessary for migration and wound healing (Kim et al., 2010). Conversely then, 
this link may be exploited in the tumourigenic sense, where abrogated mechanotransduction 
of extracellular-originating signals promotes the survival of transformed cells, thereby 
enhancing tumour progression, as well as the metastatic phenotype.  
 
An example which may provide evidence for aberrant adhesion-based signalling promoting 
cell survival concerns a scenario where increased integrin signalling was found to promote 
cell survival by delaying anoikis. Enhanced activation of FAK through the β1 integrin 
subunit delays caspase-8 activation and subsequently promotes anoikis resistance (Fannuchi 
and Veale, 2011). From here we see that it is not enough for tumours to simply evade pro-
death signals after cell detachment. Rather, tumours also require the co-activation of pro-
survival pathways allowing for cell longevity during substrate-independent growth. 
Therefore, autophagy fills the criteria of a cellular processes allowing enhanced cell survival, 
triggered in parallel to cell death signals.   
 
Considering the above, there is a reasonable basis to examine of the effect of extracellular-
originating signals on the signalling machinery initiating cellular autophagy. In addition to 
constituting a novel aspect of adhesion-based signalling and autophagy-mediated cell 
survival research, such an examination would provide insight into a poorly understood 
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molecular mechanism enabling survival of detached cells during substrate-independent 
growth. However, it is necessary to stress that the primary focus of this investigation now 
shifts towards the signalling component of integrin-mediated cell-ECM interactions 
achieving this. Consequently, those initial signalling events (i.e. phosphorylation of 
autophagy-related proteins) controlling autophagy initiation – which are indicative of an 
activated pro-survival pathway – and not survival as a function of a completed autophagic 
process (i.e. autophagosome formation) is of specific concern. Therefore, it is prudent to 
elaborate on the mTOR signalling pathway: the foremost signal transduction pathway 
regulating cellular autophagy induction. 
 
1.5. The mTOR signalling pathway is the main regulator of cellular autophagy 
 
The mammalian target of rapamycin, commonly abbreviated mTOR, is a 220 kDa 
serine/threonine protein kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related 
kinase family (Hou et al., 2007). Included in this family are other large proteins; such as 
ATM, ATR and DNA-dependant protein kinases, all of which possess a unique multi-domain 
structure (Abraham, 2004). As seen in Figure 1.4, towards the N-terminal are HEAT, FAT 
and FRB-binding domains, while the kinase, repressor and FATC domains are situated 
towards the C-terminal (Abraham, 2002; Fingar and Blenis, 2004). As a result of its 
appreciable length, mTOR exhibits extensive polypeptide folding (demonstrated in Figure 
1.5), producing a large surface area enabling many opportunities to bind and phosphorylate 
downstream protein targets; such as Raptor, Rictor, p70S6K and 4EBP-1 (Sturgill and Hall, 
2009).  
 
 
Figure 1.4: Schematic demonstrating the position of functional domains within the 220 
kDa mTOR protein kinase. HEAT, FAT and FRB-binding (or rapamycin binding) 
domains are distributed towards the N-terminal half, while the kinase, 
repressor and FATC domains are situated towards the C-terminal half (adapted 
from Fingar and Blenis, 2004). 
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Figure 1.5: Predicted three-dimensional structure of mTOR. The three-dimensional 
structure of mTOR was generated by Sturgill and Hall (2009) using SWISS-
MODEL software after a manual alignment of TOR with PI3KCγ (RCSB, PDB 
1e8x). The model shows an inactive mTORC1 complex with ATP bound at the 
active site. From the model, it is evident that a large surface is available for 
protein interactions to occur, facilitating the inclusion of mTOR into multi-
protein assemblies; such as mTORC1 and mTORC2. 
 
In Saccharomyces cerevisiae and Drosophila melanogaster two different, but homologous, 
versions of the TOR gene are expressed: TOR (in yeast and dTOR in Drosophila). 
Subsequently, the expression of TOR forms two distinct multi-protein assemblies, with each 
complex possessing unique functions (Schmelzle and Hall, 2000; Caron et al., 2010). In 
mammals however, one mTOR gene has been identified, which assemblies into two distinct 
multi-protein complexes; termed mTORC1 and mTORC2 (Fingar and Blenis, 2004). The 
distinction between mTORC1 and mTORC2 arises from the different protein binding 
partners found in each complex. The mTORC1 complex contains Raptor, mLST8, Deptor, 
FKBP38 and PRAS40, whereas the mTORC2 complex contains Rictor, mLST8, mSIN1, 
Deptor and Protor (Abraham, 2002; Zhou and Huang, 2010).  
 
Through the action of these two complexes, mTOR is positioned at the nexus of numerous 
important intracellular signal transduction pathways and so ultimately controls an array of 
essential cellular functions. As a result of its influential position, the mTOR protein kinase 
has been termed a ‘master signal regulator’, ‘master switch’ and a ‘conductor of the cellular 
signalling symphony’ (Schmelzle and Hall, 2000; Caron et al., 2010; Foster and Fingar, 
2010; Dobashi et al., 2011). These pseudonyms are an apt description because, to date, 
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mTOR is known to regulate mitochondrial metabolism, endocytosis, lipid synthesis, 
translation, ribosome biogenesis, nutrient uptake, cell survival, as well as autophagy 
(reviewed by Schmelzle and Hall, 2000; Foster and Fingar, 2010; Dobashi et al., 2011). 
 
1.5.1. mTOR regulates autophagy induction through phosphorylation of mATG-13 
  
mTOR controls cellular autophagy through the action of mTORC1, which directly 
phosphorylates autophagy-related gene-13 (mATG-13 in mammals) (Hara et al., 2008; Chan 
et al., 2009; Yang and Klionsky, 2010). Phosphorylation of mATG-13 directly leads to the 
inhibition of autophagy induction (Hara et al., 2008; Chan et al., 2009). Therefore, mATG-13 
is critical during autophagy initiation. When in complex with FIP200 and ULK-1, mATG-13 
assembles into a 3 MDa multi-protein complex, the assembly of which signifies one of the 
earliest molecular events of autophagy activation (Chan et al., 2009; Yang and Klionsky, 
2010). It is important to note that the phosphorylation of mATG-13 by mTORC1 is an 
important, initial step in autophagy regulation (see Figure 1.6) because only mATG-13, in its 
dephosphorylated state, may fully initiate mature autophagosome formation (Meijer and 
Codogno, 2004; Hara et al., 2008; Chan et al., 2009; Yang and Klionsky, 2010).  
 
The autophagic process is frequently deregulated in many cancers and is consequently 
implicated in supporting cancer progression (Brech et al., 2009; Chen and Karantza-
Wadsworth, 2009; Chen and Debnath, 2010). While deregulated autophagy may result from 
ectopic autophagy-related gene (ATG) expression and upstream regulators, such as PI3K, 
PTEN, PKB and mTOR (Brech et al., 2009), aberrant integrin adhesion may also play a role 
considering the involvement of a potential underlying mechanical component (Fung et al., 
2008).  
 
Indeed any alteration to the norm drastically affects the normal operating procedure of the 
integrin adhesion system. Deregulated cell adhesion and inappropriate mechanotransduction 
have been shown to support phenotypic transformation in epithelial tissue (Pantel et al., 
2008; Gray et al., 2010; Hanahan and Weinberg, 2011). Therefore, since it has become 
increasingly apparent that altered cell-ECM adhesion events contribute towards epithelial 
transformation, a discussion concerning disease progression through aberrant regulation of 
cell adhesion events is prudent. 
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Figure 1.6: Signalling events giving rise to cellular autophagy induction. As the first step of 
autophagy, the isolation membrane (or phagophore) elongates and sequesters 
cytoplasmic constituents, non-specifically. Union of the phagophore edges 
results in the formation of an autophagosome. A lysosome (containing 
lysosomal hydrolases) fuses with the autophagosome, forming an 
autophagolysosome, which degrades captured components along with the 
inner autophagosome membrane. While autophagolysosome formation is 
important for the autophagic process, the appropriate temporal and spatial 
regulation of autophagy induction is just as vital. The mTOR signalling pathway 
is the principal regulator of autophagy initiation signals. mTORC1 
phosphorylates and inhibits mATG-13 and ULK of the 3 MDa ATG complex, thus 
restraining autophagy induction signals – a process which is iteslf hindered by 
rapamycin or nutrient starvation (Adapted from Liang and Jung, 2009 and 
Tsuchihara et al., 2009).   
 
1.6. The aberrant regulation of adhesion-related events aids disease progression 
 
A hallmark of both benign and malignant tumours is the capacity for deregulated cell growth 
and proliferative events (Hanahan and Weinberg, 2011). However, the invasive potential of a 
cell is exclusively associated with malignancy, and malignancy is directly associated with 
alterations in cell-cell and cell-ECM interactions (Behrens et al., 1989). Therefore, the 
ectopic expression of cell adhesion molecules becomes significant when considering the 
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metastatic ability of transformed cells. Observations of rat colonic carcinomas induced with 
dimethylhydrazine exhibit dissociation of tubular structures, as well as the appearance of 
single cells at the invasion front (Gabbert, 1985; Gabbert et al., 1985). This indicates that 
invasiveness correlates well with the degree of tumour dedifferentiation (Gabbert, 1985; 
Gabbert et al., 1985). The release of carcinoma cells from the epithelia may therefore be a 
consequence of a breakdown in intercellular adhesion events, implicating oncogenic 
transformation as an instigator of metastatic potential.      
 
A well known example epitomizing alterations in intercellular adhesion is squamous cell 
carcinoma affecting the human oesophagus, or HOSCC. Squamous cell carcinomas, like 
many other transformed epithelial cell types, display characteristic changes, or disease 
hallmarks, which underpin progression to the transformed state (Lam, 2000). One such 
change is the ectopic expression of integrin proteins as demonstrated by Miller and Veale 
(2001). Moreover, the inappropriate activation of integrin-triggered focal adhesion protein 
kinases (such as ILK or FAK) also contribute towards increased cell survival and 
tumourigenesis (Driver and Veale 2006; Fanucchi and Veale, 2011). These examples 
specifically communicate the ability of extracellular originating signals to support cell 
survival processes, especially under conditions where tumours exhibit a migratory 
phenotype. 
 
1.7. Squamous cell carcinoma affecting the human oesophagus 
 
1.7.1. Carcinomas result from the oncogenic transformation of epithelial tissue 
 
‘Cancer’ is an umbrella term used to define any malignant tumour; however the term 
carcinoma specifically refers to malignant tumours arising from the epithelium (Young et al., 
2007). Further classification of carcinomas reveals the existence of adenocarcinomas, which 
arise from glandular epithelium, as well as squamous cell carcinomas, derived from stratified 
squamous epithelium (Young et al., 2007). 
 
Transition from a normal epithelium to the transformed carcinoma phenotype may be 
explained as a result of alterations within oncogenes, tumour suppressor genes and genes 
responsible for regulating homeostasis (Vogelstein and Kinzler, 2004). These alterations may 
be triggered by lifestyle, the environment or an inherent genetic predisposition (Scully and 
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Bagan, 2009). Therefore, no single genetic defect is likely to cause such a dramatic shift in 
cellular phenotype; rather it is the cumulative effect of multiple mutated genes and defective 
protein products that promote transition to the transformed state. Consequently, oncogenic 
transformation is a multistage process that involves the cumulative activation, mutation or 
loss of different genes (Behrens et al., 1989). Thus, affected cells develop morphogenetic 
abnormalities that impinge on homeostatic feedback loops, ultimately affecting the control of 
growth and proliferation events (Hanahan and Weinberg, 2011). Furthermore, affected cells 
may acquire the potential to invade neighbouring tissue, as well as the potential to 
metastasize to distant sites by means of modified cell-cell and cell-ECM contacts (Bertram, 
2001; Hanahan and Weinberg, 2011). 
 
These changes within the epithelial phenotype may result in the formation of carcinomas, 
which comprise over 90 % of human malignant tumours (Behrens et al., 1989). Carcinomas 
are aggressive epithelial cells capable of breaking through the basement membrane and 
invading the underlying mesochyme (Behrens et al., 1989). This, together with a propensity 
for malignancy, accounts for the association of poor prognosis. 
 
1.7.2. HOSCC is an appropriate model system 
 
Cancer affecting the oesophagus is considered one of the most malignant gastrointestinal 
cancers affecting humans (Lehrbach et al., 2003; Lam, 2000). Human oesophageal squamous 
cell carcinoma, or HOSCC, is currently rated the eighth most common cancer in the world 
and is responsible for approximately one sixth of all cancer related deaths worldwide (Scully 
and Bagan, 2009; Melhado et al., 2010). Moreover, HOSCC possesses a variable 
geographical distribution; where the frequency of occurrence is reportedly high in Southern 
Africa and China, as well as Iran, Uruguay, France, Italy and Puerto Rico (Lam, 2000; Scully 
and Bagan, 2009). In South Africa, HOSCC occurs predominantly in the rural regions of the 
Transkei and Soweto (Hendricks and Parker, 2002). 
 
Reports indicate a high incidence of HOSCC in individuals less than 40 years of age, where 
risk increases with each subsequent decade of life (Zhang et al., 2004). Males are found to 
have a 3 - 4 times greater risk than females, while black males have a 5 times greater risk 
than their Caucasian counterparts (Walker et al., 1984; Stoner et al., 2007). While the 
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prognosis remains poor, a 50 % mortality rate is expected from all cases. Recent studies also 
show this rate to be 3.6 months for males and 4.2 months for females (Zhang et al., 2004). 
 
HOSCC possesses a multifactorial etiology; with environmental, dietary and genetic links 
(Stoner and Gupta, 2001). Tobacco derived carcinogens; such as polycyclic aromatic 
hydrocarbons, phenol and N-nitroso-containing compounds, are implicated as major 
contributors (Stoner and Gupta, 2001; Stoner et al., 2007). In addition, excessive alcohol 
consumption may exacerbate this disease (Kato et al., 2001). Recent studies also suggest salt-
cured, salt-pickled and mouldy foods with N-nitrosamine carcinogen contamination or fungal 
toxin contamination (from Fusarium verticillioides) of home-brewed sorghum-based beers 
(popular in many townships throughout Sub-Saharan Africa) to play a role (Hendricks and 
Parker, 2002; Isaacson, 2005). However, the molecular mechanisms promoting HOSCC 
progression remain poorly understood. 
 
1.7.3. Signal transduction through key pathway intermediates may provide this link 
 
1.7.3.1. Alterations involving ILK 
A review of recent proteomic data from 187 HOSCC-associated studies found that a total of 
214 proteins were commonly altered in HOSCC (Lin et al., 2009). Most candidate proteins 
commonly exhibited alterations in expression level, cellular localization or post-translational 
modification (Lin et al., 2009). Additionally, while approximately 10 percent of aberrations 
contributed towards cell migration and cell adhesion events, over 50 percent of those proteins 
investigated were involved in signal transduction, cell cycle regulation, controlled 
transcription or translational processes, as well as apoptosis. Figure 1.7 shows a breakdown 
of these commonly affected biological functions of deregulated proteins in HOSCC. The 
meta-analysis largely concluded that abnormalities affecting these aforementioned processes 
play the most vital role in HOSCC development.  
 
At this time, the reader is reminded that ILK also plays a critical role in the regulation of 
these four processes. Consequently, the inappropriate regulation of ILK function may lead to 
the involvement of ILK in oncogenic transformation (Li et al., 1999). Indeed, Wu et al. 
(1998) have shown that ILK over-expression in epithelial cells correlates with an increase in 
tumour formation in vivo, while studies using human tumour tissue revealed ILK to be 
constitutively over-expressed in Ewing’s sarcoma and primitive nueroectodermal tumour 
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(Chung et al., 1998). Consequently, ILK is used as a biomarker for these tumours. 
Furthermore, a previous member of the Cell Biology Laboratory at the University of the 
Witwatersrand established that a relationship exists between the integrins, ILK and human 
oesophageal squamous cell carcinomas; where ILK mediates integrin associated processes in 
WHCO cell lines which may contribute towards their cancerous phenotypes (Driver Ph.D. 
Thesis, 2007).   
 
In antithesis, the contribution of mTOR was not included in the investigation conducted by 
Lin et al. (2009), despite mTOR acting as a critical upstream regulator for the majority of 
these biological processes. This is may be a result of the limited information available about 
the role played by mTOR within HOSCC-specific progression. In light of this, a discussion 
concerning aberrant mTOR function within other tumour systems may provide insight into 
possible roles of deregulated mTOR function within the HOSCC model system. 
 
1.7.3.2. Alterations involving mTOR 
The signalling components upstream and downstream of mTOR are frequently altered in a 
wide variety of human tumours; for example breast, renal cell carcinoma and non-small cell 
lung cancer (Rosner et al., 2008). The fact that mTOR integrates signals from a variety of 
sources makes any point of incoming signal transduction cascades a possible target for 
aberration. In fact, this occurs frequently in tumour suppressor genes where mutations of 
TSC1, TSC2, LKB1, PTEN, VHL, NF1 and PKD-1 trigger the development of several 
diseases; including the hamartoma syndromes Tuberous Sclerosis, Peutz-Jeghers syndrome, 
Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, Lhermitte-Duclos disease as well 
as von Hippel-Lindau disease (reviewed by Rosner et al., 2008).  
 
Considering that mTOR is a major influence during the progression of these diseases, mTOR 
was recently implicated as an attractive target for cancer therapy. This lead to the discovery 
that the mTOR signalling pathway is frequently activated in carcinomas; including HOSCC 
(Hou et al., 2007; Hirashima et al., 2012) – however these are the only known studies to 
demonstrate this in HOSCC specifically. Recently, there has been much interest in curbing 
mTOR-induced proliferation so as to stop tumourigenesis, as an increase in mTOR 
expression has been shown in advanced tumours (Villanueva et al., 2008; Hirashima et al., 
2012). Also, increased levels of p-RPS6(Ser 235/236) (a direct downstream target of mTORC1) is 
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associated with moderately or poorly differentiated tumours (Villanueva et al., 2008; 
Hirashima et al., 2012). 
 
Currently, there is a void in the scientific literature with respect to the influence of ILK on 
mTOR activity by way of ECM-signalling events. This is particularly appropriate in the case 
of HOSCC due to its highly metastatic nature. The immediate question therefore becomes: is 
mTOR a target of mechanotransduction through ILK? There is some evidence for the 
involvement of mTORC2 (McDonald et al., 2008), but not mTORC1. Thus, there is a 
reasonable basis to investigate the link between extracellular-originating signals and their 
subsequent mechanotransduction through ILK to mTOR. Therefore, adhesion-based signaling 
in this manner may provide a regulatory element for inappropriate cell survival and 
autophagic processes in HOSCC. 
 Figure 1.7: Commonly affected biological functions of deregulated proteins in HOSCC.
al. (2009) found that a total of 214 proteins were commonly altered in HOSCC. Over 50 % of these were found to be involved in 
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1.8. Objective and Aims 
 
In addition to its contribution to normal physiological homeostasis, aberrations involving the 
mTOR pathway are known to support tumour progression. An elevated instance of mTOR 
protein expression and hyper-activated mTOR signalling is associated with the transformed 
phenotype, as shown by studies using MCF-7 cells. Also, instances of elevated mTORC1 
signalling are increasingly associated with pathology; in both metabolic diseases and cancer 
progression. Even though alterations within the mTOR pathway have been identified in the 
literature, a significant gap remains concerning the influence of extracellular-originating 
signals on mTOR signalling. This is particularly relevant considering the mTOR pathway 
controls autophagy initiation and a connection between autophagy and substrate dependence 
has recently been identified. This gap is what this research seeks to fill. Therefore, with the 
main objective being to investigate the influence of extracellular-originating signals on 
mTOR signalling in HOSCC, we sought to: 
 
i. Monitor the protein expression of key mTOR signal transduction pathway 
intermediates responsible for autophagy induction using a system of moderately 
differentiated HOSCC cell lines. 
ii. Investigate the response of these signalling networks to soluble stimuli. 
iii. Determine the effect of extracellular-originating signals derived from cell-substrate 
interactions on the cellular concentration of mTOR and mTORC1 signalling. 
iv. Characterise the possible route, or routes, of mechanotransduction from sites of cell-
substrate contact to the mTOR/mTORC1 signalling pathway in HOSCC cells. 
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CHAPTER 2 
 
2. EXAMINATION OF KEY SIGNAL TRANSDUCTION 
INTERMEDIATES REGULATING AUTOPHAGY INDUCTION 
IN HOSCC CELLS 
 
2.1. Introduction 
 
Autophagy is an evolutionary conserved cell survival mechanism responsible for the 
nonspecific bulk degradation of cellular proteins and organelles. Autophagy may be classified 
into two subtypes; namely constitutive autophagy and induced autophagy (Klionsky and 
Ohsumi, 1999). Constitutive autophagy refers to a basal rate of cellular autophagic 
processing, typified by the Cvt (cytoplasm-to-vacuole targeting) pathway in yeast, which 
mediates transport of aminopeptidase-1 (Ape-1) from the cytoplasm into the vacuole 
(Klionsky and Ohsumi, 1999). Induced autophagy refers to autophagic processing that is 
triggered in response to a particular cellular stress, such as nutrient starvation or exposure to 
rapamycin (He and Klionsky, 2009). In both cases, autophagy induction requires the 
involvement of the mammalian target of rapamycin (mTOR) signalling pathway, as mTOR 
mediates signal transduction to the cellular machinery controlling autophagy induction (Jung 
et al., 2010; Neufeld, 2010; Yang and Klionsky, 2010). Therefore, monitoring the signalling 
potential of the mTOR pathway becomes the main focus of this investigation. 
 
Transmission of intracellular signals through mTOR induces its translocation into one of two 
multi-protein complexes, known as mTORC1 and mTORC2.   mTORC1 (mTOR-containing 
multi-protein complex 1) is sensitive to rapamycin treatment and is the primary mTOR 
complex involved during the regulation of cell growth, proliferation and autophagy (Jung et 
al., 2010; Neufeld, 2010; Yang and Klionsky, 2010).   mTORC2 (mTOR-containing multi-
protein complex 2) is relatively rapamycin-insensitive and is rather involved during the 
regulation of actin cytoskeletal dynamics, survival and cellular metabolism (Loewith et al., 
2002; Jacinto et al., 2004). Since mTORC1 is uniquely involved during the regulation of 
autophagy, we are particularly interested in signal transduction through the mTORC1 node of 
the mTOR pathway.   
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Signalling through mTORC1 requires the sequential activation of important upstream 
regulators, such as PI3K, PKB, Rheb-GTPases, Raptor and Rictor (Caron et al., 2010; 
Schmelzle and Hall, 2000; Fingar and Blenis, 2004), as well as the functional inhibition of 
PTEN, AMPK, TSC1, TSC2 and Deptor (Schmelzle and Hall, 2000; Fingar and Blenis, 
2004). Only once properly activated can mTORC1 regulate autophagy through inhibition of 
the ~ 3 MDa autophagy induction complex (Hosokawa et al., 2009; Jung et al., 2009). 
However, activated mTORC1 may also serve as a downstream branching point controlling 
protein synthesis and translation initiation through phosphorylation of p70S6K and 4E-BP1 
(Schmelzle and Hall, 2000; Fingar and Blenis, 2004). Therefore, the mTOR signalling 
pathway is a multifaceted one containing a complex array of pathway intermediates required 
for the appropriate activation of mTORC1. 
 
In mammalian cells, inhibition of autophagy correlates well with ribosomal protein S6 
(RSP6) phosphorylation (Blommaart et al., 1995). Since RPS6 phosphorylation is dependent 
on the activation of p-p70S6K by mTORC1, signal transduction to mTORC1 is critical 
(Brown et al., 1995; Thomas and Hall, 1997). These findings suggest that one can effectively 
follow the earliest steps controlling the induction of autophagy by monitoring the activation 
of select signal transduction intermediates holding key positions within the mTOR pathway. 
Based on our understanding of mTOR/mTORC1 signalling dynamics, we also believe the 
mTOR pathway can be successfully reduced to a few major players, although based on two 
criteria: significance of activation, and relative position within the pathway. In doing so, we 
can distil the mTOR pathway into a set of measurable protein markers comprised of key 
pathway intermediates, which represent critical nodes during the course of mTOR/mTORC1 
signalling. Our reduction of the mTOR pathway is illustrated in Figure 2.1; where we 
highlight major mTOR pathway intermediates we believe adequately fulfil this role.  
 
Each molecular marker represents an important element of the mTOR signalling pathway and 
so conveys specific pathway information. As can be seen in Figure 2.1, the 220 kDa mTOR 
protein kinase (henceforth referred to as mTOR) is positioned immediately downstream of 
the PI3K/PKB pathway; an important signalling scheme maintaining cell survival and 
homeostasis (Foster et al., 2003; Arcaro and Guerreiro, 2007; Duronio, 2008).  mTOR is 
considered the principal conduit through which biochemical signals are propagated within the 
mTOR signalling pathway; owing to the presence of the C-terminal kinase domain (Foster 
and Fingar, 2010; Dobashi et al., 2011). Therefore, by monitoring the protein expression of 
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mTOR, one may gain an understanding of how the central protein component of the mTOR 
signalling pathway responds to extracellular-originating stimuli. 
 
Since it is well established that p70S6K is a downstream target of mTORC1 (Brown et al., 
1995; Thomas and Hall, 1997), the state of RPS6(Ser 235/236) phosphorylation is used 
extensively in the literature as a marker for active mTOR signalling (Sturgill and Wu, 1991; 
Dazert and Hall, 2011). In light of this, p-RPS6(Ser 235/236) is used to convey specific 
information pertaining to the signalling potential of mTORC1. This is ideal because, as will 
be elaborated on below, active signalling through mTORC1 is directly responsible for 
autophagy regulation as mTORC1 interacts with mATG-13 of the ~ 3 MDa autophagy 
induction complex.  
 
mATG-13 (in its dephosphorylated state) forms a multi-protein autophagy induction complex 
together with ULK-1 and FIP200, which is an essential requirement for the development of  
functionally mature autophagosomes (Hara et al., 2008; Chan et al., 2009; Yang and 
Klionsky, 2010).  mTORC1 regulates this process by directly phosphorylating mATG-13 
during conditions where nutrient concentrations are not constrained, thereby inhibiting 
signals initiating autophagy induction (Chan et al., 2009; Yang and Klionsky, 2010). Since 
the state of mATG-13 phosphorylation is a crucial regulatory step for autophagy to proceed, 
the presence of mATG-13 in its dephosphorylated form signifies an important, initial 
regulatory step for autophagy induction. For this reason, we believe mATG-13 serves as an 
informative pathway intermediate signifying mTORC1-dependent autophagy regulation. 
 
It has been demonstrated, however, that extensive autophagy may result in cell death (Brech 
et al., 2009; Tsuchihara et al., 2009; Chen and Debnath, 2010). Therefore, it is necessary to 
differentiate between apoptosis, or programmed cell death-type I (PCD-Type I), and death as 
a result of excessive autophagy, or programmed cell death-type II (PCD-Type II), which may 
arise during the course of this investigation. Since the proteolytic cleavage of pro-caspase-3 
into functionally-active fragments signifies apoptosis activation, the presence of cleaved 
caspase-3 is commonly used as a molecular marker indicating this early step (Thornberry and 
Lazebnik, 1998; Chowdhury et al., 2008). Therefore, the presence of cleaved caspase-3 
signifies that any observed cell death was a result of apoptosis, rather than autophagy, and so 
was regarded as an important signal transduction intermediate. 
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Lastly, since a component of this investigation is to explore the contribution of adhesion-
based signalling to the autophagy induction process in HOSCC cells, a molecular connection 
mediating signal transmission from the ECM to the mTOR pathway is still required. Since 
ECM-originating signals are propagated in an integrin-mediated manner (Clarke and Brugge, 
1995), an integrin-triggered focal adhesion protein kinase, such as ILK, would be the most 
likely conduit providing this molecular connection. Considering that autophagy occurs in an 
FAK-independent manner (Hara et al., 2008), and ILK is a promiscuous protein kinase; 
functioning as both a molecular scaffold and signalling node at sites of focal adhesion, ILK 
and not FAK was chosen to represent signals arising from sites of cell-ECM adhesion.  
 
By monitoring the protein expression of critical signal transduction pathway intermediates, 
we aim to establish an efficient system to monitor the mTOR signalling pathway. In selecting 
key elements of this pathway to act as molecular markers and monitoring them as a set under 
standard tissue culture conditions, we may also establish the normal operating procedure for 
signal transduction through mTORC1. Consequently, we may investigate the influence of 
such signalling to the autophagy induction machinery in a series of five moderately 
differentiated HOSCC cell lines. 
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Figure 2.1: Illustration of a reduced mTOR/mTORC1 signalling pathway. By highlighting 
major players within the mTOR/mTORC1 signalling pathway, we emphasise the role and 
position of those cellular proteins included in the marker set. Consequently, by monitoring 
the protein expression of mTOR, p-RPS6
(Ser 235/236)
, mATG-13, cleaved caspase-3 and ILK, we 
establish an efficient system conveying specific signalling information. This becomes an 
extremely practical method of investigating the mTOR pathway in response to factors 
influencing autophagy induction in HOSCC cell lines.   
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2.2. Materials and Methodology 
 
2.2.1. Tissue Culture of WHCO, MCF-7 and HEK-293 Cell Lines 
Five moderately differentiated human oesophageal squamous carcinoma (HOSCC) cell lines, 
of South African origin, were obtained from the Cell Biology Research Laboratory, 
University of the Witwatersrand, Johannesburg. Cell lines were designated WHCO1, 
WHCO3, WHCO5, WHCO6 (Veale and Thornley, 1989) and SNO (Bey et al., 1976). Since 
physiologically ‘normal’ oesophageal cell lines are currently unavailable for comparative 
analysis (Jankowski et al., 1995; Underwood et al., 2010), the MCF-7 and HEK-293 cell 
lines were used as comparative controls. The SV40T-antigen (simian-virus-40 large T-
antigen)-immortalized oesophageal squamous cell line, HET-1A, is incorrectly believed to be 
representative of truly untransformed oesophagus. This is because HET-1A cells do not 
display common characteristics of ‘normal’ oesophageal squamous cells; such as E-cadherin, 
casein kinase 5/6 (CK 5/6) or the stratified epithelial marker ∆Np63 (Underwood et al., 
2010). Therefore, the HET-1A cell line was not used for comparative purposes in this 
investigation.   
 
The MCF-7 cell line, derived from a patient presenting with mammary adenocarcinoma 
pleural effusion (Soule et al., 1973), and the HEK-293 cell line, established from human 
embryonic kidney cells and first described by Graham et al. (1977), were supplied by the 
America Type Culture Collection (ATCC). All cell lines were cultured in 10 cm tissue 
culture dishes (Corning) and maintained in 10 ml Dulbecco’s Modified Eagles Medium 
(DMEM)/Hams F12 (3:1) (Appendix A, 1.2.1) supplemented with 10 % Foetal Calf Serum 
(FCS) (Highveld Biologicals), penicillin and streptomycin. Tissue cultures were incubated in 
a humid, 37 °C incubator with an atmosphere of 5 % CO2 in air. Please note that all 
procedures for one set of experiments were performed using the same batch of FCS. 
 
2.2.2. Sub-culture of WHCO, MCF-7 and HEK-293 Cell Lines 
Cell cultures were allowed to proliferate until 10 cm dishes reached a confluence of 
approximately 80 %. Medium was then aspirated and cell monolayer washed twice with 
warm (37 °C) sterile phosphate buffered saline (PBS) (Appendix A, 1.1.1). Subsequently, 
1ml Trypsin(Gibco BRL)/Ethylenediaminetetra-acetic acid (EDTA) (BDH Laboratory 
reagents) (Appendix A, 1.2.2) was added and the tissue culture dish placed into a 37 °C 
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incubator for 5 min, to augment cell-cell and cell-ECM detachment. Detachment was 
confirmed using a Leitz Watzlar Inverted Light Microscope. Subsequently, a fraction of the 
trypsinized cell-EDTA mixture was added to a new tissue culture dish with 10 ml fresh 
medium containing 10 % FCS. Tissue culture continued as previously described in 2.2.1.       
 
2.2.3. Antibodies 
Immunochemical analysis utilised an indirect antibody detection system requiring a range of 
specific primary antibodies to detect all proteins in the marker set. Since all primary 
antibodies were reared within rabbit hosts, only one type of polyclonal, goat-derived anti-
rabbit secondary antibody was necessary. This secondary antibody was conjugated to a 
horseradish peroxidase (HRP) (Separations, SA), thus facilitating detection by 
chemiluminescence. 
 
The mammalian target of rapamycin protein kinase (anti-mTOR) was detected with rabbit 
polyclonal antibodies obtained from Cell Signalling Technology®, USA. Phosphorylated 
ribosomal protein subunit 6 around Ser residues 235/236 (anti-p-RPS6Ser 235/236) was detected 
with rabbit monoclonal antibodies obtained from Cell Signalling Technology®, USA. 
Mammalian autophagy related gene-product-13 (anti-mATG-13) was a gift from Dr Sharon 
Tooze from Cancer Research UK (CRUK). Since no commercial antibodies are available for 
mATG-13, Dr Tooze and colleagues generated polyclonal antibodies against human Atg-13 
(designated KIAA0652) using the peptide sequence LAVHEKNVREFDAFVETLQ (Chan et 
al., 2009). Furthermore, cleavage fragments of activated caspase-3 (anti-cleaved caspase-3) 
were detected using rabbit polyclonal antibodies obtained from Cell Signalling Technology®, 
USA. Integrin-linked kinase (anti-ILK) and anti-actin (β isoform) were detected with rabbit 
polyclonal antibodies obtained from Sigma-Aldrich®, USA. 
 
2.2.5. Triton X-100-based Protein Extraction 
The anionic detergent Triton X-100 is known to enrich the extraction of membrane and 
cytoplasmic associated proteins (Giancotti and Ruoslahti, 1990). Therefore, a protein 
extraction buffer containing Triton X-100 is appropriate for the extraction of various cellular 
proteins physically linked to integrin glycoproteins, as well as cytoplasmic signal 
transduction intermediates.  
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Cells were allowed to proliferate until a confluence of approximately 80 % was reached. 
Cells were washed twice with PBS, then 1 ml PBS containing a phenyl-methyl-sulphonyl 
fluoride (PMSF)/Aprotinin-based (Trasylol®, Bayer S.A.) protease inhibitor solution was 
added, into which cells were gently scraped off using a rubber policeman. The cell 
suspension was transferred to a sterile eppendorf and centrifuged in a TOMY HF-120 
centrifuge (1 145 x g) for 5 min. The supernatant was removed and pellets re-suspended in 50 
- 200 µl of a Tris-based 2 % (v/v) Triton X-100 (pH 7.2) protein extraction buffer (Appendix 
A, 1.3.1), then vortexed briefly and incubated for 3 hours on ice (with intermittent mixing by 
inversion). Thereafter, samples were centrifuged at 12 000 x g in a PRISM™ Refrigerated 
Microcentrifuge for 10 min at 4 °C. The supernatant containing total cellular protein was 
decanted into a sterile eppendorf. Subsequently, Laemmli double lysis buffer (Appendix A, 
1.3.2) was added in a ratio of 1:1 to each sample, after which samples were boiled for 5 min, 
then centrifuged at 12 000 x g in a PRISM™ Refrigerated Microcentrifuge for 10 min at 4 
°C. SDS-PAGE-ready samples were stored at – 20 °C.  
 
2.2.6. Protein Estimation 
To ensure that equivalent protein concentrations were loaded for all HOSCC cell lysates, an 
estimate of protein concentration within each sample was performed utilising the 
methodology proposed by Bramhall et al. (1969). Whatman® filter paper was first hydrated 
by washing in distilled water (dH2O) for 20 min, then subjected to a series of dehydration 
steps; where 95 % ethanol, 100 % ethanol and 100 % acetone were applied in succession, 
each for 5 min (Appendix A, 1.4). Subsequently, the dehydrated filter paper was allowed to 
air-dry in a sterile fume hood. Protein standard concentrations were then prepared by 
solubilising Bovine Serum Albumin (BSA) (BDH Laboratory reagents) in Laemmli double 
lysis buffer (1µg/µl):2 % (v/v) Triton X-100 (pH 7.2) extraction buffer (1:1), and spotted onto 
the dry filter paper to create a curve possessing the following standards: 1 µg, 3 µg, 6 µg, 9 
µg, 12 µg, 16 µg and 20 µg. In addition, 2 µl duplicates of each SDS-PAGE-ready sample 
were spotted onto the filter paper. 
 
After spots were allowed to air-dry, the filter paper was placed in trichloroacetic acid (TCA) 
for 40 min (Appendix A, 1.4.2), in order to precipitate the proteins onto the filter paper 
medium. Excess TCA was removed by the addition of 0.25 % Coomassie Blue stain for 5 
min (Appendix A, 1.4.3), which was then discarded. Thereafter, fresh 0.25 % Coomassie 
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Blue stain was applied for 45 min. The filter paper was then placed in a destain solution 
(Appendix A, 1.4.4) for approximately 1 hour until background stain was completely 
removed. Stained circles that remained were indicative of precipitated protein. These were 
then removed and placed, individually, into 5 ml elution solution (Appendix A, 1.4.5) in the 
dark for approximately 3 hours. Subsequently, the absorbance of each solution was 
determined at 596 nm using an Abbota SV1100 Spectrophotometer, with elution solution 
serving as a blank. A standard curve of absorbance (OD at 596 nm) versus protein 
concentration (µg/µl) was then constructed using the absorbance from the protein standards 
of known concentration (see Appendix B, Figure B1 for sample standard curve). Therefore, 
protein concentration present in the unknown samples was determined using the standard 
curve, constructed using Microsoft® Excel 2007 (Version 12.0.6). 
 
2.2.7. SDS-PAGE (Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis) 
Proteins present in each sample were resolved by either 10 % or 12 % (w/v) discontinuous 
SDS-PAGE, following the protocol proposed by Laemmli (1970). The Mighty Small™ SE245 
Dual Gel Caster system (Hoefer Scientific) was used to construct all gels. Polyacrylamide 
gels containing sodium dodecyl sulphate (SDS) were prepared by pouring a 10 % or 12 % 
separating gel (Appendix A, 1.5.3.1) in between glass and silica plates, which were left to 
polymerise for approximately 30 min. Polymerisation was augmented by the addition of 200 
µl 4 % SDS overlay solution (Appendix A, 1.5.3.3). SDS overlay was then removed and a 5 
or 8 % stacking gel (Appendix A, 1.5.3.2) was poured above the separating gel. A comb 
possessing either 10 µl or 20 µl wells was placed into the stacking gel. The stacking gel layer 
was allowed to polymerise for approximately 20 min. 
 
Once polymerized, the SDS-PAGE gel was placed in the Mighty Small™ Electrophoresis 
Unit containing electrophoresis running buffer (pH 8.3) (Appendix A, 1.5.2.1). After the 
comb was removed, the appropriate volume of each sample was loaded into the resulting 
wells. In addition, 2 µl of PageRuler™ Prestained Protein Ladder (Fermentas Life Sciences) 
was loaded into the first well of the gel. The bands in the molecular weight marker 
represented 170, 130, 100, 70, 55, 40, 35, 25, 15 and 10 kDa (clearly seen after separation in 
Figure 2.2). Thus, samples were resolved using a constant currant of 25 mA (~ 400 V) per 
gel for 1 hour, until the 10 kDa marker was 1 cm from the bottom of the separating gel. 
Resolved proteins were visualized by placing the gel into 0.25 % Coomassie Blue stain 
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(Appendix A, 1.5.3.5) for 1.5 hours and then placed in a destain solution (Appendix A, 
1.5.3.6), overnight. The gel was subsequently digitized using a Hewlett Packard ScanJet 
G3110 desktop scanner.     
 
2.2.8. Western Immunoblot Analysis 
Western immunoblotting (immunodetection) is considered a reliable technique allowing for 
the detection and quantification of numerous polypeptide species. By exploiting the specific 
binding capabilities of monoclonal or polyclonal antibodies, specific polypeptides may be 
detected from a complex cellular mixture. In this investigation, immunodetection proceeded 
according to the protocol initially described by Towbin et al. (1979), later modified by 
Burnette (1981). 
 
Western immunoblotting initially required sample resolution by 10 or 12 % (w/v) SDS-
PAGE, as stated in 2.2.7. Subsequently, polyacrylamide gels were cut within the relevant 
range for each protein of interest, using the PageRuler™ Prestained Protein Ladder as a guide. 
Resolved proteins were then transferred onto Hybond™-C nitrocellulose membrane 
(Sartorius) using a Bio-Rad Criterion™ Blotter for 1.5 – 3 hours (depending on the 
requirements of individual proteins) in transfer buffer (pH 8.3; 4 °C) (Appendix A, 1.6.1.1) at 
a constant currant of 400 mA. The nitrocellulose membrane was then washed with the 
appropriate buffer (see Appendix B, Table B1 for specific antibody requirements). 
 
Nitrocellulose membranes were then placed in a casein-based blocking buffer solution 
(Blotto) (Appendix A, 1.6.1.2 or 1.6.1.3) for 1 hour at room temperature in order to block 
nonspecific binding sites. Thereafter, the membrane was rinsed with the appropriate buffer 
and incubated with the appropriate primary antibody (see Appendix B, Table B1 for antibody 
dilutions and incubation conditions). Unbound antibody was removed by washing the 
membrane several times with the appropriate buffer (5 min per wash). Next, the membrane 
was incubated with a goat-anti-rabbit HRP-conjugated secondary antibody (see Appendix B, 
Table B1 for antibody dilutions and incubation conditions).  Unbound antibody was again 
removed by washing the membrane several times with the appropriate buffer (5 min per 
wash), after which the membrane was placed in a luminal:peroxide mixture (1:1) 
(SuperSignal® West Pico) for 5 min in the dark (Appendix A, 1.6.2). The membrane was 
subsequently wrapped in Versafilm® clear cling-wrap and exposed to clear-blue CL-
XPosure™ X-ray film (Pierce) for 10 min in the dark. Immediately after, the film was placed 
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in a developer solution (Appendix A, 1.6.3), rinsed in water, placed in a fixer solution 
(Appendix A, 1.6.4) and rinsed in water.  
 
2.2.9. Image Capturing 
Images were digitized using a Hewlett Packard ScanJet G3110 desktop scanner. 
Magnification, contrast, brightness and cropping of all images were performed using 
Microsoft Paint® 2007 software (Version 6.1). 
 
2.2.10. Laser Densitometry and Analysis of Relative Protein Expression 
The Labworks™ Image Acquisition and Analysis software (Version 4.5) was used for 
densitometric analysis. This software allows for a semi-quantitative comparison of relative 
protein expression levels as determined by western immunoblotting. Protein expression levels 
are determined by analysing immunoblots, calculating band intensities and subtracting 
irrelevant background data, thus forming a calibration curve. The area under the curve is 
indicative of integrated optical density (IOD) or the amount of signal produced from HRP-
dependant chemiluminescence. Subsequently, IOD was used to determine protein expression 
levels, described in more detail below. 
 
Levels of relative protein expression were designated low (0 – 45 %), moderate (46 – 75 %) 
or high (76 – 100 % or above) based on the classification system originally set up by Hager et 
al. (2011) to analyse mTOR and p-RPS6 proteins in mammalian cells. This system was used 
during this investigation in order to compare protein expression across WHCO, MCF-7 and 
HEK-293 cell lines (see Appendix C, Tables C1-C5 for densitometric data). IOD for each cell 
line was represented as a percentage of that recorded for the WHCO6 or MCF-7 cell line 
(unless otherwise indicated) using GraphPad Prism® software, Version 4.0 (GraphPad 
Software, Inc., San Diego, CA, USA). 
 
2.2.11. Statistical Analysis 
Results are expressed as the mean ± S.E. Statistical significance was determined by Student’s 
t-test for comparative analysis (See Appendix D, Table D1 and Table D2) using Sigma Plot®, 
Version 12.0 (SPSS Science, Chicago, Illinois USA), where p < 0.05 indicated statistical 
significance. All experiments were repeated at least three times, unless otherwise indicated. 
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2.3. Results 
 
2.3.1. Extraction of cellular proteins from HOSCC cells  
 
The successful separation of polypeptides by SDS-PAGE confirmed the efficacy of the 
protein extraction method used to acquire cellular proteins from HOSCC cell lysates (Figure 
2.2). Since a similar banding pattern was also visible in all lanes of the SDS-PAGE gel (after 
polypeptides were stained with Coomassie Blue stain), this provided visual evidence 
supporting the accuracy of the protein estimation procedure. In addition, the clear separation 
of the molecular weight marker (MWM) in Lane 1 indicated that the blue-coloured 
polypeptide bands in Lanes 2 – 7 were also resolved by size. Since discreet polypeptide bands  
appear at the approximate molecular weight previously reported for proteins in the marker set 
(indicated by coloured arrows in Figure 2.2), this banding pattern signifies the potential 
presence of relevant mTOR pathway intermediates in HOSCC cells. Therefore, the presence 
of these bands supported proceeding to the next step of this investigation, which 
encompassed western immunoblot analysis for key mTOR pathway intermediates contained 
within the marker set. 
 
2.3.2. HOSCC cells express the 220 kDa mTOR protein and the 80 kDa mTORβ 
splicing isoform 
 
Analysis of a whole SDS-PAGE gel revealed the presence of two mTOR protein variants in 
HOSCC cells. Polypeptides corresponding to mTOR were detected at 220 and 80 kDa 
(Figure 2.3). Although the same amount of protein was loaded for each cell line (see 
Appendix B, Figure B1 for standard curve based on the dilution of BSA), the 220 kDa mTOR 
isoform was dominantly expressed in WHCO5, WHCO6 and SNO cell lines. In comparison, 
mTOR (220 kDa) protein expression was visibly reduced in WHCO1 and WHCO3 cell lines. 
However, only the WHCO1 and WHCO3 cell lines expressed the 80kDa mTORβ splicing 
isoform. 
 
Untransformed or physiologically ‘normal’ oesophageal cell lines are currently unavailable 
for comparative analysis with HOSCC cells (explained in Materials and Methodology, 
Section 2.2.1). Therefore, the breast adenocarcinoma cell line (MCF-7) and human 
embryonic kidney cell line (HEK-293) were used as controls in order to establish a relative 
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measure for mTOR expression in HOSCC cells. MCF-7 cells are known to over-express both 
mTOR and p-RPS6(Ser 235/236) (Hagner et al., 2009), while HEK-293 cells are known to 
produce endogenous levels of mTORβ (Panasyuk et al., 2009). Western blotting confirmed 
the expression of mTOR (220 kDa) polypeptide bands in MCF-7 and HEK-293 cells (Figure 
2.3). Unexpectedly, mTORβ (80 kDa) expression was also observed in the MCF-7 cell line. 
An in depth analysis of the relevant literature revealed that this is the first observation of 
mTORβ in MCF-7 cells.  
 
The specificity of the anti-mTOR antibody was also confirmed since there was no evidence 
of non-specific antibody binding in Figure 2.3. This observation indicates that the western 
blotting system used here is able to produce clear and reliable western blots. Therefore, this 
type of efficiency justifies trimming subsequent blots to conserve reagents, especially 
antibodies obtained as gifts. 
 
2.3.3. Key mTOR pathway intermediates are expressed differentially by HOSCC cells 
 
The expression of all relevant marker set proteins was confirmed in HOSCC cells by western 
blotting, under standard tissue culture conditions. Single polypeptides corresponding to 
mTOR (220 kDa), p-RPS6(Ser 235/236) (36 kDa), mATG-13 (72 kDa) and ILK (59 kDa) were 
detected in all HOSCC cell lines (Figure 2.4, A).  β-actin (46 kDa) was also detected in 
HOSCC cells. The detection of β-actin was used as a visual demonstration of equal protein 
loading between cell lines (see Appendix B, Figure B1 for standard curve). However, 
polypeptide fragments indicative of cleaved caspase-3 (17 – 27 kDa) were not detected in any 
of the HOSCC cell lines (Figure 2.4, B). 
 
Since cleaved caspase-3 is only expressed under circumstances of programmed cell death 
(Thornberry and Lazebnik, 1998; Chowdhury et al., 2008), an appropriate panel of HOSCC 
cell line controls was required to confirm cleaved caspase-3 expression. Therefore, HOSCC 
cells from the WHCO6 cell line were used, where cells were starved of serum for either 0 or 
24 hours. HOSCC cells serum-starved for 0 hours were used as a standard tissue culture 
control and designated ‘Serum + (S+)’, whereas HOSCC cells serum-starved for 24 hours 
were used as a serum-free control (SF/C).  
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Cells that became detached from the SF/C tissue culture substrate, as a result of apoptotic cell 
death, were collected from the media and used as an apoptotic control (A/C). Subsequently, 
cleaved caspase-3 expression was confirmed in A/C cells, only (Figure 2.4, B). Further 
analysis of the marker set in A/C cells by western blotting revealed a visible reduction in the 
polypeptides indicative of mTOR (220 kDa) and p-RPS6(Ser 235/236) (36 kDa) expression 
(Figure 2.4, C). However, polypeptides indicative of mATG-13 (72 kDa) and ILK (59 kDa) 
expression only appeared to be reduced to a small degree, while cleaved caspase-3 expression 
(17 – 27 kDa) was prominent in A/C cells under these conditions. 
 
Semi-quantitative densitometric analysis of the marker set revealed different levels of protein 
expression between the WHCO series of cell lines (Figure 2.5). When expressed as a 
percentage of the MCF-7 control cell line, we observed that WHCO cell lines do not 
uniformly express all proteins in the marker set. Rather, protein expression was found to vary 
between low to high levels (see Materials and Methodology, Section 2.2.10, for a clear 
explanation of how we determined levels of protein expression). Noting this, we established 
that HOSCC cells conform to certain protein expression trends, that may or may not be 
shared by all WHCO cell lines (see Table 2.1 for a detailed summary of these protein 
expression and cell line trends). This enabled the categorization of WHCO cell lines into 
groups, based on trend conformation, allowing the identification of an overriding protein 
expression trend for HOSCC cells.    
 
HOSCC cells were therefore found to be high expressers of mTOR and low expressers of 
mTORβ. Analysis of the WHCO series revealed a high concentration of mTOR in WHCO1, 
WHCO5, WHCO6 and SNO cell lines. The WHCO3 cell line, however, was a low mTOR 
expresser; expressing significantly lower concentrations of mTOR compared to MCF-7 cells 
(see Appendix D, Table D1 for a complete statistical analysis). However, only two of the five 
WHCO cell lines expressed the mTORβ splicing isoform.  mTORβ was expressed at low 
levels within the WHCO1 and WHCO3 cell lines, only. In addition, the level of mTORβ 
expression was not significantly different to those endogenous levels found in HEK-293 cells 
(see Appendix D, Table D2). 
 
HOSCC cells were also either moderate (WHCO1 and WHCO3) or high (WHCO5 and 
WHCO6) expressers of p-RSP6(Ser 235/236). The SNO cell line, however, was a low expresser 
of p-RSP6(Ser 235/236), expressing significantly lower concentrations when compared to MCF-7 
36 
 
cells (see Appendix D, Table D1 for a complete statistical analysis). Since the WHCO series 
of cell lines (WHCO1, WHCO3, WHCO6 and SNO) were also high expressers of 
dephosphorylated mATG-13 (referred to henceforth as mATG-13), HOSCC cells were 
generally high expressers of mATG-13. However, the WHCO5 cell line was the exception in 
this case; expressing significantly lower concentrations of mATG-13 compared to MCF-7 
cells (see Appendix D, Table D1). All WHCO cell lines were high expressers of ILK. Only, 
the WHCO6 and SNO cell lines were found to express significantly higher levels of ILK than 
MCF-7 cells (see Appendix D, Table D1 for these statistical analyses).  
 
Since cleaved caspase-3 was not detected in any of the WHCO cell lines, HOSCC cells were 
regarded as expressing low levels of cleaved caspase-3 under standard tissue culture 
conditions. However, analysis under apoptotic conditions revealed that HOSCC cells change 
these established trends and, not only increase cleaved caspase-3 expression, but decrease 
mTOR, p-RPS6(Ser 235/236) and mAG-13 protein expression to low levels. Only, ILK protein 
expression remained unaltered in HOSCC cells under apoptotic conditions.  
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Figure 2.2: Separation of cellular proteins extracted from HOSCC cells. The presence of 
multiple polypeptide bands of similar staining intensity demonstrated that the 
extraction of cellular proteins from HOSCC cells was successful, and that the 
protein estimation was accurate. Staining with Coomassie blue visually 
confirmed the presence of discreet polypeptide bands at the approximate 
molecular weight expected for key mTOR pathway intermediates in the marker 
set. The relative position of these polypeptides is indicated by the coloured 
arrows, in relation to the molecular weight marker (MWM) in Lane 1. mTOR 
appears in red (220 kDa), mATG-13 in purple (72 kDa), ILK in blue (59 kDa), p-
RS6
(Ser 235/236)
) in green (36 kDa) and the cleavage products indicating activated 
caspase-3 in black brackets (17 – 28 kDa). (CO1 = WHCO1; CO3 = WHCO3; CO5 
= WHCO5 and CO6 = WHCO6). 
 
 
 
 Figure 2.3: Immunodetection 
blotting using a whole SDS
protein in HOSCC cells. Both the 220 kDa and 80 kDa version of mTOR is 
expressed by HOSCC cells; however visual assessment of polypeptide bands 
suggests that mTOR concentrations varies between HOSCC cell lines. WHCO5, 
WHCO6 and SNO cell lines express a
WHCO3, whereas WHCO1 and WHC
express mTORβ.
and 80 kDa also indicate the specificity of the anti
mTOR protein. This justifies the trimming of subsequent blots. (MWM
Molecular weight marker; CO1 = WHCO1; WHCO3 = WHCO3; CO5 = WHCO5; 
CO6 = WHCO6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
of mTOR and mTORβ using a full SDS-PAGE gel.
-PAGE gel detected splice variants of the m
ppreciably higher mTOR than WHCO1 and 
O3 cell lines are the only HOSCC cells to 
 Immunodetection of discreet mTOR bands at 
-mTOR 
38 
 
 Western 
TOR 
only 220 kDa 
antibodies for the 
= 
 A.                                                                                    
 
B. 
Figure 2.4: Detection of major protein markers identif
pathway. A)  mTOR, p
WHCO series, as well as in the MCF
and 59 kDa, respectively. 
tissue culture conditions using monoclonal (anti
mATG-13) or polyclonal (anti
indicative of activated caspase
(AC) control at 17 and 27
and p-RPS6
(Ser 235/236)
while mATG-13 (72 kDa), 
polypeptides were detected in th
demonstrate equal protein loading 
       C.
 
ied for the mTOR/mTORC1 signalling 
-RPS6
(Ser 235/236)
, mATG-13 and ILK were detected in the 
-7 control cell line, at 220 kDa, 36 kDa, 72 kDa 
Marker set proteins were detected u
-p-RPS6
(Ser 235/236)
-mTOR, anti-ILK) antibodies. B) Cleavage fragments 
-3 were only detected in the 
 kDa. C)  Polypeptides corresponding to mTOR (80 kDa) 
 (36 kDa) were not detected under apoptotic conditions
ILK (59 kDa) and cleaved caspase
e apoptotic control (A/C).  β
of HOSCC cell lysates in all blots.
39 
 
nder standard 
 and anti-
apoptotic control 
, 
-3 (17 – 27 kDa) 
-actin was used to 
 
40 
 
 
Figure 2.5: Relative expression of major protein markers identified for the mTOR/mTORC1 
signalling pathway under standard tissue culture conditions (Serum +). Protein 
expression levels for marker set proteins were determined by semi-quantitative 
densitometric analysis, and expressed as a percentage of the MCF-7 cell line. The 
WHCO series was found to express differential levels of proteins contained in 
the marker set. As a general trend, HOSCC cells were high expressers of mTOR, 
mATG-13 and ILK, but either moderate or high expressers of p-RPS6
(Ser 235/236)
. 
Under these conditions, HOSCC cells were also low expressers of mTORβ and 
cleaved caspase-3, but transitioned to high cleaved caspase-3 expressers under 
apoptotic conditions (as see in the A/C control). Apoptotic conditions also lead 
to a shift in the expression of other marker set proteins, where HOSCC cells 
became low expressers of mTOR, p-RPS6
(Ser 235/236)
 and mATG-13, or high 
expressers of ILK. The presence of any significant difference is indicated 
graphically by the ‘*’ symbol. 
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Table 2.1: Summary of protein expression levels and cell line trends for major mTOR pathway intermediates in HOSCC 
cells.  
 
Protein 
Molecular 
Weight 
(kDa) 
Cell Line 
 
 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
 
 Serum + Serum + Serum + Serum + A/C Serum + Serum + 
mTOR 220 High * Low High High Low High High 
mTORβ 80 Low Low 
Not 
Present 
Not 
Present 
Not 
Present 
Not 
Present 
Low 
p-RPS6 
(Ser 235/236)
 
36 Med Med High High Low * Low High 
mATG-13 72 High High * Low High Low High High 
ILK 59 High High High * High High * High High 
Cleaved 
Caspase-3 
17 - 28 Low Low Low Low High Low Low 
 
Key: Low = 0 – 45 %; Medium (Med) = 46 – 75 %; High = 76 – 100 % (and above). Protein expression levels are based on the Hager et al., (2011) 
classification system for analyses of mTOR and p-RPS6 proteins (see Materials and Methodology, Section 2.2.10). The use of a star (*) symbol 
and red text represents a statistically significant difference, when compared to MCF-7 using a Student’s t-test, where p < 0.05 (see Appendix D, 
Table D1 and D2 for a complete statistical report). (Serum + = standard tissue culture conditions; A/C = Apoptotic control). 
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2.4. Discussion 
 
2.4.1. Elevated mTOR expression and enhanced mTORC1 signalling are common 
features of the mTOR pathway in HOSCC cells 
 
The mTOR pathway forms part of a composite signalling network regulating essential 
cellular processes, such as metabolism, transcription, translation and autophagy induction, by 
integrating signalling information from numerous sources (Schmelzle and Hall, 2000). 
Through the action of mTORC1, mTOR regulates various signal transduction pathway 
intermediates controlling these processes (Foster and Fingar, 2010; Dobashi et al., 2011). In 
order to delineate the route of signal transmission through the mTOR pathway and 
understand how those signals govern autophagy induction in HOSCC cells, it was necessary 
to monitor the protein expression of key pathway intermediates associated with both mTOR 
and autophagy induction (see Figure 2.1. for an illustration of these pathway intermediates). 
By monitoring these select cellular proteins, we established an information-rich reporter 
system conveying specific signalling information about the mTOR pathway and mTORC1-
dependent autophagy regulation. Henceforth, we refer to this reporter system as a marker set 
of proteins. 
 
All protein markers were detected in HOSCC cells under standard tissue culture conditions. 
This means that HOSCC cells express all relevant mTOR, autophagy and integrin-triggered 
signal transduction intermediates, as well as that the marker set can be detected efficiently 
under conditions that represent standard cell growth. Establishing the expression of major 
pathway intermediates under these conditions was an important prerequisite for later 
experiments in this investigation to proceed. This is because the protein expression levels 
detected here serve as a baseline of comparison for subsequent changes arising from any 
manipulation of standard tissue culture conditions. Furthermore, by establishing relative 
levels of HOSCC protein expression through comparison with the MCF-7 cell line (rather 
than to a continuous oesophageal cell line, such as HET-1A), we can find similarities within 
the corruption of the mTOR signalling pathway in solid epithelial carcinomas. We believed 
that the HET-1A cell line was not appropriate for comparative analysis during this 
investigation. This was because HET-1A cells do not truly represent untransformed or 
physiologically ‘normal’ oesophagus (Jankowski et al., 1995; Underwood et al., 2010), and 
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most importantly, the status of the mTOR pathway and mTOR protein expression is currently 
unknown in these cells.  
 
The MCF-7 cell line therefore provides a more suitable comparison as MCF-7 cells are 
understood to over-express the mTOR protein kinase (Hagner et al., 2009) and display 
elevated signalling through mTORC1. Alterations of the mTOR pathway in MCF-7 cells was 
found to be a consequence of an amplification in the S6K1 gene (Bӓrlund et al., 2000a; 
Bӓrlund et al., 2000b), as well as a result of activating mutation affecting the p110 subunit of 
PI3K (Bachman et al., 2004; deGraffenried et al., 2004). Mutation of PI3K leads to a 
constitutively active PI3K/PKB signalling pathway. These alterations enhance mTOR 
signalling as the PI3K/PKB pathway is the canonical upstream regulator of the mTOR 
pathway, and p70S6K is a downstream target of mTORC1. Therefore, the MCF-7 cell line 
represents a more appropriate control cell line for comparative analysis. 
 
Semi-quantitative densitometric analysis of marker set protein expression revealed HOSCC 
cells express similarly high levels of mTOR and mTORC1 signalling compared to MCF-7 
cells (Figure 2.5). Ectopic mTOR expression and aberrant mTORC1 signalling has been 
reported in poorly- and well-differentiated ESCC cells of Chinese origin (Hou et al., 2007; 
Hirashima et al., 2012), where atypical functioning of the mTOR/mTORC1 signalling 
pathway is associated with the progression of solid tumours. Since HOSCC cells were found 
to parallel these findings, it is reasonable to suggest that aberrant mTOR/mTORC1 signalling 
plays a similar role in HOSCC of South African origin.  
 
A high instance of mTORC1 signalling does not detract from HOSCC cells exhibiting a high 
basal rate of autophagy induction under standard tissue culture conditions. At first, this seems 
incongruous, since mTORC1 signalling typically inhibits autophagy; however autophagy is 
reported to be upregulated in many solid tumours, including EC9706 ESCC cells (Kondo et 
al., 2005; Liu et al., 2011). Enhanced autophagy induction is thought to provide a selective 
survival advantage by providing resistance to chemotherapeutic agents and increasing tumour 
aggressiveness through the provision of essential metabolites and energy under stress (Bursh 
et al., 1996; Kanzawa et al., 2004; Longo et al., 2008). Considering that HOSCC cells 
display enhanced cell survival and anoikis resistance (Fanucchi and Veale, 2009; Fanucchi 
and Veale, 2011), increased basal autophagy may be another component facilitating these 
events. 
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HOSCC cells also exhibited increased potential for mechanotransduction through high 
expression of the promiscuous, integrin-triggered protein kinase; ILK. These findings were in 
agreement with data previously reported for HOSCC cells by Driver and Veale (2006). ILK 
is known to play a central role in numerous intracellular signalling pathways affecting 
mTOR/mTORC1 signalling, such as the PI3K/PKB and Wnt signalling pathways (Wu and 
Dedhar, 2001). Therefore, an increased propensity for ILK-based signalling combined with 
ectopic mTOR protein expression may contribute towards transformation and tumourigenesis 
in HOSCC cells, and provide a rational basis to consider the impact of adhesion-based signal 
transduction during mTORC1-dependent autophagy regulation. 
 
2.4.2. Expression of the 80 kDa mTORβ splicing isoform in HOSCC may be one 
explanation for increased signalling through mTORC1 
 
An 80 kDa splicing variant of mTOR, termed mTORβ by Panasyuk et al. (2009), was 
discovered in two HOSCC cells, namely WHCO1 and WHCO3. After an extensive search of 
the available literature, mTORβ expression is currently only confirmed in HEK-293 cells 
and, to our knowledge; this is the only report of mTORβ in HOSCC, as well as MCF-7 cells. 
The WHCO1 and WHCO3 cell lines were the only HOSCC’s to exhibit the lowest mTOR 
protein expression, as well as moderate mTORC1 signalling. Since mTORβ is expressed in 
these cell lines only, mTORβ may compensate for reduced mTOR protein expression and 
function to maintain elevated mTORC1 signalling. Panasyuk et al. (2009) do report that 
mTORβ is capable of interacting with both Raptor (of mTORC1) and Rictor (of mTORC2) in 
vitro, and so may readily participate in established mTOR pathway functions, such as 
phosphorylating p70S6K, 4E-BP1 and PKB. Therefore, HOSCC cells expressing mTORβ 
will likely gain an advantage to mTORC1-dependant signalling events. 
 
mTORβ is not expressed in the SNO cell line, however, which possesses a high mTOR 
protein expression, but has a low instance of mTORC1 signalling. This discrepancy between 
WHCO1, WHCO3 and SNO cell lines may indicate the presence of functionally crippling 
mutations affecting the mTOR gene within the SNO cell line, or hint at the presence of other 
common alterations affecting upstream or downstream mTOR pathway components 
(reviewed by Pópulo et al., 2012). Therefore, the expression of mTORβ (depicted in Figure 
2.6 in HOSCC cells may be a significant discovery as its presence may indicate a further 
corruption affecting the mTOR signalling pathway in HOSCC.  
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Figure 2.6: Schematic representation of the 80 kDa mTORβ splicing isoform compared to 
the well characterised 220 kDa mTOR protein kinase. mTORβ is composed of 
706 amino-acids, in antithesis to the larger 220 kDa mTOR protein kinase, which 
is composed of 2 549 amino-acids. mTORβ retains an intact FRB, RD and FATC 
domains with a notable decrease in amino-acids comprising HEAT-repeat and 
FAT domains. (Adapted from Fingar and Blenis 2004, and Panasyuk et al., 2009). 
 
In conclusion, monitoring major mTOR pathway intermediates is an effective means of 
following the mTOR signalling pathway in HOSCC cells. By combining mTOR, p-RPS6(Ser 
235/236)
, mATG-13, ILK and cleaved caspase-3 into as a set of protein markers, one establishes 
an information-rich reporter system conveying specific information about the mTOR 
pathway, the influence of mTORC1 on autophagy induction, as well as the potential for 
adhesion-based signal transduction. Through the use of these key pathway intermediates, we 
have established that the mTOR protein is ectopically expressed, that there is enhanced 
mTORC1 signalling and that an elevated rate of basal autophagy induction are common 
features of HOSCC cells. Importantly, by establishing marker set protein expression levels 
under standard tissue culture conditions, these relative protein concentrations can be used as a 
base line for further experimentation. This effectively allows for the comparison of protein 
expression levels under different tissue culture conditions, which forms the basis for the next 
chapter of this investigation.  
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CHAPTER 3 
 
3. INVESTIGATION OF THE mTOR SIGNALLING NETWORK IN 
HOSCC CELLS 
 
3.1. Introduction 
 
A survey of the current literature shows that extracellular-originating signals may be either 
agonistic or antagonistic towards the mTOR signalling pathway (Sarbassov et al., 2005b; 
Corradetti and Guan, 2006; Sabatini, 2006; Shor et al., 2009; Caron et al., 2010). Soluble 
mitogens, such as growth factors and amino-acids, activate mTORC1 under conditions of 
high abundance (Sarbassov et al., 2005b; Corradetti and Guan, 2006; Sabatini, 2006). 
However, hypoxia, hyper-osmotic pressure, energy depletion, viral infection, as well as 
reactive oxygen species (ROS) and DNA damaging agents, may cause cellular stress 
inhibiting the activation of mTORC1 (Corradetti and Guan, 2006; Shor et al., 2009; Caron et 
al., 2010). While the influence of each is clearly important for the specific regulation of 
mTOR within the broader context of mammalian systems (see Table 3.1 summarising the 
effects of major agonists and antagonists on mTORC1 activation), this set of analyses focuses 
mainly on those factors influencing the ability of mTORC1 to regulate autophagy induction 
in HOSCC cells.  
 
It is well established that mitogenic stimuli derived from growth factors and amino-acids 
influence homeostasis by augmenting cell growth and proliferation, as well as by triggering 
autophagy as a cell survival response when absent (Levine and Klionsky, 2004; Zustiak et al., 
2008; Burman and Ktistakis, 2010; Wang and Levine, 2010).  Since mitogenic signalling may 
directly affect the intracellular signalling pathways regulating growth and proliferation 
processes, such as the PI3K/PKB, MAPK signalling cascade and mTOR signalling pathway 
(Seger and Krebs, 1995; Lemmon and Schlessinger, 2010), the contribution of these stimuli 
becomes a major focus of this investigation. While hypoxia, hyper-osmotic stress, ROS and 
energy depletion may also effect the activation of mTORC1, our understanding of 
mTOR/mTORC1 signalling dynamics leads us to believe that these influences are context-
dependant, and so would be standardized under standard tissue culture conditions.  
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Soluble mitogens therefore elicit biochemical signals that affect mTORC1 signalling through 
two main modes of regulation, forming what is generally accepted as canonical and non-
canonical mTOR regulation (Memmott and Dennis, 2009). Canonical mTOR regulation 
primarily involves input from the PI3K/PKB pathway and requires a PKB-dependant 
mechanism for mTORC1 activation. Input from the PI3K/PKB signalling pathway (shown in 
red) directly causes mTORC1 activation as depicted in Figure 3.1. Non-canonical mTOR 
regulation circumvents biochemical signals transmitted through the PI3K/PKB pathway, and 
so rather utilizes PKB-independent mechanisms (depicted in blue) to affect mTORC1 
(Memmott and Dennis, 2009).  
 
3.1.1. The canonical mTOR pathway utilizes a PKB-dependent mechanism 
 
In response to mitogenic stimuli elicited by RTK’s, intracellular propagation of biochemical 
signals ultimately influences mTOR signalling through PI3K/PKB signalling pathway (see 
Figure 3.1, Box A). PI3K is a lipid kinase activated by the binding of growth factors (such as 
EGF) to RTK’s (such as EGR – which is over-expressed in HOSCC cells) (Osaki et al., 2004; 
Driver and Veale, 2006), which phosphorylates phosphoinositides and activates PKB. This 
process is itself regulated by the tumour suppressor PTEN (Harrington et al., 2005). PKB is 
sequentially phosphorylated on of Thr 308 (by PDK1) and Ser 473 (by either ILK or 
mTORC2) resulting in its complete activation (Walker et al., 1998; Harrington et al., 2005). 
Since mTORC2 may also phosphorylate PKB(Ser 473), demonstrated both in vitro and in vivo 
(Sarbassov et al., 2005b), mTOR may regulate itself at this level in the form of a positive 
feedback loop. 
 
When active, PKB physically associates with, and thereby activates, numerous substrates; 
however the phosphorylation of TSC2 and PRAS40 are the most vital for mTORC1 
signalling in this canonical pathway (Inoki et al., 2002; Kovacina et al., 2003). TSC2 forms a 
heterodimeric complex with TSC1 that actively inhibits mTORC1. However, when 
phosphorylated by PKB on Ser 939 and Thr 1462, the GAP (GTPase-activating protein) 
activity of TSC1/TSC2 is inhibited – leading to the activation of the Rheb-GTPase (Manning 
et al., 2002). Consequently, Rheb may directly activate mTORC1 leading to downstream 
signalling through two main effector kinases: namely p70S6K and 4E-BP1. When activated, 
p70S6K may directly phosphorylate RPS6 at Ser 235/236, whereas phosphorylation of 4E-
BP1 leads to its functional inactivation, thus diminishing its inhibitory affect on eIF4E (Bai 
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and Jiang, 2010). Moreover, p70S6K may target mTOR itself creating another positive 
feedback loop (Bai and Jiang, 2010).  
 
Clearly, a lack of PI3K and PKB activation, as well as decreased inhibition of TSC1/TSC2 
and PRAS40 leads to a decrease in signalling through mTORC1, events necessary for the 
induction of autophagy. However, these events are mimicked during non-canonical mTOR 
regulation, where the availability of nutrients, growth factors and chemical inhibition of 
mTOR may induce an autophagic response.    
 
3.1.2. The non-canonical mTOR pathway functions independently of PKB 
 
3.1.2.1. Availability of essential nutrients and amino-acids 
 
The mTOR pathway is responsive to the availability of essential nutrients, such as amino-
acids found in standard tissue culture serum (like that of foetal calf origin); in particular to 
levels of the branched chain amino-acids leucine and isoleucine (see Figure 3.1, Box B). An 
increase in cellular concentrations of leucine and isoleucine was shown to induce 
phosphorylation of p70S6K and 4E-BP1 (Findlay et al., 2007). The molecular mechanisms 
responsible are thought to include MAP4K3 (demonstrated in serum deprived HeLa cells), 
however the class III PI3K (hVps34) may also be involved as hVps34 activates mTOR by a 
mechanism dependent on PI(3,4,5)P3 generation, but independent of TSC2 or Rheb (Byfield 
et al., 2005; Nobukuni et al., 2005).  
 
Despite strong support for these mechanisms accounting for mTOR activation, the recent 
discovery of Rag-GTPases as binding partners of Raptor have become a popular explanation 
for amino-acid-induced mTOR-stimulation (Sancak et al., 2008). Sekiguchi et al. (2001) used 
cells transfected with constitutively active and inactive Rag mutants, and identified four Rag 
proteins (Rag A-D), which function as heterodimers to promote the co-localization of Rheb 
with mTORC1. This demonstrated that Rag proteins are both necessary and sufficient for 
amino-acid activation of mTOR. Therefore, these four Rag proteins (Rag A-D) may provide 
the molecular connection responsible for transducing amino-acid-based stimuli to the mTOR 
signalling machinery.   
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3.1.2.2. Growth factors and other mitogens 
 
The mTOR signalling pathway may also be activated by the mitogen-activated protein kinase 
(MAPK) signal transduction cascade (see Figure 3.1, Box C). MAPK signalling is stimulated 
by known agonists present in tissue culture serum; such as growth factors, hormones and 
chemokines, which bind to cognate RTK’s and G-protein coupled receptors (GPCR’s) or 
directly activate protein kinase C (PKC) (McKay et al., 2007; Rozengurt, 2007). MAPK 
pathways consist of an initial GTPase-regulated kinase (a MAPKKK – such as RAS-GTPase) 
that activates a kinase intermediate (a MAPKK – such as RAF, MEKK) through a 
phosphorylation event, which in turn leads activation of downstream effector kinases (a 
MAPK – such as ERK and p90RSK) (McKay et al., 2007; Rozengurt, 2007). ERK and 
p90RSK are noteworthy as they participate in extensive pathway integration with the mTOR 
signalling network. At the upstream level, both ERK and p90RSK influence the TSC1/TSC2 
complex allowing for increased signalling through mTORC1.  
 
ERK and p90RSK may induce phosphorylation of Raptor (a defining protein subunit of 
mTORC1) promoting mTORC1 phosphorylation of p70S6K and 4E-BP1 (Foster et al., 2010; 
Carreire et al., 2011). Moreover, p90RSK may phosphorylate RPS6(Ser 235/236) (Roux et al., 
2007). This particular function of p90RSK becomes an issue of concern as p-RPS6(Ser 235/236) 
is used in this study as a marker for active mTORC1 signalling. 
 
3.1.3. Additional aspects of non-canonical mTOR regulation: specific inhibition with 
rapamycin 
 
Aberrant activation of mTOR signalling contributes towards much pathology, including 
tumourigenesis (Foster and Toschi, 2009). In light of this, mTOR has become an attractive 
therapeutic target with many clinical trials experiencing some success with modern analogues 
of its natural inhibitor, the macrolide ester rapamycin. Rapamycin, first isolated from the 
bacterium Streptomyces hygroscopicus, is a potent antifungal and immunosuppressive agent 
(Vézina et al., 1975). When rapamycin binds the intracellular receptor, FKBP12, rapamycin 
may inhibit the kinase activity of mTOR through interaction with the mTOR FRB domain 
(Brown et al., 1994). Rapamycin treatment decreases mTORC1 activity in a dose-dependent 
manner (Foster and Toschi, 2009) and therefore constitutes an additional level of complexity 
regulating mTOR signalling (see Figure 3.1, Box D). Hence, it would be irresponsible to 
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ignore this aspect of mTOR regulation as this may afford the opportunity to explore the 
implications of mTOR-specific inhibition as a therapeutic tool for the treatment of SCC 
affecting the human oesophagus.  
 
Therefore, with the aim of investigating the mTOR signalling network in HOSCC cells, we 
examined the unique contribution of soluble extracellular-originating stimuli that effectively 
support regulated cell growth and proliferation, under standard tissue culture conditions. This 
provides an opportunity to dissect the impact of canonical- and non-canonical modes of 
mTOR regulation in HOSCC cells known to over-express key biochemical receptors, such as 
EGFR. It also allows us to determine how specific modes of mTOR regulation impact 
mTORC1-dependant autophagy induction. Thus, the ability of HOSCC cells to modulate the 
signalling machinery inducing autophagy was examined through: i) negating canonical 
mTOR pathway regulation by specific inhibition of PI3K; ii) modulation of mTORC1 
signalling by withdrawal of essential growth factors, nutrients and amino-acids found in 
standard tissue culture serum; iii) specific inhibition of mTOR with rapamycin; and iv) the 
potential for signal integration between mTOR and MAPK pathways by specific inhibition of 
p90RSK.    
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Table 3.1: Major agonists and antagonistic factors known to influence the 
mTOR signalling network in mammalian systems. 
 
Agonist/ 
Antagonist 
Affect on 
mTORC1 
Activation 
Proteins 
Involved 
Molecular 
Mechanism 
Major 
References 
Growth 
Stimulators 
EGF, 
Insulin 
↑ 
PI3K, 
PKB, 
ERK, 
RSK 
Reduces TSC1/TSC2 
inhibition by 
phosphorylation of 
PKB, ERK and RSK 
Potter et al. 
(2002); 
Roux et al. 
(2004) 
Amino-acid 
Depletion 
Leucine, 
Isoleucine 
↓ 
Rheb, 
Raptor, 
hVps34, 
hVPS15 
Many competing 
hypotheses 
Hara et al. 
(1998); 
Gao et al. (2002) 
Hyperosmotic 
Stress 
Sorbitol, 
NACl 
↓ 
Not 
completely 
elucidated 
An unknown osmotic 
stress-induced 
phosphatase disrupts 
the mitochondrial 
protein gradient 
Parrott and 
Templeton 
(1999); 
Desai et al. 
(2002) 
ROS 
Peroxide, 
Thiol oxidants 
Unclear: 
↑ and ↓ 
Raptor, 
mTORC1 
May involve disulfide 
reduction of mTOR 
Bae et al. (1999); 
Sarbassov and 
Sabatini (2005a) 
Hypoxia 
Decreased 
oxygen supply 
↓ 
REDD1, 
HIF-1 
HIF-1-induced REDD1 
expression enhances 
TSC1/TSC2 inhibition 
of mTOR 
Hudson et al. 
(2002); 
Arsham et al. 
(2003) 
Energy 
Depletion 
Low ATP:ADP 
ratio 
↓ 
LKB1, 
AMPK 
Phosphorylation of 
AMPK increases 
TSC1/TSC2 activity 
Inoki et al. 
(2003b); 
Corradetti et al. 
(2004) 
Viral Infection 
Adenovirus, 
HCMV 
Unclear: 
↑ and ↓ 
Adenovirus; 
E4-ORF1, 
HCMV: 
EGFR 
Several virus-
dependant 
mechanisms 
proposed 
Kudchodkar et 
al. (2004); 
O’Shea et al. 
(2005) 
DNA 
damaging 
Agents 
Etoposide, 
Methyl 
methane-
sulfonate 
↓ 
p53, 
REDD1 
Upregulation of p53 
through 
several proposed 
mechanisms 
Tee and Proud 
(2000); 
Beuvink et al. 
(2005) 
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Figure 3.1: A simplified visual schematic of the mTOR signalling network. Important signal transduction pathways that influence signalling 
through mTORC1, as well as mTORC2, are depicted. Canonical upstream regulators of mTORC1, such as PI3K/PKB (Box A), are 
influenced by soluble mitogens like insulin and growth factors. In addition, non-canonical upstream regulators may influence 
mTORC1 activity; such as essential nutrients and amino-acids (Box B), MAPK-derived stimuli (Box C), rapamycin (Box D), as well as 
hypoxia, Wnt signals and energy status, either directly through physical interactions with mTOR/mTORC1 or indirectly through 
critical upstream nodes (Adapted from Soulard and Hall, 2007). 
A 
B 
D 
C 
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3.2. Materials and Methodology 
 
3.2.1. Tissue Culture of WHCO, MCF-7 and HEK-293 Cell Lines 
All cell lines were cultured as described previously in Chapter 2, Section 2.2.1. 
 
3.2.2. Sub-culture of WHCO, MCF-7 and HEK-293 Cell Lines 
As previously described (see Chapter 2, Section 2.2.2). 
 
3.2.3. Serum-free Tissue Culture 
Cell cultures were exposed to an environmental stress simulating starvation conditions so as 
to bring about a change in cell behaviour, and therefore a particular survival response. Since 
the removal of serum is a commonly used method used to achieve this in the literature 
(Avruch et al., 2009; Bai and Jiang, 2010), serum withdrawal was employed here. 
Consequently, cell cultures were allowed to proliferate under standard tissue culture 
conditions until 10 cm dishes reached a confluence of approximately 80 %. The medium was 
then aspirated and cell monolayer washed twice with PBS (37 °C) (Appendix A, 1.1.1). 
Subsequently, 10 ml fresh tissue culture medium lacking 10 % FCS was added. Tissue 
cultures were then incubated in a humid, 37 °C incubator with an atmosphere of 5 % CO2 in 
air for 24 hours. 
 
3.2.4. Antibodies 
As previously described (see Chapter 2, Section 2.2.3). 
 
3.2.5. Pathway Inhibition Studies 
 
3.2.5.1. Specific inhibition of PI3K with LY294002 
Vlahos et al. (1994) showed that LY294002, or 2-(4-morpholinyl)-8-phenyl-4H-1-
benzopyran-4-one, completely and specifically abolished Bovine brain phosphatidylinositol 
3-kinase activity (IC50 = 0.43 µg/ml; 1.40 µM). However, previous studies in the Cell biology 
Research Laboratory, University of the Witwatersrand, Johannesburg, observed that 20 µM 
LY294002 was the appropriate concentration required to induce PI3K-specific inhibition in 
HOSCC cells (Shaw Ph.D. Thesis, 2011).  
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Therefore, cell cultures were allowed to proliferate until 6 cm dishes reached a confluence of 
approximately 80 %. The medium was then aspirated and cell monolayer washed twice with 
PBS. Subsequently, 3 ml fresh tissue culture medium with 10 % FCS was added, containing a 
final concentration of 20 µM LY294002 (Sigma-Aldrich®, USA) (Appendix A, 1.8.1). 
HOSCC cells treated with 20 µM LY294002 were designated ‘L+’, while an untreated 
control (designated ‘L-‘) was simultaneously prepared. Tissue cultures were subsequently 
incubated in a humid, 37 °C incubator with an atmosphere of 5 % CO2 in air for 1 hour. 
Please note that all procedures for one set of experiments were performed using the same 
batch of FCS. 
 
3.2.5.2. Specific inhibition of mTOR with rapamycin 
Since very few studies have specifically looked at the affect of rapamycin treatment on the 
mTOR/mTORC1 signalling pathway in moderately differentiated HOSCC, the appropriate 
tissue culture conditions were chosen after considering the study performed by Hou et al. 
(2007). Hou et al. (2007) investigated the effects of rapamycin and siRNA against mTOR in 
poorly- (EC9706) and well-differentiated (Eca 109) ESCC cells. Here, changes in both 
mTOR and p70S6K mRNA and protein expression levels were detected in response to 20, 50 
and 100 nM concentrations of rapamycin for 6 and 24 hours, as these conditions were found 
to induce mTOR-specific changes to cell proliferation, survival and apoptosis in squamous 
cell carcinomas, specifically.  
 
Therefore, since a similar response in South African-derived HOSCC was expected, cell 
cultures were allowed to proliferate until 6 cm dishes (Nunc) reached a confluence of 
approximately 80 %. The medium was then aspirated and cell monolayer washed twice with 
PBS (37 °C). Subsequently, 3 ml fresh tissue culture medium with 10 % FCS was added, 
containing a final concentration of 0, 20, 50 and 100 nM rapamycin (Sigma-Aldrich®, USA) 
(Appendix A, 1.9.1). Tissue cultures were incubated in a humid, 37 °C incubator with an 
atmosphere of 5 % CO2 in air for 6 or 24 hours. Please note that all procedures for one set of 
experiments were performed using the same batch of FCS. 
 
3.2.5.3. Specific inhibition of p90RSK with BI-D1870 
Cell cultures were allowed to proliferate until 6 cm dishes reached a confluence of 
approximately 80 %. The medium was then aspirated and cell monolayer washed twice with 
PBS (37 °C). Subsequently, 3 ml fresh tissue culture medium with 10 % FCS was added, 
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containing a final concentration of 10 µM as described by Sapkota et al. (2007) (Appendix A, 
1.10.1). BI-D1870 was obtained from the Division of Signal Transduction Therapy, 
University of Dundee. Simultaneously, controls for each cell line containing 0.1 % DMSO 
were prepared. Tissue cultures were then incubated in a humid, 37 °C incubator with an 
atmosphere of 5 % CO2 in air for 30 min. Please note that all procedures for one set of 
experiments were performed using the same batch of FCS. 
    
3.2.6. Triton X-100-based Protein Extraction 
As previously described (see Chapter 2, Section 2.2.5). 
 
3.2.7. Protein Estimation 
As previously described (see Chapter 2, Section 2.2.6). 
 
3.2.8. SDS-PAGE (Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis) 
As previously described (see Chapter 2, Section 2.2.7). 
 
3.2.9. Western Immunoblot Analysis 
As previously described (see Chapter 2, Section 2.2.8). 
 
3.2.10. Image Capturing 
As previously described (see Chapter 2, Section 2.2.9). 
 
3.2.11. Laser Densitometry and Analysis of Relative Protein Expression 
Semi-quantitative densitometric analysis was used to determine protein expression across the 
WHCO series, as well as MCF-7 and HEK-293 cell lines, as previously described in Chapter 
2, Section 2.2.10. Additionally, both raw and worked densitometric data is available in 
Appendix C, Tables C6-C13. 
 
3.2.12. Statistical Analysis 
Results are expressed as the mean ± S.E. Statistical significance was determined by Student’s 
t-test for comparative analysis (see Appendix D, Table D3) using Sigma Plot®, Version 12.0 
(SPSS Science, Chicago, Illinois USA), where p < 0.05 indicates statistical significance. All 
experiments were repeated at least three times, unless otherwise indicated. 
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3.3. Results 
 
3.3.1. Specific inhibition of PI3K with LY294002 increased mTOR and ILK protein 
expression, but decreased p-RPS6(Ser 235/236) and mATG-13 in HOSCC cells 
 
Specific inhibition of PI3K with LY294002 did not visibly modulate the concentration of 
polypeptide bands indicative of mTOR (220 kDa), ILK (59 kDa) and cleaved caspase-3 (17 – 
27 kDa) (Figure 3.2, A and B). However, clearly visible changes in the concentration of 
polypeptides indicative of p-RPS6(Ser 235/236) (36 kDa)  and mATG-13 (72 kDa) were detected. 
In addition, multiple bands were observed in proximity to mATG-13 (Figure 3.2, A), while 
cleaved caspase-3 (17 – 27 kDa) was only visible in the WHCO6 apoptotic cell (A/C) control 
(Figure 4.5, B). 
 
Semi-quantitative densitometric analysis of single polypeptide bands revealed a change in 
relative protein expression levels across all WHCO cell lines in response to PI3K-specific 
inhibition with LY294002 (Figure 3.3). Levels of marker set protein expression were 
expressed as a percentage of the WHCO6 cell line (without LY294002 treatment; L-), since 
WHCO6 cells consistently expressed high levels of all major pathway intermediates detected 
under standard tissue culture conditions (established earlier in Chapter 2, Section 2.4). For 
this reason, the WHCO6 cell line was also used as a loading control enabling the comparison 
of protein expression between individual western blots, and is used as such throughout the 
rest of this investigation. 
 
By organising all signal transduction pathway intermediates into a table summarising changes 
in the levels of protein expression (such as that seen in Table 3.2), we observed that specific 
trends in protein expression emerged between the WHCO series of cell lines. In general, 
mTOR protein abundance was increased upon inhibition of PI3K; where HOSCC cells 
became high mTOR protein expressers. Only the WHCO6 was the exception to this trend. 
Similarly, WHCO1, WHCO3, WHCO5 and MCF-7 cells tended to increase ILK protein 
expression (with the exception of the WHCO6 and SNO cell lines); consequently maintaining 
elevated ILK in HOSCC cells. 
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In response to specific inhibition of PI3K, HOSCC cells became low p-RPS6(Ser 235/236)  
protein expressers; where WHCO1, WHCO5, WHCO6, SNO and MCF-7 cells commonly 
decreased p-RPS6(Ser 235/236) protein expression. However, this excluded the WHCO3 cell line, 
as p-RPS6(Ser 235/236) protein expression increased. Following this trend, mATG-13 protein 
expression remained moderate-to-high, despite HOSCC cells commonly decreasing cellular 
concentrations of dephosphorylated mATG-13. Only the WHCO5 cell line exhibited an 
increase for mATG-13 protein expression. Moreover, specific inhibition of PI3K with 
LY294002 was insufficient to induce an increase in cleaved caspase-3 protein expression in 
HOSCC cells.  
 
 
 
 
 
 
 
 A. 
B. 
 
Figure 3.2: Immunodetection of 
after specific inhibition of PI3K with LY294002. A)
abundance were detected for mTOR (220 kDa), 
for ILK (59 kDa) and mATG
was insufficient to induce cleavage of pro
was only detected in apoptotic cell (A/C contro
to demonstrate equal protein loading of 
20 μM LY294002; A/C
 
 
 
 
 
 
significant signal transduction intermediates
 Visible changes in polypeptide 
p-RPS6
(Ser 235/236)
-13 (72 kDa), in HOSCC cells. B) Specific inhibition of PI3K 
-caspase-3, as cleaved caspase
l). In both A) and B), β
HOSCC cell lysates. (L+/L
 = Apoptotic Cell control; CO6 = WHCO6). 
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Figure 3.3: Specific inhibition of PI3K alters the expression of key mTOR pathway 
intermediates in HOSCC cells. Semi-quantitative densitometric analysis of 
protein expression was determined relative to the WHCO6 (L
-
) cell line. As a 
common trend, HOSCC cells increased mTOR and ILK protein abundance, but 
decreased p-RPS6
(Ser 235/236)
 and mATG-13 expression. Cleaved caspase-3 
remained undetectable under these tissue culture conditions, and was only 
detectable in apoptotic control cells. Since not all western blots were repeated 
more than once, the significance of these data could not be calculated. (L- = 
Without PI3K-specific inhibition with LY294002; L+
 
= Including PI3K-specific 
inhibition with LY294002; A/C = Apoptotic Cell control). 
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Table 3.2: Summary of the protein expression levels obtained for significant mTOR signal transduction intermediates after 
specific inhibition of PI3K with LY294002. 
 
Protein Cell Line 
 
WHCO 1 WHCO 3 WHCO  5 WHCO 6 SNO  MCF-7 
 
↑/
↓ 
H/M/
L 
% ∆ 
↑/
↓ 
H/M/ 
L 
% ∆ 
↑/
↓ 
H/M/ 
L 
% ∆ 
↑/
↓ 
H/M/ 
L 
% ∆ 
↑/
↓ 
H/M/ 
L 
% ∆  
↑/
↓ 
H/M/ 
L 
% ∆ 
mTOR ↑ High 36.0 ↑ Low 228.6 ↑ High 50.8 ↓ High 
-
16.0 
↑ Med 17.1 ↑ High 68.0 
p-RPS6 
(Ser 235/236)
 
↓ Low 
- 
50.0 
↑ Low 140.0 ↓ Low 
-
76.6 
↓ Low 
-
62.0 
↓ Low 
-
93.2 
↓ Low 
-
94.3 
mATG-13 ↓ High 
- 
2.4 
↓ High 
- 
14.40 
↑ High 56.5 ↓ High 
-
14.0 
↓ High 
-
35.0 
↓ Med 
-
65.5 
ILK ↑ High 4.7 ↑ Med 0.010 ↑ Med 36.5 ↓ High 
-
21.0 
↓ High 
-
30.7 
↑ Med 20.7 
Cleaved 
Caspase-
3 
/ Low N.A. / Low N.A. / Low N.A. / Low N.A. / Low N.A. / Low N.A. 
 
Key: Low = 0 – 45 %; Medium (Med) = 46 – 75 %; High = 76 – 100 % (and above). Protein expression levels are based on the Hager et al., (2011) 
classification system for analyses of mTOR and p-RPS6 proteins (see Materials and Methodology, Section 3.2.11). Change in relative marker set protein 
expression is expressed as percent change (% ∆), designated by either positive (↑) or negative (↓) arrows. For the calculation of percent change, see 
Appendix B, Equation B1. The forward slash (/) symbol indicates that no change has occurred. 
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3.3.2. Serum withdrawal modulates the mTOR/mTORC1 pathway in HOSCC cells 
 
Removal of the growth stimulatory effects of serum visibly altered the protein expression of 
key mTOR pathway intermediates in HOSCC cells. Single polypeptide bands corresponding 
to mTOR (220 kDa), p-RPS6(Ser 235/236) (36 kDa), mATG-13 (72 kDa) and ILK (59 kDa) were 
detected, however the concentrations of mTOR and p-RPS6(Ser 235/236) was visibly diminished 
(Figure 3.4, A). Clear changes in the concentrations of mATG-13 and ILK polypeptide bands 
were not apparent. In addition, single polypeptide bands corresponding to cleaved caspase-3 
(17 – 27 kDa) were not detected in HOSCC cells under serum-free conditions, but were only 
present in WHCO6 apoptotic control (A/C) cells (Figure 3.4, B). β-actin (46 kDa) was also 
detected by western blot, where its uniform expression represented equal protein loading 
between the WHCO series of cell lines. 
 
Semi-quantitative densitometric analysis of single polypeptide bands revealed a change in 
relative protein expression levels across the WHCO series of cell lines in response to serum 
withdrawal after 24 hours (Figure 3.5). Levels of marker set protein expression were 
expressed as a percentage of the WHCO6 cell line (under standard tissue culture conditions; 
serum +), where protein expression between WHCO cell lines was determined to be low, 
moderate or high (see Materials and Methodology, Section 3.2.11 for an explanation of the 
Hager et al. (2011) classification system for protein expression). After organizing major 
signalling intermediates into a table summarising levels of protein expression, we noticed that 
specific trends emerged, both within the level of protein expression and between the WHCO 
series of cell lines (Table 3.3). 
 
In general, serum withdrawal induced HOSCC cells to decrease mTOR protein expression. A 
decrease in mTOR expression was observed in WHCO3, WHCO5, WHCO6 and MCF-7 
cells, which became moderate or low mTOR expressers. Notably, cells of the WHCO3 cell 
line significantly decreased mTOR protein expression (see Appendix D, Table D3 for a 
complete statistical analysis). In antithesis, cells of WHCO1 and SNO cell lines increased 
mTOR protein expression, where the increase in SNO cells was considered to be a significant 
change (a report of this statistical analysis is also available in Appendix D, Table D3).  
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All HOSCC cells experienced a decrease in RPS6(Ser 235/236) phosphorylation (clearly observed 
in Figure 3.5 and Table 3.3), where p-RPS6(Ser 235/236) expression changed to either moderate 
or low. Serum withdrawal significantly decreased p-RPS6(Ser 235/236) expression in WHCO3, 
WHCO6 and SNO cells (see Appendix D, Table D3 for a complete statistical analysis). As a 
result of this decrease for RPS6(Ser 235/236) phosphorylation in all HOSCC cells, mATG-13 
protein expression was generally increased (Figure 3.5 and Table 3.3). There was an increase 
in mATG-13 abundance in WHCO1, WHCO6 and SNO cell lines; however not in cells of the 
WHCO3 or WHCO5 lines. The change exhibited by mATG-13 in the WHCO3 cell line was 
considered to be a significant decrease (a report of this statistical analysis is available in 
Appendix D, Table D3). 
 
It was also apparent that HOSCC cells generally decreased ILK protein expression in 
response to serum withdrawal (seen in Figure 3.5 and Table 3.3). A significant decrease was 
observed in WHCO3 and WHCO6 cell lines (see Appendix D, Table D3 for all statistical 
analyses), however despite this trend, ILK protein expression remained high in HOSCC cells. 
Only SNO cells increased ILK protein abundance. Furthermore, cleaved caspase-3 remained 
undetectable in the WHCO series of cell lines in response to serum withdrawal. Therefore, 
HOSCC cells were classified as low cleaved caspase-3 expressers under serum-free tissue 
culture conditions. 
 
Besides for these trends in marker set protein expression, we noticed common behavioural 
responses regarding the mTOR pathway between WHCO cell lines. Cell lines were observed 
to behave in a similar manner in response to serum withdrawal, although there were some 
outliers. The first type of behavioural response was shown by the WHCO3 and WHCO5 cell 
lines because they decreased the expression of all proteins monitored in the marker set. The 
second type of behavioural response was displayed by the WHCO1, WHCO6 and SNO cell 
lines as they followed the same trends in p-RPS6(Ser 235/236) and mATG-13 expression, but 
only differed by one protein trend (either mTOR or ILK expression) in response to serum 
withdrawal. Consequently, HOSCC cells conformed to different types of protein expression 
trends, as well as displayed different behavioural responses, when growth stimulatory signals 
from serum were removed.   
 A. 
B. 
Figure 3.4: Immunodetection of
response to the withdrawal of serum
marker set proteins 
mTOR, p-RPS6
(Ser 235/236)
the MCF-7 cell line, at 220, 36, 72
fragments indicative of activated caspase
cell (A/C) control at 17, 19 and 28 kDa. 
demonstrate equal protein loading of 
culture conditions; S
Apoptotic Cell control
 
 
 
 
 critical signal transduction intermediates
. A) Single polypeptide bands signifying 
were detected after serum-free tissue culture for 24 hours. 
, mATG-13 and ILK were detected in HOSCC cell
 and 59 kDa, respectively. 
-3 were only detected in 
In both A) and B), β
HOSCC cell lysates. (S+ = 
- = serum-free tissue culture conditions for 24 hours; A/C
). 
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Figure 3.5: Serum withdrawal modulates the protein expression of key signal transduction 
intermediates of the mTOR pathway in HOSCC cells. Semi-quantitative 
densitometric analysis of protein expression for each signalling intermediate 
contained within the marker set is expressed as a percentage of the WHCO6 cell 
line. A visible change in protein expression can be seen for marker set proteins 
when each is detected under serum-free tissue culture conditions after 24 hours. 
As a general trend, HOSCC cells decreased mTOR, p-RPS6
(Ser 235/236)
 and ILK 
protein expression, but increased mATG-13 protein expression. The cleavage 
fragments indicating activated caspase-3 were not detected under these 
conditions, indicating that serum withdrawal for this time period is insufficient to 
induce an apoptotic response. Since all western blots were repeated more than 
once, the significance of these data could be determined. Significant difference is 
therefore indicated graphically through the use of the star (*) symbol. (S+ = 
Standard tissue culture conditions; S- = serum-free tissue culture conditions for 
24 hours; A/C = Apoptotic Cell control). 
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Table 3.3: Summary of the protein expression levels for key mTOR signal transduction intermediates in HOSCC cells after serum 
withdrawal for 24 hours.  
 
Protein Cell Line 
 
WHCO1 WHCO3 WHCO 5 WHCO6 SNO MCF-7 
 
↑/
↓ 
H/M/
L 
% ∆ 
↑/
↓ 
H/M/
L 
% ∆ 
↑/
↓ 
H/M/
L 
% ∆ 
↑/
↓ 
H/M/
L 
% ∆ 
↑/
↓ 
H/M/
L 
% ∆ 
↑/
↓ 
H/M/
L 
% ∆ 
mTOR ↑ High 28.6 
* 
↓ 
* 
Low 
* 
-80.9 
↓ Med -46.2 ↓ Med -45.0 
* 
↑ 
* 
High 
* 
13.0 
↓ High -39.1 
p-RPS6 
(Ser 235/236)
 
↓ Low -36.1 
* 
↓ 
* 
Low 
* 
-98.8 
↓ Med -27.0 
* 
↓ 
* 
Low 
* 
-60.0 
* 
↓ 
* 
Low 
* 
-30.0 
↓ Med -25.6 
mATG-
13 
↑ Med 44.7 
* 
↓ 
* 
Low 
* 
-79.5 
↓ Low -45.8 ↑ High 26.0 ↑ Med 0.00 ↑ High 153.5 
ILK ↓ High -18.5 
* 
↓ 
* 
Med 
* 
-27.3 
↓ High -15.3 
* 
↓ 
* 
High 
* 
-13.0 
↑ High 2.02 ↓ Med -23.9 
Cleaved 
Caspase-
3 
/ Low N.A. / Low N.A. / Low N.A. / Low N.A. / Low N.A. / Low N.A. 
 
Key: Low = 0 – 45 %; Medium (Med) = 46 – 75 %; High = 76 – 100 % (and above). Protein expression levels are based on the Hager et al., (2011) 
classification system for analyses of mTOR and p-RPS6 proteins (see Materials and Methodology, Section 3.2.11). Change in relative marker set protein 
expression is expressed as percent change (% ∆), designated by either positive (↑) or negative (↓) arrows. For the calculation of percent change, see 
Appendix B, Equation B1. The use of a star (*) symbol, as well as red text, represents a statistically significant difference when compared to WHCO6 cell 
line, determined using a Student’s t-test; where p < 0.05 (see Appendix D, Table D3 for a statistical report). The forward slash (/) symbol indicates that no 
change has occurred. 
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3.3.3. Rapamycin treatment differentially modulates mTOR, mATG-13 and ILK 
expression, but abolishes RPS6(Ser 235/236) phosphorylation in HOSCC cells 
 
Since the PI3K/PKB pathway is the most commonly accepted route for biochemical signals 
affecting the mTOR pathway (Hay, 2005; Bhasker and Hay, 2007; Bai and Jiang, 2010), we 
believed it was first necessary to assess the influence of soluble mitogenic signals transmitted 
from PI3K to mTOR/mTORC1. Only after these mechanisms of canonical mTOR regulation 
were established in HOSCC cells did we think it appropriate to examine the effects of 
relevant non-canonical modes of mTOR regulation, such as nutrient deprivation and 
rapamycin treatment. For these reasons we now continue with the second part of this analysis 
- specific inhibition of the mTOR signalling pathway with rapamycin.  
 
After exposing HOSCC cells to rapamycin, we monitored the same set of key protein 
markers by western blotting (Figure 3.6). However, only cells of the WHCO6 (Figure 3.6, A) 
and SNO lines (Figure 3.6, B) were selected for rapamycin treatment. This was because the 
WHCO6 cell line is currently used as an important internal control (the reader is reminded 
that the WHCO6 cell line is standard carried through separate experiments providing a means 
to compare protein expression between different western blots). Additionally, WHCO6 and 
SNO cell lines conform to unique behavioural and protein expression trends (see Section 
3.3.1) and so characterise the diversity present within the HOSCC model system. Since these 
cell lines are an appropriate representation of the WHCO series, we monitored the marker set 
in response to rapamycin within these HOSCC cells, only.    
 
Exposure to rapamycin, for either 6 or 24 hours, noticeably altered polypeptides 
corresponding to mTOR (220 kDa), p-RPS6(Ser 235/236) and mATG-13 (72 kDa), but not ILK 
(59 kDa) (Figure 3.6, A - C). The uniformity of β-actin polypeptide bands (46 kDa) suggest 
that an equal amount of protein was loaded for all HOSCC cell lysates. Furthermore, since 
the concentration of β-actin did not change, this seems to indicate that rapamycin does not 
affect β-actin gene expression in HOSCC cells. 
 
Semi-quantitative densitometric analysis confirmed that rapamycin altered marker set protein 
expression levels within HOSCC cells, at both 6 and 24 hours (Figure 3.7, A - D). Changes in 
protein expression were expressed as percentage of the WHCO6 cell line not treated with 
rapamycin (0 nM). These data show that specific inhibition of mTOR resulted in the 
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differential modulation of mTOR protein expression in HOSCC cells (Figure 3.7, A). As the 
concentration of rapamycin increased, so too did the level of mTOR protein expression in 
WHCO6 and MCF-7 cell lines. This trend was not observed in the SNO cell line, however. 
We could not identify any definitive protein expression trend for mTOR in the SNO cell line 
as the expression of mTOR varied greatly in response to rapamycin treatment. Despite this, 
mTOR protein expression was generally higher in HOSCC cells treated for 6 hours than 
HOSCC cells treated for 24 hours, but generally lower after treatment in comparison to 
HOSCC cells not exposed to rapamycin.  
  
Semi-quantitative densitometric analysis also showed that rapamycin treatment decreased p-
RPS6(Ser 235/236) protein expression in all HOSCC cells  (Figure 3.7, B). These changes 
occurred in a dose-dependent manner for each cell line, producing an identical decreasing 
trend in RPS6(Ser 235/236) phosphorylation at both 6 and 24 hours. Normally, a steep rise in 
mATG-13 concentration would accompany decreasing RPS6(Ser 235/236) phosphorylation 
(Loewith et al., 2002). However, with an increase in rapamycin concentration, the protein 
expression of mATG-13 protein expression generally decreased in HOSCC cells, somewhat 
resembling a dose-dependent decrease for mATG-13 expression in WHCO6 and SNO cell 
lines (Figure 3.7 C). A steep change in mATG-13 protein expression was observed at 24 
hours for WHCO6 cells, whereas this trend occurred at both 6 and 24 hours for the SNO cell 
line.  
 
Furthermore, inhibition of mTOR with rapamycin did not modulate ILK protein expression 
(Figure 3.7, D). As the concentration of rapamycin increased, ILK protein expression 
remained relatively constant in both WHCO6 and SNO cell lines, as well as MCF-7 cells. A 
noticeable change was only observed in cells of WHCO6 cell line at 6 hours post treatment, 
where ILK seemed to experience a dose-dependent decrease in protein expression. However, 
since not all western blots were performed more than once, an accurate statistical analysis 
could not be performed. Consequently, this affected our reporting of significant alterations in 
marker set protein expression. However, we did succeed in showing that specific inhibition of 
mTOR modulates key mTOR pathway intermediates, especially abolishing RPS6(Ser 235/236) 
phosphorylation in HOSCC cells (shown in Table 3.4). 
 A. 
 
B. 
 
 
C. 
Figure 3.6: Immunodetection of 
intermediates in HOSCC cells 
rapamycin. Increasing concentrations of rapamycin 
induced visible change
to mTOR (220 kDa), p
(72 kDa), but not ILK
WHCO6 (A), SNO (B) and MCF
(46 kDa) demonstrate
cell lysates. HOSCC cells are clearly susceptible to 
rapamycin treatment as exposure modulated mTOR and 
p-RPS6
(Ser 235/236)
 protein concentrations, even at 
concentrations as low as 20 nM
mATG-13 polypeptides
in mTORC1 signalling and 
unaffected by rapamycin treatment
cells were treated with rapamycin; nM = nanomolar 
concentration of rapamyc
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Figure 3.7: Effects of rapamycin on the protein expression of key signal transduction 
pathway intermediates. A) mTOR protein expression increased in a dose-
dependent manner in cells of the WHCO6 line, however this trend was not 
evident in SNO or MCF-7 cells. B) RPS6
(Ser 236/236)
 phosphorylation was also 
completely abolished in all HOSCC cells, occurring in a  dose-dependent 
manner. C) A trend increase in mATG-13 protein expression was observed only 
in the SNO cell line, while there was no clear pattern for mATG-13 expression 
in the WHCO6 cell line 6 or 24 hours post rapamycin treatment. D) ILK protein 
expression was generally unaffected after rapamycin treatment and remained 
high in cells of the SNO line. However, a dose-dependent decrease for ILK 
expression was observed 6 hours post treatment in WHCO6 cells. Since not all 
western blots were repeated more than once, the significance of these data 
could not be determined. (hr = indicates the amount of hours cells were 
treated with rapamycin; nM = the specific nanomolar concentration of 
rapamycin used). 
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Table 3.4: Summary of protein expression levels obtained after specific inhibition of mTOR with rapamycin. 
Protein 
Rapamycin Treatment 
Conditions 
Cell Line 
 
 WHCO6 SNO MCF-7 
 
Time 
(hr) 
Concentration 
(nM) 
↑/↓ H/M/L % ∆ ↑/↓ H/M/L % ∆ ↑/↓ H/M/L % ∆ 
mTOR 
6 
20 ↑ High 35.00 ↓ Med -19.23 ↓ High 
-
15.91 
50 ↑ High 63.00 ↓ Low -43.59 ↑ High 10.61 
100 ↑ High 98.00 ↓ Med -14.10 ↑ High 4.55 
24 
20 ↓ High -20.00 ↑ High 26.92 ↑ High 4.55 
50 ↓ High -5.00 ↓ Med -26.92 ↑ High 2.27 
100 ↓ High -2.00 ↓ Low -70.51 ↓ High -7.58 
p-RPS6 
(Ser 235/236)
 
6 
20 ↓ Low -61.00 ↓ Low -55.29 ↓ Low 
-
91.67 
50 ↓ Low -70.00 ↓ Low -62.35 ↓ Low 
-
98.81 
100 ↓ Low -81.00 ↓ Low -68.24 ↓ Low 
-
98.81 
24 
20 ↓ Low -86.00 ↓ Low -98.82 ↓ Low 
-
97.62 
50 ↓ Low -93.00 ↓ Low -98.82 ↓ Low 
-
97.62 
100 ↓ Low -98.00 ↓ Low -96.47 ↓ Low 
-
96.43 
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Table 3.4 continued 
Protein 
Rapamycin Treatment 
Conditions 
Cell Line 
 
 WHCO6 SNO MCF-7 
 
Time 
(hr) 
Concentration 
(nM) 
↑/↓ H/M/L % ∆ ↑/↓ H/M/L % ∆ ↑/↓ H/M/L % ∆ 
mATG-13 
6 
20  ↓ Med -35.00 ↑ High 29.03 ↑ Low 56.00 
50  ↓ Low -74.00 ↑ High 49.68 ↑ Low 12.00 
100  ↑ High 19.00 ↓ High -15.48 ↑ Low 72.00 
24 
20  ↑ High 69.00 ↑ High 18.71 ↑ Low 8.00 
50  ↓ Low -84.00 ↑ High 40.65 ↓ Low -24.00 
100  ↓ Low -80.00 ↓ High -38.06 ↑ High 300.00 
ILK 
6 
20  ↓ High -13.00 ↑ High 10.28 ↑ High 81.93 
50  ↓ Med -34.00 ↑ High 3.74 ↑ High 42.17 
100  ↓ Low -56.00 ↓ High -15.89 ↑ High 53.01 
24 
20  ↓ High -4.00 ↓ High -15.89 ↑ High 51.81 
50  ↓ High -14.00 ↑ High 18.69 ↑ High 25.30 
100  ↑ High 27.00 ↓ High -1.87 ↑ High 181.93 
 
Key: Low = 0 – 45 %; Medium (Med) = 46 – 75 %; High = 76 – 100 % (and above). Protein expression levels are based on the Hager et al., (2011) 
classification system for analyses of mTOR and p-RPS6 proteins (see Materials and Methodology, Section 3.2.11). Change in relative marker set 
protein expression is expressed as percent change (% ∆), designated by either positive (↑) or negative (↓) arrows. For the calculation of percent 
change, see Appendix B, Equation B1. The use of a forward slash (/) symbol indicates that no change has occurred. 
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3.3.4. RPS6(Ser 235/236) is phosphorylated by mTORC1 in the absence of 
MAPK/p90RSK signals in HOSCC cells 
 
Although recent reports suggest that BI-D1870 is an effective and specific inhibitor of 
p90RSK signalling (Kang et al., 2007; Chen and MacKintosh, 2009; Xian et al., 2009), we 
needed to establish that BI-D1870 could produce an observable decrease in RPS6(Ser 235/236) 
phosphorylation. Therefore, we specifically inhibited p90RSK in HEK-293 cells with BI-
D1870 according to the manufacturer’s instructions (see Materials and Methodology, Section 
3.2.5.3). Through western blotting we observed that only the abundance of p-RPS6(Ser 235/236) 
(36 kDa) polypeptides, and not mTOR (220 kDa), were affected (Figure 3.8, A). β-actin (46 
kDa) was also detected, where its expression was found to be uniform, thus representing 
equal protein loading of the HEK-293 cell lysates. 
 
Once we established that this concentration of BI-D1870 could effectively reduce p-RPS6(Ser 
235/236)
 protein expression in commonly used substrate-dependent cells of mammalian origin, 
we used BI-D1870 to inhibit p90RSK signalling in the WHCO series of cell lines. Here, the 
WHCO5, WHO6, and SNO cell lines were used as representatives of HOSCC. 
Immunodetection of mTOR (200 kDa) and p-RPS6(Ser 235/236) (36 kDa) polypeptides revealed 
that inhibition of p90RSK with the same concentration of BI-D1870 produced no clear 
change in mTOR or p-RPS6(Ser 235/236) protein abundance (Figure 3.8, B). This lack of change 
was corroborated by the detection of identical β-actin polypeptide bands (46 kDa), which 
indicate consistency during protein loading of HOSCC cell lysates. 
  
Semi-quantitative densitometric analysis of mTOR and p-RPS6(Ser 235/236) polypeptide 
revealed that only RPS6(Ser 235/236) phosphorylation, and not mTOR protein expression levels, 
were decreased in HEK-293 cells following specific inhibition of p90RSK with BI-1870 
(Figure 3.9). However, similar modulation of mTOR and p-RPS6(Ser 235/236) protein expression 
levels was not observed in HOSCC cells. mTOR and p-RPS6(Ser 235/236) protein expression did 
not decrease appreciably in HOSCC cells. In fact, besides these minimal changes, p-RPS6(Ser 
235/236)
 protein expression increased in the SNO cell line. Furthermore, no noteworthy changes 
to mTOR or p-RPS6(Ser 235/236) protein expression were observed in the MCF-7 cell line. 
Consequently, when p90RSK signalling was inhibited with BI-D1870, HOSCC cells were 
observed to generally decrease both mTOR and p-RPS6(Ser 235/236) protein expression (see 
Table 3.5 for a summary of these trends).  
 A 
B 
Figure 3.8: Immunodetection of
p90RSK with BI-D1870. A)
reduced the concentration of 
HEK-293 cell line. However, n
Similarly, specific inhibition
concentration of m
HOSCC cells. By including the detection of 
equal amounts of protein 
cells; DMSO = cells treated with 0.1 % dimethyl sulphoxide; BI = cells treated with 
the p90RSK-sepcific inhibitor BI
 
 
 
 
 
 
 
 
 
 
 
 critical signal transduction intermediates
 Specific inhibition of p90RSK with BI
p-RPS6
(Ser 235/236)
 (36 kDa) polypeptide band in the 
o clear change in mTOR (220 kDa) was observed. 
 of p90RSK with BI-D1870 did not visibly reduce
TOR (220 kDa) or p-RPS6
(Ser 235/236)
 (36 kDa) polypeptides in 
β-actin (46 kDa), we demonstrate that 
were loaded for all HOSCC cell lysates
-D1870; CO6 = WHCO6). 
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 after inhibition of 
-D1870 visibly 
B) 
 the 
. (U = Untreated 
75 
 
 
Figure 3.9: Relative protein expression levels for mTOR and p-RPS6
(Ser 235/236)
 after specific 
inhibition of p90RSK with BI-D1870. Semi-quantitative densitometric analysis 
revealed that HOSCC cells decrease mTOR protein expression minimally after 
inhibiting p90RSK signalling with BI-D1870, in comparison to an empty vector 
containing only 0.1 % DMSO. p-RPS6
(Ser 235/236)
 protein expression was simiarly 
affected in HOSCC cells, however an increase in RPS6
(Ser 235/236)
 was apparent in 
the SNO cell line. Since treatment with BI-D1870 clearly decreased p-RPS6
(Ser 
235/236)
 protein expression in the HEK-293 cell line, these data show that the 
action of BI-D1870 could be reproduced as reported in the literature. Since not 
all western blots were repeated more than once, the significance of these 
changes in protein expression was not determined. (U = Untreated cells; DMSO 
= cells treated with 0.1 % dimethyl sulphoxide; BI = cells treated with the 
p90RSK-sepcific inhibitor BI-D1870). 
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Table 3.5: Summary of mTOR and p-RPS6
(Ser 236/236)
 protein expression levels obtained after specific inhibition of p90RSK 
with BI-D1870.  
 
Protein Cell Line 
 
WHCO 5 WHCO6 SNO MCF-7 HEK-293 
 
↑/
↓ 
H/M/
L 
% ∆ 
↑/
↓ 
H/M/
L 
% ∆ 
↑/
↓ 
H/M/
L 
% ∆ 
↑/
↓ 
H/M/
L 
% ∆ 
↑/
↓ 
H/M/
L 
% ∆ 
mTOR ↓ Med -20.00 ↓ Med -29.41 ↓ Med -22.73 ↑ High 1.22 ↑ High 9.52 
p-RPS6
(Ser 235/236)
 ↓ Med -5.63 ↓ Med -13.33 ↑ High 26.87 ↑ Med 2.04 ↓ Low -66.67 
 
Key: Low = 0 – 45 %; Medium (Med) = 46 – 75 %; High = 76 – 100 % (and above). Protein expression levels are based on the Hager et al., (2011) 
classification system for analyses of mTOR and p-RPS6 proteins (see Materials and Methodology, Section 3.2.11). Change in relative marker set 
protein expression is expressed as percent change (% ∆), designated by either positive (↑) or negative (↓) arrows. For the calculation of percent 
change, see Appendix B, Equation B1. 
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3.4. Discussion 
 
3.4.1. The PI3K/PKB signalling pathway is an upstream regulator of the mTOR 
signalling pathway in HOSCC cells 
 
Having demonstrated that key signal transduction intermediates may function as a set of 
protein markers providing specific mTOR pathway information (see Chapter 2); we 
monitored these same protein intermediates during our investigation of mechanisms 
influencing canonical and non-canonical mTOR signalling in HOSCC cells. Although 
numerous factors are known to affect signalling through the mTOR pathway, we believed 
biochemical signals elicited by soluble stimuli to be the most relevant, as these types of 
signals are reported to have the greatest effect during mTORC1-dependant autophagy 
induction (Yan and Lamb, 2012). Therefore, by denying HOSCC cells the appropriate means 
to regulate mTOR and mTORC1, we are able to determine how HOSCC cells affect cell 
survival by altering the mTOR signalling pathway. In this way, it becomes possible to 
delineate the circumstances, as well as the signalling sequences, regulating mTORC1-
dependant autophagy induction in HOSCC cells.  
 
The first form of mTOR regulation we examined was signal transduction through the 
PI3K/PKB signalling pathway, since this pathway is widely accepted as the canonical 
regulator of mTOR signalling. Indeed, previous studies probing the relationship between 
PI3K and mTOR show that PI3K and PKB are situated upstream of mTOR (Hay, 2005; 
Bhaskar and Hay, 2007), and actively regulates signal transmission through mTORC1 (Hay, 
2005; Bai and Jiang, 2010). Thus, we believed it was necessary to confirm this signalling 
paradigm in HOSCC cells. Since inhibition of PI3K commonly decreases PKB activation, 
and consequently mTORC1 signalling (Martelli et al., 2010), we perturbed the activity of 
PI3K with a commonly used inhibiter, commercially known as LY294002 (Blommaart et al., 
1997).  
 
Inhibition of PI3K with LY294002 specifically affects signalling through the PI3K/PKB 
pathway in HOSCC cells. PI3K-specific inhibition was shown to decrease PKB(Ser 473) 
phosphorylation (see Appendix B, Table B2), thus directly affecting the activation of 
downstream signal transduction pathways reliant on PKB-dependant signals (Shaw Ph.D. 
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Thesis, 2011). Since inhibition of PI3K reduced mTOR and mTORC1 signalling, this 
confirmed a direct relationship between the PI3K/PKB signalling pathway and the mTOR 
signalling pathway in HOSCC cells. Having shown that specific inhibition of PI3K with 
LY294002 effectively inhibits mTORC1 signalling, we expected that reduced mTORC1-
dependant regulation of the ~ 3 MDa autophagy induction complex would follow. 
Consequently, we believed that HOSCC cells would possess an elevated potential for 
autophagy. However, the potential for autophagy induction (conveyed through 
dephosphorylated mATG-13 in the protein marker set) seemed to abate when we obstructed 
PI3K signalling. Therefore, this may indicate that mTOR-dependent autophagy induction 
may not be critically influenced by the PI3K/PKB signalling pathway in HOSCC cells.  
 
mATG-13 has only recently become an important autophagy marker because its 
dephosphorylation directly precedes the initiation of autophagy induction (Hara et al., 2008; 
Chan et al., 2009; Hosokawa et al., 2009; Jung et al., 2009). However, the phosphorylation 
status of mATG-13 may be difficult to decipher by immunoblot (Hara et al., 2008; Hosokawa 
et al., 2009; Jung et al., 2009), since multiple mATG-13 bands are common (Chan et al., 
2009), a phenomenon we also observed. The main reason given for this occurrence is the 
different states of mATG-13 phosphorylation which exist, both in vitro and in vivo¸ resulting 
from subsequent interactions with ULK – which may also phosphorylate mATG-13 (Hara et 
al., 2008; Hosokawa et al., 2009; Jung et al., 2009). Nevertheless, we believe that these 
polypeptide bands do represent different states of mATG-13 phosphorylation, and may be a 
consequence of negating PI3K-dependant survival signals through the application of 
LY294002. Therefore, depletion of PI3K/PKB survival signalling may modulate the 
behaviour of other autophagy-regulatory elements, such as Bim and Beclin-1 (Luo et al., 
2012). Since there is a lack of comparable data within the current literature, showing this 
influence on autophagy induction by way of mATG-13 expression, we believe these findings 
to be unique, but in need of further corroboration. 
 
Inhibition of PI3K signalling was also insufficient to induce an apoptotic response in HOSCC 
cells. Moreover, since negating these types of survival signals did not affect integrin-
triggered focal adhesion protein kinases, such as ILK, it may be concluded that ILK protein 
expression is not transcriptionally regulated by PI3K signalling. Rather, ILK is situated 
upstream of the PI3K/PKB pathway in HOSCC cells. 
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3.4.2. Excluding essential nutrients alters mTORC1 signalling to autophagy induction 
in HOSCC cells 
 
The removal of growth stimulants (such as essential amino-acids, growth factors and other 
soluble mitogens) ultimately affects the activation of those signal transduction cascades 
regulated by RTK’s and MAPK’s (Tsujimoto and Shimizu, 2005; Avruch et al., 2009; 
Takahara et al., 2006; Mason and Rathmell, 2010). Therefore, by excluding serum from 
standard tissue culture conditions, we negate these survival signals and isolate non-canonical 
mechanisms regulating mTOR signalling. In the absence of serum, HOSCC cells were forced 
to alter the concentration of mTOR and signalling through mTORC1. This means that even 
though HOSCC cells possess an aberrantly activated mTOR pathway under standard tissue 
culture conditions (established in Chapter 2), the upstream regulators of mTOR signalling in 
HOSCC maintain susceptibility to typical agonists found in serum, which impinge on 
mTORC1 activity during conditions of nutrient deprivation.  
 
We believed that HOSCC cells would undergo autophagic processing as a result of reduced 
signalling through mTORC1, because autophagy is reportedly triggered through the removal 
of essential nutrients and soluble mitogens (Fingar et al., 2002: Fingar and Blenis, 2004; 
Fingar et al., 2004). By inhibiting mTORC1 signalling through the exclusion of serum, we 
confirmed that autophagy was induced in HOSCC cells through a similar nutrient-dependant 
mechanism. HOSCC cells maintained a moderate to high potential for autophagic processing 
(as shown by increasing concentrations of dephosphorylated mATG-13). An increase in the 
potential for autophagy under these tissue culture conditions indicates that signals initiating 
autophagy induction remain under control of the mTOR/mTORC1 pathway in HOSCC cells. 
 
Autophagy induction is a very rapid response (approximately 8 minutes), occurring very soon 
after excluding these types of mTOR pathway agonists (Kabeya et al., 2000). Fully mature 
autophagolysosomes are readily observed after 15 – 30 minutes (Kabeya et al., 2000). The 
rapid onset of autophagy in response to a lack of soluble extracellular-originating signals 
suggests that autophagy serves an important survival role ensuring cell longevity in response 
to nutrient limiting conditions, until pro-survival signals are re-attained. Since those initial 
signalling events signalling apoptosis did not occur (evident from a lack of detectable cleaved 
caspase-3), this suggests that the induction of autophagy precedes the initiation of pro-death 
signals. 
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3.4.3. Rapamycin inhibits mTORC1 signalling in HOSCC cells 
 
We have established that a biochemical signal must first stimulate PI3K signalling before 
reaching the mTOR signalling pathway. This indicates that the most commonly accepted 
mechanism of mTORC1 regulation is canonical regulation through the PI3K/PKB signalling 
pathway in HOSCC cells. Additionally, we have established that the mTOR pathway is 
susceptible to nutrient deprivation triggering an autophagic response in HOSCC cells, 
suggesting that mTOR maintains the ability to sense cellular abundance of essential nutrients 
and amino-acids. Therefore, in the general scheme of intracellular cellular signalling, these 
conclusions represent key findings contributing to our understanding of the mTOR signalling 
network in HOSCC. Since we have now gained both a positional and functional context for 
the mTOR signalling pathway in HOSCC cells, it was appropriate that these discoveries 
precede an investigation into the susceptibility of the mTOR pathway to rapamycin 
inhibition. 
 
The susceptibility of the mTOR pathway to rapamycin in HOSCC was investigated, 
assuming that rapamycin could bind to mTOR and suppress its kinase activity in a similar 
manner as described by Foster and Toschi (2009). Here, rapamycin sterically hinders the 
ATP binding pocket, disallowing ATP to associate with mTOR. In support of this 
assumption, a detailed survey of the literature revealed no missense mutations affecting 
rapamycin binding in HOSCC (Hou et al., 2007; Karbowiniczek et al., 2008; Molinolo et al., 
2007; Chantaravisoot and Tamanoi, 2010; Hirashima, et al., 2012).  
 
In response to different nanomolar concentrations of rapamycin (where HOSCC cells 
exposed to rapamycin for either 6 or 24 hours), a trend increase in mTOR protein expression 
was observed in HOSCC cells of South African origin. In contrast, this trend was not 
observed in a study by Hou et al. (2007), where the authors investigated the effects of 
rapamycin and siRNA against mTOR in poorly- (EC9706) and well-differentiated (Eca 109) 
HOSCC cells of Chinese origin (otherwise known as ESCC cells). Here, both mTOR and 
p70S6K mRNA and protein expression levels decreased in response to 20 nM and 50 nM 
rapamycin. This apparent disparity between squamous cell carcinomas of South African and 
Chinese origin may signify a particularly insightful difference into HOSCC aetiology. 
Despite this difference in mTOR abundance, the signalling potential of mTORC1 was 
completely diminished in HOSCC cells of the WHCO series, as well as MCF-7 breast 
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carcinoma cells. This trend was also reported in ESCC cells according to Hou et al. (2007). 
Therefore, HOSCC cells exhibited a dose-dependent decrease in mTORC1 signalling, 
observed in part through mTOR inhibition, as well as a rapamycin-induced decrease in 
p70S6K protein expression – also observed by Hou et al. (2007).    
          
Decreasing mTORC1 signalling should produce an increase in dephosphorylated mATG-13, 
signifying autophagy induction. This trend increase was not always observed in HOSCC, 
where mATG-13 protein expression steadily decreased in response to 20 and 50 nM 
rapamycin (6 hours post treatment) and 50 and 100 nM rapamycin (24 hours post treatment). 
This was an unexpected result since signalling through mTORC1 is reported to be the main 
regulator triggering autophagy (Tsuchihara et al., 2009). An evaluation of current literature 
revealed that while mTOR is considered the principal regulator of autophagy, other cellular 
mechanisms may also play a role in autophagy induction. For example the tumour suppresser 
p53, as well as Beclin1, Bif1 and UVRAG pathway elements may also regulate autophagy 
induction, and importantly, are unaffected by rapamycin treatment (Brech et al., 2009; Chen 
and Debnath, 2010). Therefore, these other autophagy regulating mechanisms may 
compensate for the loss in mTORC1 signalling as a result of rapamycin treatment.  
 
The protein abundance of ILK is not especially affected by rapamycin treatment; however 
rapamycin may affect the recruitment of ILK to focal adhesions (Foster and Toschi, 2009). 
However, the impact of this influence of rapamycin in HOSCC cells would perhaps form the 
basis of another investigation, and would rather be of outstanding interest to studies focussing 
on adhesion-based signal transduction if an association between ILK and mTOR (or other 
mTOR pathway components) was determined. 
 
3.4.4. The mTOR/mTORC1 signalling pathway leads to RPS6(Ser 235/236) 
phosphorylation in HOSCC cells 
 
Upon forming a multi-protein complex with Raptor, mLST8 and PRAS40, mTOR forms a 
functional, rapamycin-sensitive signalling complex known as mTORC1 (Abraham, 2002; 
Zhou and Huang, 2010). mTORC1 directly phosphorylates and activates p70S6K, a well 
characterised downstream target of mTOR, which subsequently phosphorylates and activates 
RPS6(Ser 235/236) (Abraham, 2002; Zhou and Huang, 2010). p-RPS6(Ser 235/236) plays a key role 
in cap-dependant translation initiation of 5ʹ-Top mRNA’s, and is therefore fundamental 
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during cell growth and proliferation processes (Gingras et al., 2001; Roux et al., 2007; Zhou 
and Huang, 2010). Hence, the phosphorylation status of RPS6(Ser 235/236) and p70S6K is 
regarded as a molecular marker indicating active signalling through mTORC1 (Dazert and 
Hall, 2011). For these reasons, p-RPS6(Ser 235/236) was selected as a relevant signalling 
intermediate. However, phosphorylation of RPS6(Ser 235/236) may also occur through another 
cellular pathway component, namely p90RSK; an effector kinase of the MAPK signalling 
cascade (Dazert and Hall, 2011; Roux et al., 2007).  
 
Both MAPK/p90RSK and mTOR/mTORC1 signalling pathways experience extensive signal 
integration (or pathway crosstalk) (Carrière et al., 2008; Mendoza et al., 2011). p90RSK may 
bind to and activate Raptor of mTORC1, as well as negate the inhibitory action of the 
TSC1/TSC2 complex, a critical upstream regulatory node of the mTOR signalling pathway, 
(Carrière et al., 2008; Mendoza et al., 2011). In light of the above, we ascertained the unique 
contribution of MAPK/p90RSK- and mTOR/mTORC1-dependent signalling on RPS6(Ser 
235/236)
 phosphorylation in WHCO and MCF-7 cell lines. Therefore, the ability of mTORC1 to 
phosphorylate RPS6(Ser 235/236) in the absence of MAPK/p90RSK was assessed using a newly 
developed p90RSK-specific inhibitor, BI-D1870, which targets all four RSK isoforms 
(Sapkota et al., 2007). Before assessing the action BI-D1870 in HOSCC cells, we confirmed 
that BI-D1870 could specifically inhibit p90RSK-dependant RPS6(Ser 235/236) phosphorylation 
in the HEK-293 cell line. HEK-293 cells were used because Sapkota et al. (2007) initially 
demonstrated a BI-D1870-dependent reduction in p-RPS6(Ser 235/236) using this cell line. 
 
Sapkota et al. (2007) also demonstrated that concentrations of 0.1 µM BI-D1870 was 
sufficient to inhibit p90RSK-dependent signalling in vitro. However, ten times this 
concentration was necessary to achieve the same effect in vivo. Therefore, after 
demonstrating that 10 µM BI-D1870 was sufficient to decrease p-RPS6(Ser 235/236) in HEK-293 
cells, it was shown that p90RSK-specific inhibition did not appreciably change p-RPS6(Ser 
235/236)
 in HOSCC cells. This indicates that while MAPK/p90RSK signalling is responsible for 
a small component of RPS6(Ser 235/236) phosphorylation, mTORC1-dependant signalling is the 
major upstream regulator responsible for a larger fraction of RPS6(Ser 235/236) phosphorylation. 
This would further corroborate our using p-RPS6(Ser 235/236) in the protein marker set to 
indicate mTORC1 signalling. 
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Since p90RSK-specific inhibition differentially also altered mTOR protein expression in 
HOSCC cells, these data indicate that, the MAPK/p90RSK signalling pathway may play an 
uncharacterised role in the regulation of mTOR transcriptional events. However, this 
observation may only apply to squamous cells carcinomas affecting the human oesophagus. 
Since not all western blots were repeated more than once, however, a better indication of this 
would be given through statistical analysis of RPS6(Ser 235/236) phosphorylation. Nevertheless, 
the design of this investigation served our purposes to show that the majority of RPS6(Ser 
235/236)
 is phosphorylated by mTORC1 in HOSCC cells. 
 
In conclusion, an investigation of the mTOR signalling network in HOSCC cells revealed 
that soluble extracellular-originating stimuli are capable of regulating the concentration of 
mTOR, and signalling through mTORC1 by way of canonical and non-canonical 
mechanisms. In the absence of PI3K-dependent signals, we established that the mTOR 
pathway generally reduces signalling through mTORC1, indicating a canonical form of 
mTOR pathway regulation, as well as that mTOR is situated downstream of the PI3K/PKB 
pathway in HOSCC cells. We also established that mTOR maintains the ability to sense 
cellular abundance of essential nutrients and amino-acids, thereby triggering an autophagic 
response in HOSCC cells. However, while rapamycin was shown to potently inhibit 
mTORC1 in HOSCC cells, the same effect on autophagy induction was not observed. This 
was found to be unique to HOSCC and may indicate that induction of the autophagic process 
is more tightly regulated by other signalling inputs, which may supersede mTORC1, in 
HOSCC cells in comparison to other squamous cell carcinomas. Lastly, we established that 
while the MAPK/p90RSK pathway contributes to RPS6(Ser 235/236) phosphorylation, signalling 
through mTOR/mTORC1 is the major player in HOSCC. Therefore, all of the above analyses 
forms the necessary foundation to investigate whether mechanical extracellular-originating 
stimuli (derived from adhesion-based signal transduction) influences the mTOR/mTORC1 
signalling pathway in HOSCC cells. 
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CHAPTER 4 
 
4. ECM MODULATION OF THE mTOR/mTORC1 SIGNALLING 
PATHWAY IN HOSCC CELLS 
 
4.1. Introduction 
 
Epithelial cells require stable connections between one another, as well as with a supporting 
extracellular matrix (ECM), in order to create an organized three-dimensional tissue structure 
(Gumbiner, 1996). Specialised components of the cell adhesion machinery facilitate these 
cell-cell and cell-ECM connections, ultimately allowing the assembly of different tissue types 
(Juliano, 2002). While cell-cell interconnectivity is mediated by cadherins and adherens 
junctions, forming intercalated epithelial sheets (Gumbiner, 1996), adhesion to the ECM 
arises through different permutations of α and β integrin heterodimers that bind specific 
extracellular matrix components (Gumbiner, 1996; van Der Flier and Sonenberg, 2001). 
Integrin-mediated cell-ECM adhesion, in particular, plays an important role during the 
regulation of numerous cellular processes; such as proliferation, differentiation, migration, 
cell survival and even tumour progression (Juliano, 2002; Brakebusch and Fӓssler, 2003; 
Brunton et al., 2004). Therefore, attachment to the ECM is an essential cellular requirement 
in order to maintain cellular homeostasis and the integrity of epithelial tissue (Gumbiner, 
1996; Juliano, 2002). 
 
The extracellular matrix is secreted and thus formed by surrounding epithelial cells (Shwartz, 
2010). The ECM is composed of several different types of glycoproteins, such as fibronectin 
and laminin, proteoglycans, such as heparin sulphate, and collagens that together form an 
integrated three-dimensional extracellular network to which cells adhere (Boudreau and 
Bissell, 1998). Collagen is reported to be the most abundant ECM molecule, where more than 
20 different types are known to exist (Boudreau and Bissell, 1998; Rozario and DeSimone, 
2010). Of these present within mammalian ECM networks, Type I collagen is the most 
ubiquitous and well described structural collagen, whereas Type IV collagen is mainly 
present within the basal lamina or basement membrane (Roskelley et al., 1995; Rozario and 
DeSimone, 2010). Similarly, fibronectin is also an important ECM constituent; however 
fibronectin is present in appreciably lower quantities to collagen, but remains an important 
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ligand for cell adhesion and during adhesion-based signal transduction (Roskelley et al., 
1995; Shwartz, 2010). 
 
When collagen and fibronectin physically interact with specific α/β integrin heterodimers, 
these associations stimulate adhesion-based signalling events in substrate-dependant 
epithelial cells (Brakebusch and Fӓssler, 2003). This type of integrin-mediated signalling is 
currently understood to be bi-directional, where cells may influence their microenvironment 
through a process known as inside-out signalling (Harburger and Calderwood, 2009). 
However, outside-in signalling may also occur (illustrated in Figure 4.1); whereby the 
microenvironment rather influences numerous cellular processes. For example substrate 
composition, stiffness and geometry may function as guidance cues during stem-cell 
differentiation and development (Engler et al., 2006). Additionally, mechanical stress in 
muscle, bone, cartilage and blood vessels plays a critical role in the maintenance of tissue 
homeostasis (Jaalouk and Lammerding, 2009).  
 
The process of ECM-originating signalling (depicted in Figure 4.1) shows how focal 
adhesions become enriched with activated integrins, such as α1β1 and α2β1, in response to 
collagen (van Der Flier and Sonnenberg, 2001). However, focal adhesions may become 
enriched with αvβ3 and α5β1 integrins in response to fibronectin (van Der Flier and 
Sonnenberg, 2001). These cell-ECM binding events induce conformational changes within 
integrin extracellular and cytoplasmic domains (Harburger and Calderwood, 2009). 
Subsequently, structural proteins are recruited, such as Nck2, PINCH, Parvin and Paxillin, 
which serve as molecular platforms supporting protein-protein interactions around the 
cytoplasmic tails of activated integrin heterodimers (Baker and Zaman, 2010). In addition, 
the phosphorylation (and activation) of protein kinases involved in intracellular signalling 
cascades occurs, in particular ILK (Brabek et al., 2004; Subauste et al., 2004). Since protein 
recruitment and phosphorylation occurred mainly at sites of focal adhesion, focal adhesions 
rather than the actin cytoskeleton are considered the origin of mechanotransduction events 
(Goldmann, 2012).  
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The intracellular transmission of extracellular-originating stimuli may also have far reaching 
affects on context-dependent cell survival processes, such as the induction of autophagy, 
which is triggered when cell-ECM contacts are lost (Fung et al., 2008). These findings 
suggest that cell-ECM interactions are essential for mechanotransduction to occur, providing 
a rationale for the importance of attachment during adhesion-based signalling. Furthermore, 
these observations demonstrate a functional linkage exists between ECM-originating signals, 
integrin-triggered protein kinases and specific cell survival processes. Therefore, we believe 
that autophagy may share a similar functional linkage with components of integrin-mediated 
cell adhesion, such as ILK. 
 
It is therefore increasingly apparent that cells perceive biophysical information, such as 
traction forces, matrix geometry and substrate elasticity, in addition to biochemical cues (Lim 
et al., 2010). Considering the exact molecular mechanisms controlling the induction of 
autophagy by ECM-originating signals are still incompletely delineated, by investigating this 
aspect we may uncover a role for ILK as a conduit during ECM regulation of autophagy 
induction. Moreover, since autophagy induction is regulated by the mTOR signalling 
pathway, we believe that ILK achieves this by interacting with components of the mTOR 
pathway. Therefore, with the aim of delineating the route of mechanotransduction from sites 
of cell-substrate contact to the cellular machinery initiating autophagy induction, we 
examined the influence of mechanically-derived extracellular-originating on the 
mTOR/mTORC1 signalling pathway in HOSCC cells.  
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Figure 4.1: Mechanotransduction of extracellular-originating stimuli through ILK. After 
unmasking of integrin extracellular domains, specific pairs of α/β integrins bind 
components of the extracellular matrix, such as collagen and fibronectin. Cell-
ECM interactions recruit focal adhesion proteins that tether integrins to the 
actin cytoskeleton, and signal to important pathway intermediates. ILK is the 
main example of an integrin-triggered focal adhesion protein kinase that in fact 
functions as both a molecular scaffold for multi-protein assemblies, as well as a 
molecular conduit for mechanotransduction. Since ILK directly phosphorylates 
numerous key pathway intermediates (such as Akt/PKB and GSK-3β), 
mechanically-derived extracellular-originating signals may be propagated 
intracellular to bring about a change in gene expression, consequently 
influencing cell behaviour and survival processes. Consequently, we believe 
that autophagy is a cell survival pathway affected by adhesion-based signalling. 
(Figure adapted from Brakebusch and Fӓssler, 2003). 
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4.2. Materials and Methodology 
 
4.2.1. Tissue Culture of WHCO and MCF-7 Cell Lines 
All cell lines were cultured as described previously in Chapter 2, Section 2.2.1. 
 
4.2.2. Sub-culture of WHCO and MCF-7 Cell Lines 
As previously described (see Chapter 2, Section 2.2.2). 
 
4.2.3. Provision of Extracellular matrix (ECM)-originating Stimuli 
 
4.2.3.1. Growth of WHCO and MCF-7 Cell Lines on a Fibronectin-coated Substrate 
Cell cultures were supplied with mechanical stimuli in the form of sterile 6 cm standard 
tissue culture dishes (Nunc) pre-coated with 10 µg/ml fibronectin (Roche) (Appendix A, 
1.11.1). Fibronectin was left to polymerize for 1 hour under a sterile laminar flow cabinet. 
Before use, the supernatant was carefully removed and washed twice with PBS. Standard 
tissue culture then continued as previously described. Please note that all procedures for one 
set of experiments were performed using the same batch of FCS. 
 
4.2.3.2. Growth of WHCO and MCF-7 Cell Lines on a Collagen-coated Substrate 
Cell cultures were supplied with mechanical stimuli in the form of sterile 6 cm standard 
tissue culture dishes pre-coated with 100 µg/ml collagen. Collagen was purified from rat-tail 
tendon, as described by Teng et al. (2006) (Appendix A, 1.12.1). Subsequently, collagen-
coated substrates were left to polymerize for 2.5 hours under a sterile laminar flow cabinet. 
Before use, the supernatant was carefully removed and washed twice with PBS. Standard 
tissue culture then continued as previously described. Please note that all procedures for one 
set of experiments were performed using the same batch of FCS. 
 
4.2.4. Antibodies 
Immunochemical analysis of all key protein intermediates was performed using an indirect 
antibody detection system. However, in addition to the primary and HRP-conjugated 
secondary antibodies listed in Chapter 2 (Section 2.2.3), focal adhesion kinase (anti-FAK) 
was detected with rabbit polyclonal antibodies obtained from Santa Cruz Technology®, 
whereas the regulatory associated protein of mTOR (anti-Raptor) was detected with rabbit 
monoclonal antibodies obtained from Cell Signalling Technology®, USA.  
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4.2.5. Combinatorial Tissue Culture with an ECM-originating Stimulus and Specific 
Inhibition of PI3K 
 
4.2.5.1. Growth of WHCO and MCF-7 cells on a Fibronectin-coated Substrate with 
the concurrent inhibition of PI3K with LY294002  
Sterile 6 cm standard tissue culture dishes were pre-coated with 10 µg/ml fibronectin as 
described above (see Section 4.2.3.1). Subsequently, cell cultures were allowed to proliferate 
until 6 cm dishes reached a confluence of approximately 80 %. The medium was then 
aspirated and cell monolayer washed twice with PBS. Subsequently, 3 ml fresh tissue culture 
medium with 10 % FCS was added, containing a final concentration of 20 µM LY294002 
(Appendix A, 1.8.1). Henceforth, these samples were referred to as ‘FN & L+’. Tissue 
cultures were then incubated in a humid, 37 °C incubator with an atmosphere of 5 % CO2 in 
air for 1 hour. Simultaneously, untreated (U), 10 µg/ml fibronectin (FN) and 20 µM  
LY294002 (L+) controls were prepared for comparative purposes. It is important to note that 
all procedures for one set of experiments were performed using the same batch of FCS. 
 
4.2.6. 2 % Triton-X-100-based Protein Extraction 
As previously described (see Chapter 2, Section 2.2.5). 
 
4.2.7. Protein Estimation 
As previously described (see Chapter 2, Section 2.2.6). 
 
4.2.8. Co-Immunoprecipitation Assay 
Co-Immunoprecipitation (Co-IP) is a sensitive immunoassay allowing for the determination 
of a physical association between proteins of interest from a complex mixture of cellular 
extracts (Wang and Malbon, 2011). By exploiting the specific nature of antibody-antigen 
interactions, this molecular method conveys information pertaining to the presence, or 
absence, of specific protein-protein interactions that occur under standard tissue culture 
conditions. 
 
In order to ascertain if mechanically-derived extracellular-originating signals are transmitted 
directly to mTORC1, we investigated whether a physical association occurred between 
mTOR and key integrin-triggered protein kinase intermediates, such as ILK and FAK. Cells 
were lysed in RIPA buffer (Appendix A, 1.7.1) for approximately 3 hours at 4 °C. 
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Afterwards, lysates containing 400 µg of protein (determined by Protein Estimation as 
described in 4.2.7) were incubated with 2 µl undiluted anti-mTOR antibody (Cell Signalling 
Technology®, USA), overnight at 4 °C in IP buffer (pH 8.0; Appendix A, 1.7.4). This allows 
the anti-mTOR antibody to bind to the mTOR protein kinase by means of the Fab-region. The 
above was performed on WHCO and MCF-7 cell lines and included a negative control, to 
which no anti-mTOR antibody was added. 
 
The following day, immune complexes were precipitated with 20 µl protein G Sepharose 
beads (overnight at 4 °C) allowing Protein G Sepharose beads to bind the Fc-region of the 
antibody, bound to mTOR. Beads were initially washed thrice with 1 ml IP buffer in order to 
remove any ethanol in which beads were stored. The following day, samples were 
centrifuged in a SORVAL® MC (12V) centrifuge (12 000 x g; 30 sec) and the supernatant 
removed. The pellet was then washed thrice with 700 µl IP buffer, the last wash being 0.1% 
IP buffer. 
 
IP samples were prepared for SDS-PAGE by centrifugation (12 000 x g; 30 sec; 4 °C), by 
discarding the supernatant and adding 40 – 50 µl single Laemmli lysis buffer. Samples were 
then boiled for 5 min in a boiling water bath, centrifuged (12 000 x g; 10 min; 4 °C) and 
stored at – 20 °C. This preparation releases the protein of interest and associated protein. IP 
samples consisting of Protein G Sepharose beads, anti-mTOR antibodies, the 220 kDa mTOR 
protein kinase, as well as any proteins physically associated with mTOR, were resolved by 10 
% SDS-PAGE (Section 4.2.9). Subsequently, the presence of mTOR-associated proteins, 
such as Raptor, as well as focal adhesion protein kinases thought to interact with mTOR, such 
as ILK and FAK, were detected by western immunoblotting analysis (Section 4.2.10). 
 
4.2.9. SDS-PAGE (Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis) 
As previously described (see Chapter 2, Section 2.2.7). 
 
4.2.10. Western Immunoblot Analysis 
Immunodetection of key protein intermediates present within WHCO and MCF-7 cell lysates 
was performed as previously described (see Chapter 2, Section 2.2.8). Additionally, see 
Appendix B, Table B1 for commonly used primary and secondary antibody dilutions, 
including incubation conditions for FAK and Raptor.  
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4.2.11. Image Capturing 
As previously described (see Chapter 2, Section 2.2.9). 
 
4.2.12. Laser Densitometry and Analysis of Relative Protein Expression 
Semi-quantitative densitometric analysis was used to determine protein expression across 
WHCO and MCF-7 cell lines, performed as previously described (see Chapter 2, Section 
2.2.10). Additionally, raw and worked densitometric data is available in Appendix C, Tables 
C14 - C17. 
 
4.2.13. Statistical Analysis 
Results are expressed as the mean ± S.E. Statistical significance was determined by Student’s 
t-test for comparative analysis (see Appendix D, Table D4 and Table D5) using Sigma Plot®, 
Version 12.0 (SPSS Science, Chicago, Illinois USA), where p < 0.05 indicates statistical 
significance. All experiments were repeated at least three times, unless otherwise indicated. 
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4.3. Results 
 
4.3.1. ECM-originating signals modulate mTOR abundance and RPS6(Ser 235/236) 
phosphorylation in HOSCC cells 
 
Appreciable changes in the concentration of both mTOR and p-RPS6(Ser 235/236) polypeptides 
were observed when HOSCC cells were grown on substrates coated with either fibronectin or 
collagen (Figure 4.2). Immunodetection revealed that the concentration of polypeptide bands 
indicative of mTOR (220 kDa) increased after the WHCO series of cell lines were grown on 
fibronectin. However, noticeable decreases in mTOR abundance occurred within WHCO5 
and SNO cell lines. Furthermore, the concentration of polypeptide bands at 36 kDa were also 
absent in the WHCO5 cell line, indicating a decrease in p-RPS6(Ser 235/236). Immunodetection 
also revealed that HOSCC cells grown in the presence of collagen decreased the 
concentration of both mTOR (220 kDa) and p-RPS6(Ser 235/236) (36 kDa) polypeptides within 
WHCO5 and WHCO6 cells. These obvious changes in mTOR and p-RPS6(Ser 235/236) 
polypeptide abundance were not observed in MCF-7 cells grown in the presence of either 
fibronectin or collagen. 
 
Since we were unable to detect mTOR and p-RPS6(Ser 235/236) in the WHCO5 cell line (after 
growth on fibronectin- or collagen-coated substrates), as well as in the WHCO6 cell line 
(after exposure to collagen), we repeated immunodetection for these proteins. By doubling 
the amount of protein for each cell lysate, we were able to detect polypeptides indicative of 
mTOR (220 kDa) and p-RPS6(Ser 235/236) (36 kDa) (see Appendix B, Figure B2 for these 
repeated western blots). 
 
Semi-quantitative densitometric analysis revealed that exposure to fibronectin and collagen 
altered mTOR (220 kDa) and p-RPS6(Ser 235/236) (36 kDa) protein expression in all HOSCC 
cells (Figure 4.3). Relative protein expression was calculated as a percentage of that 
determined for untreated (U) cells of the WHCO6 cell line (see Chapter 3 for a clear 
explanation regarding the continued use of this line). This enabled us to determine the levels 
of mTOR and p-RPS6(Ser 235/236) protein expression (see Materials and Methodology, Section 
4.2.12 for an explanation of this analysis). Consequently, this allowed the identification of 
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trends in protein expression and HOSCC cell behaviour in response to substrates coated with 
fibronectin or collagen.  
 
When fibronectin was provided as a substrate, HOSCC cells commonly increased mTOR and 
p-RPS6(Ser 235/236) protein expression (Figure 4.3). Summarising these data clearly identified 
these trends (see Table 4.1). WHCO1, WHCO3, WHCO6, SNO, as well as MCF-7 cells, 
responded by increasing mTOR protein expression, significantly in the SNO cell line (see 
Appendix D, Table D4 for a complete statistical analysis). The WHCO5 cell line, however, 
responded by decreasing mTOR protein expression levels. Furthermore, WHCO3, WHCO6, 
SNO and MCF-7 cells showed an increase for p-RPS6(Ser 235/236). The WHCO1 cell line 
showed a decrease in p-RPS6(Ser 235/236) protein expression, however this was found to be a 
minimal change. Thus RPS6(Ser 235/236) phosphorylation remained high in the WHCO1 cell 
line.  
    
When collagen was provided as a substrate, HOSCC cells generally increased mTOR and p-
RPS6(Ser 235/236) protein expression (see Figure 4.3 and Table 4.1). WHCO1, WHCO3, SNO, 
as well as MCF-7 cells, responded by increasing mTOR, whereas the WHCO5 and WHCO6 
cell lines decreased mTOR expression to low levels. Significant changes were determined in 
the WHCO1 and WHCO6 cell lines (see Appendix D, Table D4 for these statistical analyses). 
Additionally, WHCO3, SNO and MCF-7 cells showed an increase for p-RPS6(Ser 235/236) 
(Table 4.1). The WHCO1, WHCO5 and WHCO6 cell lines were found to decrease p-
RPS6(Ser 235/236) protein expression to low levels. However, this change in p-RPS6(Ser 235/236) 
was minimal in the WHCO1 cell line. Thus RPS6(Ser 235/236) phosphorylation remained high in 
the WHCO1 cell line.  
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Figure 4.3: Relative mTOR and p-RPS6
(Ser 235/236)
 protein expression changed in response to 
substrates coated with fibronectin or collagen. Changes in protein expression 
were calculated as a percentage of that determined for the untreated (U) 
WHCO6 cell line. Treatment with either fibronectin or collagen resulted in the 
modulation of mTOR and p-RPS6
(Ser 235/236)
 protein expression in all HOSCC cells. 
As a general trend, fibronectin and collagen increased mTOR and p-RPS6
(Ser 
235/236)
 protein expression. In addition, Fibronectin induced a significant increase 
in p-RPS6
(Ser 235/236)
 protein expression in the SNO cell line. Collagen, however, 
induced a significant increase in mTOR expression in WHCO1 cells, but also 
induced a significant decrease in mTOR expression in WHCO6 cells. Since all 
western blots were repeated more than once, the significance of these data 
could be determined. Significant difference is therefore indicated graphically 
through the use of joined star (*) symbols.   
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Table 4.1: Summary of mTOR and p-RPS6
(Ser 236/236)
 protein expression levels after growth HOSCC cells were grown on either 
fibronectin or collagen.   
 
 Cell Line 
 WHCO 1 WHCO 3 WHCO 5 WHCO 6 SNO MCF-7 
 
↑/
↓ 
H/M/
L 
% ∆ 
↑/
↓ 
H/M/
L 
% ∆ 
↑/
↓ 
H/M/
L 
% ∆ 
↑/
↓ 
H/M/
L 
% ∆ 
↑/
↓ 
H/M/
L 
% ∆ 
↑/
↓ 
H/M/
L 
% ∆ 
F
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n
 
(
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N
)
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↑ Med 89.2 ↑ Low 33.3 ↓ Low 
-
88.5 
↑ High 5.0 ↑ Low 34.5 ↑ Low 
600.
0 
p
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P
S
6
 
(
S
e
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2
3
5
/
2
3
6
)
 
↓ High 
313.
5 
↑ Med 66.6 ↓ Low 
-
82.0 
↑ High 
-
95.0 
* 
↑ 
* 
High 
* 
203.
5 
↑ Low 
150.
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(
C
N
)
 
m
T
O
R
 
* 
↑ 
* 
High 
* 
-5.45 
↑ Low 11.1 ↓ Low 
-
59.6 
* 
↓ 
* 
Low 
* 
27.0 
↑ High 78.7 ↑ High 3.06 
p
-
R
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6
 
(
S
e
r
 
2
3
5
/
2
3
6
)
 
↓ High 0.01 ↑ Med 33.3 ↓ Low 
-
57.5 
↓ Low 
-
79.0 
↑ High 74.7 ↑ High 11.2 
 
Key: Low = 0 – 45 %; Medium (Med) = 46 – 75 %; High = 76 – 100 % (and above). Protein expression levels are based on the Hager et al., (2011) 
classification system for analyses of mTOR and p-RPS6 proteins (see Materials and Methodology, Section 4.2.12). Change in relative marker set 
protein expression is expressed as percent change (% ∆), designated by either positive (↑) or negative (↓) arrows. For the calculation of percent 
change, see Appendix B, Equation B1. The use of a star (*) symbol, as well as red text, represents a statistically significant difference when 
compared to WHCO6 (U) cell line, determined using a Student’s t-test; where p < 0.05 (see Appendix D, Table D4 for a statistical report). 
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4.3.2. Neither ILK nor FAK influence the transduction of ECM-originating signals to 
mTOR 
 
Having determined that exposure to fibronectin and collagen influence the cellular abundance 
of mTOR and p-RSP6(Ser 235/236) in HOSCC cells, we considered the possibility that 
mechanotransduction to the mTOR pathway may occur through a direct protein-protein 
interaction with an integrin-triggered focal adhesion protein kinase intermediate, such as ILK. 
Moreover, since autophagy was demonstrated to occur in an FAK-independent manner (Hara 
et al., 2008), we believed it was also necessary to confirm this in HOSCC. We therefore 
examined whether ILK acted as a relay for mechanotransduction linking adhesion-based 
signals to mTOR and mTORC1. 
 
Co-immunoprecipitation analysis revealed that neither ILK nor FAK participated in a 
physical protein-protein interaction with mTOR in HOSCC cells (Figure 4.4, A). The 
inclusion of both positive and negative controls corroborated these results. Subsequently, 
polypeptide bands indicative of ILK (59 kDa) and FAK (125 kDa) were only detected in the 
positive control. The positive control constituted a WHCO6 cell lysate obtained under 
standard tissue culture conditions, whereas the negative control comprised a co-
immunoprecipitation sample lacking anti-mTOR antibodies. 
 
The co-immunoprecipitation analysis was repeated to detect an mTOR-Raptor interaction in 
HOSCC cells to ensure that the lack of detectable ILK and FAK polypeptides was not a 
technique-based error. Raptor is known to interact with the 220 kDa mTOR protein and is 
generally considered the defining protein binding partner associated with the mTORC1 
complex (Kim et al., 2002; Hara et al., 2002; Zhou and Huang, 2010). Essentially, the ability 
to detect an mTOR-Raptor interaction would represent a ‘proof of principle’ control verifying 
that mTOR does not interact with ILK or FAK in HOSCC cells. Polypeptides indicative of 
the Raptor protein were detected at 150 kDa in HOSCC cells, as well as the MCF-7 cell line 
(Figure 4.4, B). Raptor was not detected in the negative control sample lacking anti-Raptor 
antibodies, but was clearly present at 150 kDa in the positive control comprising a WHCO6 
cell lysate obtained under standard tissue culture conditions (Table 4.2). Therefore, a physical 
protein-protein interaction between mTOR and Raptor was observed in all HOSCC cells, 
validating the negative result between mTOR, and ILK and FAK. 
 A. 
 
B. 
 
Figure 4.4: mTOR does not 
kinase intermediate
(59 kDa) and FAK (125 kDa) were not observed after co
analysis using mTOR (220 kDa) as a bait protein. 
interaction between mTOR and 
through the detection of a physical protein
and Raptor (150 kDa), providing an additional ‘proof of principle’ control.  
 
Table 4.2: Protein-protein interact
common integrin
 
Protein 
Molecular 
Weight 
(kDa) 
  WHCO1
ILK 59 
FAK 125 
Raptor 150 Yes
physically associate with common integrin
s, such as ILK or FAK. A) Polypeptide bands indicative of ILK 
-immunoprecipitation 
B) The lack of a physical protein 
ILK, as well as mTOR and FAK,
-protein interaction between mTOR 
ion profile established between 
-triggered focal adhesion proteins
Cell Line 
 WHCO3 WHCO5 WHCO6 SNO
No No No No 
No No No No 
 Yes Yes Yes 
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-triggered protein 
 was corroborated 
 
mTOR and 
 in HOSCC cells.  
 MCF-7 
No No 
No No 
Yes Yes 
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4.3.3. ECM-modulation of mTOR and p-RPS6(Ser 235/236) is disrupted after specific 
inhibition of PI3K in HOSCC cells 
 
Thus far we established that integrin stimulation influences the mTOR signalling pathway in 
HOSCC cells, and that the intracellular propagation of ECM-based signals to mTOR does not 
involve a direct interaction with ILK or FAK. Consequently, we believe these data point 
towards the involvement of a critical upstream signalling node which is both intimately 
involved during the regulation of mTOR/mTORC1, and affected by adhesion-based 
signalling. We are of the opinion that the PI3K/PKB pathway constitutes the signalling 
machinery responsible for relaying mechanotransduction information to mTOR for three 
main reasons: 1) PI3K is positioned upstream of the mTOR pathway (established in Chapter 
3); 2) PI3K regulates mTORC1 signalling (also confirmed in Chapter 3); and 3) PI3K 
signalling is influenced by mechanical stimuli (Guinebault, 1995). Considering the above, 
adhesion-based signalling through PI3K may also influence the induction of cellular 
autophagy through its regulation of mTORC1. Therefore, we investigated adhesion-based 
regulation of mTOR/mTORC1 signalling in HOSCC cells by providing mechanical stimuli, 
while simultaneously disrupting signals propagated through the PI3K/PKB pathway. 
 
By specifically blocking the kinase ability of PI3K with LY294002, we effectively inhibited 
the transduction of adhesion-based stimuli to the mTOR/mTORC1 signalling pathway in 
HOSCC cells. Immunodetection revealed that HOSCC cells produced clearly visible changes 
in mTOR and p-RPS6(Ser 235/236) polypeptide abundance, at 200 kDa and 36 kDa respectively 
in both the WHCO series, as well as the MCF-7 cell line (Figure 4.5). The WHCO5, 
WHCO6, SNO and MCF-7 cell lines were chosen in particular because they represent lines 
that modulate the mTOR pathway in a unique manner when exposed to either canonical 
stimuli (such as PI3K-specific inhibition with LY294002), or non-canonical stimuli (for 
example nutrient deprivation, inhibition of mTOR with rapamycin, as well as when 
mechanical signals are provided in the form of a fibronectin-coated substrate).  
 
Semi-quantitative densitometric analysis of mTOR polypeptide bands revealed that the 
WHCO series of cell lines commonly increased mTOR expression in response to fibronectin 
(Figure 4.6, A). The WHCO series also increased mTOR expression after specific inhibition 
of PI3K with LY294002 (Figure 4.6, A). Only the WHCO6 cell line responded differently 
and rather significantly decreased mTOR expression to low levels (see Appendix D, Table D5 
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for a complete statistical analysis). Interestingly, the combination effect of fibronectin and 
PI3K-specific inhibition mimicked the changes seen in mTOR expression reported after 
inhibition of PI3K with LY294002 (Table 4.3.). Here, mTOR protein expression was 
generally increased in HOSCC cells, but decreased in the WHCO6 cell line. 
 
Furthermore, densitometric analysis of p-RPS6(Ser 235/236) polypeptides revealed that HOSCC 
cells generally exhibited high RPS6(Ser 235/236) phosphorylation in response to fibronectin 
(Figure 4.6, B). However, specific inhibition of PI3K with LY294002 commonly reduced the 
phosphorylation of RPS6(Ser 235/236) in the WHCO series of cell lines. This modulation caused 
a significant change in the WHCO6 cell line (see Appendix D, Table D5 for a complete 
statistical report). Combination treatment with fibronectin and PI3K-specific inhibition 
reproduced the trend reported for PI3K-specific inhibition with LY294002 (Table 4.3.). Here, 
p-RPS6(Ser 235/236) expression was reduced in all HOSCC cells, but was significantly altered in 
the WHCO6 and even MCF-7 cell lines (see Appendix D, Table D5 for a complete statistical 
report). Therefore, blocking PI3K with LY294002 disrupts the mechanotransduction of 
fibronectin-derived adhesion-based stimuli to mTOR and mTORC1 in HOSCC cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 A. 
 
B. 
 
Figure 4.5: mTOR and RPS6
(Ser 235/236)
treatment with fibronectin and sp
confirmed visible changes in polypeptide abundance for mTOR (220 kDa) and p
RPS6
(Ser 235/236)
 (36 kDa). WHCO5, WHCO6 and SNO cell lines were chosen to 
represent the diverse 
the HOSCC model 
and MCF-7 cell lysates. (U = Untreated HOSCC cells; FN = Substrate coated with 
Fibronectin; L+
 
= specific inhibition of PI3K with LY294002)
 
 
 
 
 
 
 
 
 
 phosphorylation were altered after c
ecific inhibition of PI3K. 
behavioural and protein expression tren
system. β-actin demonstrated equal protein loading of HOSCC 
. 
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A. 
 
 
B.
 
Figure 4.6: Relative percentage of mTOR and p-RPS6
(Ser 235/236)
 protein expression after HOSCC cells were treated with a combination of 
fibronectin and specific inhibition of PI3K with LY294002. Semi-quantitative densitometric analysis of mTOR and p-RSP6(Ser 
235/236) protein expression was determined relative to the untreated (U) WHCO6 cell line. A) HOSCC cells generally increased 
mTOR protein expression in response to fibronectin and after specific inhibition of PI3K. This trend was also observed in response 
to combined treatments. B) HOSCC cells generally increased RPS6
(Ser 235/236)
 phosphorylation in response to fibronectin treatment. 
However, in response to PI3K-specific inhibition, HOSCC cells decreased p-RPS6
(Ser 235/236)
 protein expression as a common trend. 
Similarly, this effect was observed in response to the combined treatment with fibronectin and PI3K-specific inhibition; where 
HOSCC cells decreased RPS6
(Ser 235/236)
 phosphorylation. Since all western blots were repeated more than once, the significance of 
these data could be determined. Significant difference is therefore indicated graphically through the use of lines connecting star 
(*) symbols.  ((U = Untreated HOSCC cells; FN = Substrate coated with Fibronectin; L+
 
= specific inhibition of PI3K with LY294002).
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Table 4.3: Summary of mTOR p-RPS6
(Ser 235/236)
 protein expression levels after combination treatment with fibronectin 
and specific inhibition of PI3K with LY294002. 
 
Protein Treatment Cell Line 
  WHCO5 WHCO6 SNO MCF-7 
  ↑/↓ H/M/L % ∆ ↑/↓ H/M/L % ∆ ↑/↓ H/M/L % ∆ ↑/↓ H/M/L % ∆ 
mTOR 
Fibronectin 
(FN) 
↑ High 40.00 ↑ High 14.00 ↑ High 130.77 ↑ Med 1.56 
LY294002 
(L+) 
↑ High 35.00 
* 
↓ 
* 
Low 
* 
-85.00 
↑ High 189.74 ↓ Med -1.56 
FN & L+ ↑ Med 35.00 
* 
↓ 
* 
Low 
* 
-85.00 
↑ Med 189.74 ↓ Low -1.56 
p-RPS6 
(Ser 235/236)
 
Fibronectin 
(FN) 
↑ High 50.70 ↑ High 4.00 ↓ High -27.10 ↑ High 28.21 
LY294002 
(L+) 
↓ Low -38.03 
* 
↓ 
* 
Med 
* 
-50.00 
↓ Med -42.99 
* 
↓ 
* 
Low 
* 
-66.67 
FN & L+ ↓ Med -9.86 
* 
↓ 
* 
Med 
* 
-44.00 
↓ High -28.04 
* 
↓ 
* 
Low 
* 
-60.26 
 
Key: Low = 0 – 45 %; Medium (Med) = 46 – 75 %; High = 76 – 100 % (and above). Protein expression levels are based on the Hager et al., (2011) 
classification system for analyses of mTOR and p-RPS6 proteins (see Materials and Methodology, Section 4.2.12). Change in relative marker set 
protein expression is expressed as percent change (% ∆), designated by either positive (↑) or negative (↓) arrows. For the calculation of 
percent change, see Appendix B, Equation B1. The use of a star (*) symbol, as well as red text, represents a statistically significant difference 
when compared to the WHCO6 (U) cell line, determined using a Student’s t-test; where p < 0.05 (see Appendix D, Table D5 for a statistical 
report). 
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4.4. Discussion 
 
4.4.1. Mechanical stimuli influence the mTOR/mTORC1 signalling pathway in 
HOSCC cells 
 
Observations of cell spreading on fibronectin-coated substrates demonstrate that mechanical 
signalling induces the phosphorylation and activation of integrin-triggered focal adhesion 
protein kinases, such as FAK (Wu and Dedhar, 2001; Hanks et al., 2003). This presumably 
allows for the induction of matrix-derived survival signalling through FAK/c-Jun interactions 
(Almeida et al., 2000), as well as Rac and Rho signalling events (Huveneers and Danen, 
2009). Fibronectin treatment also stimulates cap-dependant translation initiation, an mTOR-
dependant process (Gorrini et al., 2005). Therefore, fibronectin-induced FAK 
phosphorylation provides a regulatory link between mechanical stimuli originating from the 
ECM and mTOR/mTORC1 activation, as activated FAK causes TSC2 inactivation (Gan et 
al., 2006), which is a negative regulator of p-p70S6K. This allows FAK to activate 
mTOR/mTORC1 signalling on this level. The possibility of this form of mTOR regulation 
was observed in HOSCC cells as fibronectin commonly increased both mTOR abundance 
and RPS6(Ser 235/236) phosphorylation. Since mTORC1 may be activated by ECM-originating 
stimuli through focal adhesion protein kinases, like FAK, this provided a rationale to further 
examine the molecular mechanisms achieving this. 
 
When oesophageal cells attached to collagen, signalling through mTOR/mTORC1 increased. 
Consequently, exposure of HOSCC to this type of ECM component may affect the mTOR 
signalling machinery in a manner akin to fibronectin-induced mechanotransduction. Collagen 
positively regulates PKB phosphorylation through the action of ILK, allowing for the 
survival of substrate-dependant cells like fibroblast (Nho et al., 2005). In addition, both ILK 
and PKB may phosphorylate and inhibit GSK-3β, which normally regulates TSC1/TSC2, 
leading to increased mTORC1 signalling (Mak et al., 2005; Volker et al., 2007). Increased 
collagen-dependant signalling in this manner implicates signalling through ILK, which is 
suggested as an instigator of epithelial morphogenesis (Schöck and Perrimon, 2002), as 
architectural changes in fibrillar collagen, and subsequently ILK activation, may contribute 
towards cancer progression (Egeblad et al., 2010). Therefore, this form of ILK-dependent 
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mTOR regulation may contribute to tumourigenesis in HOSCC, given that HOSCC cells 
commonly over-express ILK (Driver and Veale, 2006). 
 
Mechanically-derived extracellular-originating stimuli clearly impinge on the mTOR 
pathway. Mechanotransduction subsequently influences both cellular concentrations of 
mTOR, as well as signalling through mTORC1, which may explain seminal observation by 
Fung et al. (2008) regarding autophagy induction in substrate-dependant cells. Fung and 
colleagues (2008) observed that the induction of autophagy followed cell detachment from 
the ECM. Therefore, since it is apparent that ECM-dependant mechanotransduction enhances 
mTORC1 signalling, and considering the mTOR pathway is responsible for autophagy 
inhibition, the lack of adhesion-based signalling to the mTOR pathway (arising when cells 
become detached from a substrate) may account for decreased signalling through mTORC1. 
Consequently, decreased signalling through mTORC1 would allow for increased cellular 
concentrations of dephosphorylated mATG-13. Therefore, increased mATG-13 would 
enhance pro-autophagy signalling and the potential for autophagy induction.  
 
4.4.2. ILK, an integrin-triggered focal adhesion protein kinase, does not physically 
associate with mTOR 
 
The realisation that mechanically-derived stimuli directly impinge upon the mTOR/mTORC1 
pathway calls into question the exact route of signal transmission from sites of cell-ECM 
contact to the mTOR signalling machinery. The intracellular propagation of adhesion-based 
signals is known to involve the activation of integrin-triggered protein kinases, such as ILK 
and FAK (Wu and Dedhar, 2001; Hanks et al., 2003), which cluster around sites of focal 
contact. When activated, these protein kinases assist in focal adhesion biogenesis, as well as 
mechanotransduction events influencing gene expression and ultimately cell behaviour 
(Brakebusch and Fӓssler, 2003; Legate et al., 2006; Hannigan et al., 2011). Therefore, the 
involvement of an integrin-triggered focal adhesion protein kinase may provide the molecular 
connection required between the integrin adhesion system and mTOR. Consequently, we 
hypothesised a direct protein-protein interaction between mTOR and ILK, since autophagy 
induction was found to be FAK-independent (Hara et al., 2008). However, we also included 
FAK considering the integral involvement of FAK during anoikis resistance in HOSCC cells 
(Fanucchi and Veale, 2011). 
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Proteins require a means of physical interaction facilitating the transmission of biochemical 
information (Ubbink, 2009). Intracellular signals are therefore conveyed by creating a short 
lived (nanosecond) encounter complex, formed by interacting protein species (Ubbink, 2009). 
By exploiting protein-protein complex formation, one may detect the protein components of 
the so-called ‘signalsomes’ through molecular techniques, such as fluorescently-tagged 
fusion proteins, as well as co-immunoprecipitation analysis (Wang and Malbon, 2011).  
 
Co-immunoprecipitation revealed that mTOR does not form a signalsome complex with 
either ILK or FAK. This means that neither ILK nor FAK functions as direct conduit for 
mechanotransduction to the mTOR/mTORC1 pathway. Therefore, autophagy regulation 
presumably involves an indirect mechanism using one of these focal adhesion protein 
kinases. The lack of involvement of FAK was expected; since a recent study observed that 
abnormalities were not encountered by FAK-/- knockout mouse embryonic fibroblasts 
(MEF’s) to induce autophagy (Hara et al., 2008). This suggests that FAK does not play a 
critical role in autophagy through mTOR regulation. Consequently, it follows that ILK is the 
focal adhesion protein kinases involved, however clearly not through a direct protein-protein 
interaction with mTOR.  
 
We initially hypothesised that the transmission of ECM-originating signals occurs by means 
of a direct ILK/mTOR protein interaction. An association between ILK and the main protein 
component of mTORC2; Rictor (McDonald et al., 2008), was thought to allude to this 
possibility. However, exclusion of an ILK-mTOR protein complex rather suggests potential 
for an indirect functional relationship between ILK and mTORC1. This was determined to be 
a valid observation, and not a product of the methodology, because a true mTOR-Raptor 
interaction was detected. This means that the intracellular propagation of adhesion-based 
stimuli may only occur through a common signalling pathway downstream of ILK, but 
upstream of mTOR. Since canonical regulation of mTOR through PI3K suits these criteria 
(determined previously in Chapter 3), the involvement of the PI3K/PKB pathway was 
thought to provide this indirect, molecular connection between ILK and mTOR/mTORC1. 
 
 
 
 
 
107 
 
4.4.3. ECM-modulation of mTOR/mTORC1 signalling occurs in an integrin-
triggered, but PI3K-dependent manner 
 
While there is considerable information available pertaining to the regulation of mTOR 
signalling in response to soluble stimuli (Soulard and Hall, 2007; Memmot and Dennis, 
2009), comparatively less is known concerning the contribution of ECM-originating signals. 
Therefore, to understand how attachment to an extracellular matrix may influence the mTOR 
signalling pathway in HOSCC, we provided ECM components normally encountered by 
oesophageal cells, while simultaneously negating signal transduction through channels used 
by soluble mitogenic stimuli. In this way, we provide evidence for a PI3K-dependant 
mechanism during the ECM modulation of mTOR/mTORC1. To our knowledge, this is also 
the first report of such regulation of mTOR in SCC of the human oesophagus.   
 
One of the few studies demonstrating ECM modulation of the mTOR/mTORC1 signalling 
pathway found that fibronectin influences cap-dependant translation initiation by activating 
mainly β1 integrins (Gorrini et al., 2005). Importantly, this process was highly sensitive to 
the inhibition of PI3K, suggesting this pathway may play a role during adhesion-based signal 
transduction. Furthermore, only one other analysis investigated the importance of common 
ECM components, like fibronectin, on the mTOR pathway in non–small cell lung carcinoma 
(NSCLC) cells (Han et al., 2006). During this investigation, the authors demonstrated that 
attachment to fibronectin increased p-PKB, p-p70S6K and p-4EBP-1 protein expression in 
NSCLC. Moreover, growth on fibronectin reduced PTEN and p-AMPKα activity, which are 
both negative regulators of mTOR/mTORC1 signalling. Therefore, these data strongly 
suggests that fibronectin activates the PI3K/PKB/mTOR/mTORC1 pathway, at least in 
NSCLC cells. However, one aspect of adhesion-based signalling these findings do not 
adequately explore is the molecular mechanisms achieving this type of pathway activation. 
This is because the sequence of activated pathway intermediates, from a cell signalling point 
of view, is not clearly delineated. 
 
In comparison to the above, we showed that the mTOR pathway in HOSCC cells is also 
activated in response to fibronectin. By using fibronectin in combination with specific PI3K 
inhibition, we demonstrated that fibronectin stimulates mTORC1 through a mechanism 
dependent on the activation of PI3K. Here, when PI3K was blocked, mechanical stimuli 
elicited by fibronectin were diminished. Consequently, we believe this would also directly 
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impinge on the ability of mTORC1 to regulate autophagy induction, resulting in an increased 
autophagy potential in HOSCC cells when mechanical signals are not transduced through the 
PI3K/PKB pathway.  
 
Based on our understanding of ECM modulation of mTOR/mTORC1 signalling in HOSCC 
cells, we believe these findings indicate that cellular attachment to the ECM enhances the 
ability of mTOR to regulate autophagy. Indeed the ECM is capable of directing intricate 
cellular process, such as gene expression, epithelial morphogenesis, as well as cell survival 
(Ramirez and Rifkin, 2003; Berrier and Yamada, 2007; Rozario and DeSimone, 2010). 
However when HOSCC cells lose cell-ECM attachment, this diminishes signal transduction 
to mTORC1, subsequently affecting mTOR-dependent autophagy regulation, thus increasing 
autophagic processing. In highly tumourigenic epithelial phenotypes with an increased 
propensity for metastasis, like HOSCC (Lam, 2000; Lehrbach et al., 2003; Lin et al., 2009), 
the induction of autophagy in this manner may constitute a cell survival strategy augmenting 
dissemination to distant sites. 
 
In conclusion, it is evident that extracellular matrix-originating stimuli are capable of 
influencing the mTOR signalling pathway in HOSCC. By exposing HOSCC cells to major 
ECM components naturally encountered by oesophageal epithelial cells (such as fibronectin 
and collagen), we demonstrate that biophysical stimuli modulate cellular concentrations of 
mTOR and enhance signalling through mTORC1. We also establish that the intracellular 
propagation of ECM-based signals to mTOR does not involve a direct interaction with ILK or 
FAK. Rather, adhesion-based stimuli influences the mTOR/mTORC1 signalling pathway in 
an integrin-triggered, but PI3K-dependant manner – since specifically blocking PI3K 
perturbed transmission of adhesion-based stimuli to the mTOR/mTORC1 signalling pathway. 
Moreover, since signalling through mTORC1 increased in the presence of adhesion-based 
stimuli, but was diminished when PI3K/PKB signalling is blocked, we believe that 
mTORC1-dependent autophagy induction is affected by the state of cellular attachment. 
Importantly, these findings indicate that the potential for autophagy induction increases as 
cell-ECM interactions dissipate. Therefore, these data strongly suggest mTOR is a target for 
adhesion-based signal transduction, which influences cell survival through mTORC1.  
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CHAPTER 5 
 
5. GENERAL DISCUSSION AND CONCLUSION 
 
5.1. The mTOR/mTORC1 signalling pathway is activated in moderately differentiated 
HOSCC cells 
 
The mammalian target of rapamycin (mTOR) is a 220 kDa Ser/Thr protein kinase comprising 
the main signal transduction intermediate of the mTOR signalling pathway (Schmelzle and 
Hall, 2000; Caron et al., 2010; Foster and Fingar, 2010; Dobashi et al., 2011). mTOR 
functions as a master regulator of intracellular signals and so combines nutrient, energy and 
mechanical stimuli to maintain homeostasis in epithelial tissue (Schmelzle and Hall, 2000; 
Foster and Fingar, 2010; Dobashi et al., 2011). Aberrant signalling through the mTOR 
pathway is associated with numerous human pathologies; such as melanoma, Tuberous 
Sclerosis complex, Cowden’s disease, Proteus syndrome and Peutz-Jeghers syndrome 
(reviewed by Vivanco and Sawyers, 2002; Guerten and Sabatini, 2005; Inoki et al., 2005). In 
addition, inappropriate signalling through the mTOR pathway is reported to be transforming 
within solid epithelial tumours affecting the prostate (Li et al., 1997; Dreher et al., 2004), 
breast (Li et al., 1997; Vivanco and Sawyers, 2002) and lungs (Vivanco and Sawyers, 2002; 
Barnes and Kumar, 2003). Therefore, any alteration to the normal operating procedure of the 
mTOR signalling pathway may result in aberrant mTOR function, and consequently mTOR-
based disease progression. 
 
Despite a history of mTOR-specific analyses of solid epithelial tumours, very few studies 
have focussed on characterising the mTOR pathway as a molecular mechanism promoting 
progression of human oesophageal squamous cell carcinoma (HOSCC).  HOSCC is a highly 
metastatic epithelial cancer with great tumourigenic potential (Tew et al, 2005; Bird-
Lieberman and Fitzgerald, 2009), currently rated the eighth most common cancer in the 
world, and is responsible for approximately one sixth of all cancer related deaths worldwide 
(Scully and Bagan, 2009; Melhado et al., 2010). HOSCC presents symptomatically late, with 
a poor prognosis, and so any measurable molecular irregularities would be useful to improve 
diagnosis. Currently, elevated mTOR protein abundance, as well as increased expression of 
mTOR downstream targets (such as p-p70S6K, 4E-BP1 and p-RSP6(Ser 235/236)) are used with 
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increasing frequency as biomarkers indicating transformation (Lin et al., 2009; Hager et al., 
2011; Pal and Figlin, 2011). This suggests that modifications to the mTOR/mTORC1 
signalling pathway may serve as a central instigator for tumourigenesis. Therefore, 
significant changes to mTOR and mTORC1 are noteworthy and may improve diagnosis of 
HOSCC at even earlier stages. 
 
In this study, moderately differentiated HOSCC cells were used as a cellular model in which 
to investigate major signal transduction intermediates associated with the mTOR pathway. 
We determined that these intermediates conveyed pathway-specific information, such as 
signalling through mTORC1, regulation of autophagy induction and mechanotransduction 
through integrin-adhesion systems. Additionally, controlled tissue culture conditions 
permitted the manipulation of appropriate growth-stimulatory signals. These parameters 
allowed essential growth and proliferation to occur, as well as the establishment of important 
baseline data to which further manipulations could be compared. 
 
Inherently, the MCF-7 cell line served as a useful comparison to analyse the 
mTOR/mTORC1 signalling pathway in HOSCC. The main reasons for this included: a) 
MCF-7 cells over-express the mTOR protein kinase (Hagner et al., 2009); b) MCF-7 cells 
display elevated signalling through mTORC1 (Hagner et al., 2009), thought to be a 
consequence of a constitutively active PI3K/PKB signalling pathway (deGraffenried et al., 
2004). Activating mutations affecting the p110 subunit of PI3K (Bachman et al., 2004) 
directly affect mTOR signalling as the PI3K/PKB pathway is an upstream regulator of mTOR 
(Sekulic et al., 2000); c) The S6K1 gene is amplified in MCF-7 cells (Bӓrlund et al., 2000a; 
Bӓrlund et al., 2000b).  
 
Similar to MCF-7 cells, we determined that the majority of HOSCC cells expressed elevated 
cellular concentrations of mTOR, as well as enhanced signalling through mTORC1 – 
observed through high instances of RPS6(Ser 235/236) phosphorylation. Surprisingly, we also 
discovered that HOSCC cells exhibited an elevated autophagy induction potential; a 
characteristic of transformation providing a distinct survival advantage to solid epithelial 
tumours (Chen and Debnath, 2010). Elevated autophagy reportedly supports cellular fitness 
and survival of established tumour cells, such as iBMK and HeLa cells, in response to stress 
(Degenhardt et al., 2006). Moreover, we also discovered that ILK was expressed ectopically 
in both HOSCC and MCF-7 cells, suggesting an increased transduction potential for 
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adhesion-based stimuli. Ultimately, we do find that HOSCC cells exhibit similar trends to 
transformed MCF-7 cells; such as an activated mTOR signalling pathway, where increased 
mTOR abundance and mTORC1 signalling are commonplace. It must be noted that we do 
not mean to suggest that the molecular mechanisms which underpin aberrant 
mTOR/mTORC1 signalling are the same for HOSCC and MCF-7 cells. We only highlight 
the fact that the mTOR pathway manifest in HOSCC cells is analogous to a cellular system 
known to possess a corrupt mTOR signalling pathway, such as MCF-7. Therefore, 
aberrations such as these may contribute towards corruption of mTOR-dependant cellular 
processes, such as proliferation and autophagy, resulting in tumourigenesis and inappropriate 
survival signalling in HOSCC cells.  
 
5.2. Expression of the 80 kDa mTORβ splicing isoform is variable in HOSCC cells 
 
We established an association between cellular concentrations of mTOR and the degree of 
RPS6(Ser 235/236) phosphorylation in HOSCC, where a high occurrence of mTOR generally 
indicated a high degree of RPS6(Ser 235/236) phosphorylation. This type of association was clear 
in the MCF-7 cell line, and has also been reported in patients with advanced renal cell 
carcinoma (Cho et al., 2007). In fact, the link between the expression of mTOR and p-
RSP6(Ser 235/236) has proved invaluable as a predictive tool for sarcomas during targeted mTOR 
therapy (Iwenofu et al., 2008). However, in certain HOSCC cell lines (WHCO1 and 
WHCO3) where this relationship did not occur, we noted that high mTORC1 signalling did 
not necessitate high concentrations of mTOR. Interestingly, only these WHCO cell lines 
expressed the 80 kDa mTOR splicing isoform, termed mTORβ (Panasyuk et al., 2009). 
 
mTORβ was found to be neither a cleavage product, nor the result of protein degradation and 
possesses the required potential to affect signal transmission through mTORC1 (Panasyuk et 
al., 2009). The mTORβ splice variant is capable of interacting with known upstream 
regulators of the 220 kDa version of mTOR, namely Raptor and Rictor (Panasyuk et al., 
2009). In addition, mTORβ readily phosphorylates p70S6K, 4EBP-1 and PKB in vitro. 
Panasyuk et al. (2009) report further that mTORβ over-expression transforms immortalized 
cells, is tumourigenic in nude mice models and significantly reduces the G1 phase of the cell 
cycle. Since mTORβ retains intact FRB, RD and FATC domains, remaining subject to all 
mTOR-like regulation, and assuming mTORβ possess the above qualities in HOSCC, the 
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expression of mTORβ in WHCO1 and WHCO3 cells may be a plausible explanation for the 
maintenance of elevated RPS6(Ser 235/236) phosphorylation levels in these lines only. 
 
In the SNO cell line, where the opposite was true (i.e. high mTOR expression, but low 
RPS6(Ser 235/236) phosphorylation), we considered that activating mutations affecting mTOR 
gene expression or the mTOR kinase domain were possible explanations for this disparity, in 
light of no mTORβ expression. Significant differences in gene expression are reported to 
result from ectopic mTOR-related tumour suppressers and oncogenes in ovarian and breast 
cancer (Heinonen et al., 2008; Laudański et al., 2011). Furthermore, single amino acid 
changes have been identified with regard to mTOR and human cancer. Sato et al. (2010) 
recently examined the Sanger Centre Cancer Genome Database (COSMIC) for changes such 
as these, identifying ten functional amino acid changes relating to the mTOR gene in tumours 
affecting skin, breast, intestine and the digestive tract. Only four mutations involving the 
kinase domain, M2011V (mucinous carcinoma of the overy), S2215Y (adenocarcinoma 
affecting the large intestine), P2476L (glioma in the brain) and R2505P (kidney clear cell 
renal carcinoma), was examined for mutant expression and constitutive mTOR activation. 
Interestingly, only S2215Y and R2505P conferred constitutive activation to mTOR. 
Therefore, it is conceivable that WHCO1, WHCO3, WHCO5 and WHCO 6 cell lines contain 
mutations akin to either S2215Y and R2505P, while the SNO cell line may contain M2011V 
and/or P2476L – possible kinase inactivating mutations.  
 
Frequent activation of mTOR-dependant signalling in human cancer may also arise from 
constitutive activation of upstream regulators, such as PKB, TSC1, TSC2 and Rheb, leading 
to the activation of mTOR (Yuan and Cantley, 2008). It is important to remember that PKB 
negates the inhibitory affect of TSC1/TSC2 which impinges on the mTOR-activating Rheb-
GTPase. Therefore, one would need to investigate TSC1 and TSC2, as well as the Rheb-
GTPase, for functional mutations to ascertain a proper understanding. Moreover, 
experimental evidence from human colorectal cancer (Nozawa et al., 2007) and malignant 
melanoma (Karbowiniczek et al., 2008) implicate a role for hyperphosphorylation of mTOR, 
p70S6K and RPS6. Moreover, genetic disorders resulting from the activation of TSC1/TSC2 
(Inoki et al., 2005), or decreased expression of negative upstream regulators, such as 
PRAS40 and DEPTOR, may lead to the activation of mTOR (Sancak et al., 2007; Peterson et 
al., 2009). Consequently, while single amino acid changes affecting the mTOR kinase 
domain may play a role, the contribution of the plethora of other upstream possibilities 
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activating mTOR cannot be discounted and could be explored further as component of 
another investigation. However, the fact that SNO does not express mTORβ reinforces the 
notion that one (or more) of these common functionally crippling mutations may be present 
within the mTOR protein kinase expressed specifically by the SNO cell line.   
 
5.3. The PI3K/PKB signalling pathway functions as a canonical regulator of 
mTOR/mTORC1 
 
The PI3K/PKB signalling pathway is now known to function as a critical, upstream 
regulatory system controlling essential cellular processes; such as growth, proliferation and 
cell survival (Cantley, 2002). Specific inhibitors of this pathway (such as Wortmannin and 
LY294002) are used to target phosphatidylinositol 3-kinases, ultimately showing that the 
lipid products generated by PI3K’s are essential for PKB activation (Vlahos et al., 1994; 
Nicholson et al., 2003). As a result, PI3K-dependant PKB activation was identified as a 
ubiquitous intracellular signalling scheme, since the importance of PI3K/PKB signalling was 
also observed in KB-3-1 and KB-v1 cells (Nicholson et al., 2003), as well as in HeLa, HEK-
293T, A549 and BEL-7404 cell lines (human liver cancer cells) (Crabbe, 2007; Liu et al., 
2011). Deregulated signalling through PI3K and PKB is known to contribute towards 
malignant transformation in epithelial tissues (Krasilnikov, 2000). This indicates that PI3K-
dependant PKB activation is a key regulatory event necessary for growth, proliferation and 
cell survival, and even tumourigenesis. 
 
Inhibition of PI3K was shown to decrease PKB activation, and thus mTORC1 signalling 
(Martelli et al., 2010). We demonstrate this also occurs in HOSCC cells, where mTORC1 
signalling commonly decreased in response to specific inhibition of PI3K. These results 
convey specific positional information pertaining to the PI3K and mTOR pathways in 
HOSCC cells; where PI3K is situated upstream of mTOR/mTORC1. Furthermore, these 
findings indicate that the PI3K/PKB signalling pathway indeed functions as a canonical, 
upstream regulator of mTORC1 signalling in the WHCO series of cell lines. In addition, 
these results signify that PI3K signalling may critically influence mTORC1-dependent 
survival signalling. This was observed through an increase in autophagy induction potential, 
demonstrated by the increase in dephosphorylated mATG-13 protein expression in HOSCC 
cells.  
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Interestingly, this potential increase in autophagy initiation was not observed in earlier 
studies using thrombin-activated platelets, where specific inhibition of PI3K (also by 
LY294002) negated complete autophagosome formation (Blommaart et al., 1997). These 
finding are therefore unique in this respect, and point towards the involvement of the 
PI3K/PKB pathway during the regulation of autophagy induction signals – perhaps through 
those cellular proteins that play important roles in autophagosome formation; such as 
ULK1/2, Bif and Beclin 1 (Brunn et al., 1996; Blommaart et al., 1997). Specific inhibition of 
PI3K and mTORC1, was in fact was found to contribute directly to autophagy induction and 
promote autophagosome formation (Xie and Klionsky, 2007; Jung, et al., 2009). Currently, 
the use of tailored multi-kinase inhibitors (such as PI-103) is a novel means of targeting both 
PI3K and mTOR (Hayakawa et al., 2007), compounding decreased signalling through both 
pathways. Such strategies have proved useful in a panel of aggressive glioma cell lines, both 
in vitro and in vivo (Fan et al., 2006), and so may hold similar promise in HOSCC 
considering the efficacy of hindering PI3K and mTOR signalling through PI3K inhibition.     
 
5.4. Removal of proliferative signals triggers an autophagic response in HOSCC cells 
 
Tissue culture in the absence of serum constitutes a useful method to investigate the cellular 
responses reliant on these growth-promoting factors, such as the induction of autophagy, 
demonstrated by modulation of both mTOR and mTORC1 signalling in HOSCC upon the 
removal of serum (Langdon, 2004; O’Conner and O’Driscoll, 2006). During standard tissue 
culture conditions, serum supplies the agonistic factors necessary for the appropriate 
regulation of mTOR signalling through canonical and non-canonical mechanisms. Therefore, 
the withdrawal of serum was shown to affect normal intracellular signal transduction from 
pathways such as PI3K/PKB, hsVP34 and Rag GTPases (Yan et al., 2010), since these 
signalling mechanisms transduce growth factor and amino-acid stimuli to the mTOR pathway 
(Avruch et al., 2009; Foster and Fingar, 2010). In Chapter 3, we observed serum-dependant 
modulation of the mTOR signalling pathway in HOSCC cells (i.e. altered cellular 
concentrations of mTOR and decreased signalling thorough mTORC1), a cellular response 
also documented in human neuroblastoma (Edelstein et al., 2011), as well as human U2OS 
osteosarcoma cells (Fingar et al., 2004). As a consequence of nutrient depletion, decreased 
mTOR/mTORC1 signalling slows cell growth by arresting the G1 phase of the cell cycle 
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(Fingar et al., 2002; Fingar and Blenis, 2004; Fingar et al., 2004), supporting the role of 
mTOR as a sensor of nutrient availability in HOSCC. 
 
While growth factor-dependant signalling to mTOR (supplied by serum) involves canonical 
regulation through PI3K/PKB, the mechanism for amino-acid-dependant regulation of mTOR 
by RagGTPases remained incompletely understood. However, the recent discovery that 
glutamine, in combination with the branched chain amino-acids leucine and isoleucine, 
positively regulate mTORC1 signalling through RagB- and RagC-GTPases (Durán et al., 
2012), constitutes a major breakthrough in understanding the mechanism of mTOR regulation 
by amino-acids. Durán et al. (2012) recently demonstrated that inhibition of glutaminolysis 
(the conversion of glutamine into α-ketoglutarate) prevents RagB- and RagC-GTPase 
activity, and as a result, signalling through mTORC1. Conversely, enhanced glutaminolysis 
increased signalling through mTORC1. Therefore, these and future discoveries in this regard 
may provide a basis to understanding the contribution of nutrients in disease; such as 
glutamine addiction prevalent in many cancers (Fingar and Blenis, 2004; Durán et al., 2012).  
 
5.5. The mTOR signalling pathway in HOSCC is susceptible to rapamycin 
 
mTOR was first identified as a biologically relevant target of rapamycin by Brown et al. 
(1994) when two structural variants of rapamycin (16-keto-rapamycin and 25,26-iso-
rapamycin) were used to classify targets of the FKBP-rapamycin complex. Soon after, it was 
discovered that treatment with rapamycin (at physiologically relevant concentrations as low 
as 1 nanomolar (Sabers et al., 1995; Zhou and Huang, 2010) could specifically suppress the 
phosphorylation of common mTOR substrates (such as p70S6K and 4E-BP1) in transformed 
epithelial cell lines; including Human breast cancer cells MCF-7 and MCF-7R (Chen et al., 
2003). Investigations focussing on the specific inhibition of mTOR within these rapamycin-
sensitive cells in comparison to rapamycin-resistant cell lines, such as MDA-MB-231 cells,  
revealed that mTOR functions as a ‘master signal regulator’ directing essential cellular 
processes; such as cell growth, cell cycle, metabolism and autophagy (Fingar and Blenis, 
2004; Zhou and Huang, 2010). 
 
In Chapter 3 we explored the impact of the mTOR/mTORC1 signalling pathway on cell 
proliferation (the extent of RPS6(Ser 235/236) phosphorylation) and autophagy induction (cellular 
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concentration of mATG-13) by inhibiting the kinase ability of mTOR. We demonstrated that 
while mTOR inhibition does not affect the protein expression of focal adhesion kinases (such 
as ILK), rapamycin potently perturbs elevated signalling through mTORC1 in HOSCC of 
South African origin. In fact, RPS6(Ser 235/236) phosphorylation, and thus mTORC1 signalling, 
may be completely abolished through exposure to low (nanomolar) concentrations of 
rapamycin. These findings may indicate promise for those diagnosed with HOSCC in 
Southern Africa, since those affected experience late detection resulting from poor diagnostic 
methodologies for screening high-risk populations (Kachala, 2010). Decreasing signalling 
through the mTOR/mTORC1pathway through exposure to rapamycin may therefore provide 
a form of control for this disease, other than a surgical option (Bancewicz, 1990). Moreover, 
aberrant mTOR signalling is implicated in the progression of other human cancers; such as 
breast and ovarian (Campbell et al., 2004), melanoma (Madhunapantula et al., 2009), and 
renal cell carcinomas (Kondo et al., 2001). In addition, deregulated mTOR/mTORC1 
pathway activities have been observed in several other human diseases; such as diabetes, 
Cowden’s disease (Inoki et al., 2005), Tuberous Sclerosis complex (TSC) (Kenerson et al., 
2002), Lymphangioleiomyomatosis (LAM) (Johnson and Tattersfield, 2002). Therefore, we 
strongly contend that these findings provide support for rapamycin and its derivatives as 
viable therapeutic agents to curb aberrant mTOR-dependant signalling events.   
 
5.6. RPS6(Ser 235/236) is phosphorylated by mTORC1 in the absence of MAPK/p90RSK-
dependent signal transduction in HOSCC 
 
Initially, we considered the activation state of each mTOR multi-protein complex (i.e. 
mTORC1 or mTORC2) as a possibly more informative means to monitor the signalling 
potential of mTOR. This was a viable option since each mTOR complex displays mTOR-
specific phosphorylation patterns. Copp et al. (2009) established that mTORC1 is 
predominantly phosphorylated at S2448, by both PKB and p70S6K, whereas mTORC2 is 
predominantly phosphorylated at S2481. Commercial phospho-mTOR antibodies for these 
sites are also available, allowing for immunodetection of each active complex. However, this 
line of reasoning was abandoned after considering the propensity for carcinomas to 
hyperphosphorylate mTOR at these sites (Karbowiniczek et al., 2008; Sato et al., 2010). In 
addition, since the mutational status of mTOR is currently unknown in these HOSCC cell 
lines, detecting phosphorylated mTOR may convey incorrect information concerning the 
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activation of mTORC1 – the complex responsible for RSP6(Ser 235/236) and mATG-13 
phosphorylation.  
 
Since the anti-mATG-13 antibody was used to detect dephosphorylated mATG-13, 
specifically (Chan et al., 2009), we used the extent of RPS6(Ser 235/236) phosphorylation as 
downstream marker for active mTORC1 signalling. However, p90RSK (an effector kinase of 
the MAPK signalling cascade) may also phosphorylate RPS6(Ser 235/236) (Nguyen, 2008). 
Therefore, we assessed the ability of mTORC1 in HOSCC cells to phosphorylate RPS6(Ser 
235/236)
 in the absence of MAPK/p90RSK signals by using a newly developed p90RSK-
specific inhibitor, BI-D1870, designed to target all four RSK isoforms (Sapkota et al., 2007). 
As specific p90RSK inhibition with BI-D1870 decreases p-PKB(Thr 308), but not the degree of 
PKB(Ser 473) phosphorylation – a downstream target of mTORC2 (Chen and MacKintosh, 
2009), we expected that mTORC1 activity would be similarly unaffected by BI-D1870. 
Indeed we demonstrated, for the first time, that inhibition of p90RSK decreased the 
phosphorylation of RPS6(Ser 235/236) in HOSCC cells between 5.0 and 13.0 % only, where 
appreciable levels of p-RPS6(Ser 235/236) remained. This indicates that mTOR/mTORC1-based 
signals are responsible for RPS6(Ser 235/236) phosphorylation in the absence of active p90RSK 
in the WHCO cell lines investigated here.  
 
In contrast to other small molecule inhibitors of p90RSK (such as FMK and SL0101), BI-
D1870 has shown remarkable affinity for all four RSK splice variants, especially in HEK-293 
cells, while not significantly affecting the important cellular kinases; such as GSK-3β, PKB, 
mTOR, AGC-like kinases and PDK1 (Sapkota et al., 2007; Nguyen, 2008). For these 
reasons, BI-D1870 (an amino-terminal kinase domain - or NTKD - ATP-binding 
dihydropteridinone) was a superior choice over the NTKD ATP-binding inhibiter 
kaemperfol-glycoside SL0101, as well as the pyrolopyrumidine FMK (which binds 
irreversibly to the CTKD ATP-binding region of RSK2) (Nguyen, 2008). However, since BI-
D1870 is both a novel and expensive inhibitor, the use of BI-D1870 is poorly reported in the 
literature. Other than Sapkota et al. (2007), the publications of Kang et al. (2007), Chen and 
MacKintosh (2009) and Xian et al. (2009) are the only examples in the primary literature to 
specifically inhibit p90RSK with BI-D1870. Therefore, these findings are unique in that, to 
our knowledge, the inhibition of MAPK/p90RSK signalling has never been attempted in SCC 
of the oesophagus. Furthermore, this is the first study comparing differential RSP6(Ser 235/236) 
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phosphorylation by mTORC1 and p90RSK to gain an understanding of those initial 
signalling events indicating proliferative cellular events. 
 
Considering the influence of the MAPK pathway in mTORC1 signalling (seen through some 
HOSCC cells increasing p-RPS6(Ser 235/236), as well as p90RSK-sepcific inhibition modulating 
the concentration of cellular mTOR), it would be interesting to determine the concentration of 
BI-D1870 necessary for p90RSK-specific inhibition in order to critically decrease p-RPS6(Ser 
235/236)
. In addition, it would also be interesting to investigate the combined effect of 
rapamycin and BI-D1870 on both mTOR and mTORC1 signalling in HOSCC, as these data 
may have therapeutic implications for curbing hyperactive p-p38 induced MAPK/p90RSK 
signalling, recently shown to play a key role in malignant transformation in ESCC’s (Zheng 
et al., 2012). Therefore, through the use of this p90RSK inhibitor, we determined that an 
activated mTOR signalling pathway leads to RPS6(Ser 235/236) phosphorylation in HOSCC 
cells, of which an essential requirement for this is signalling through mTORC1.    
 
5.7. ECM-modulation of the mTOR signalling pathway utilizes PI3K to regulate 
autophagy induction in HOSCC 
 
Cells require stable cell-cell and cell-ECM connections to create an organized tissue structure 
(Gumbiner, 1996). Components of the cell adhesion machinery facilitate these types of 
connections and allow individual cells to assemble into diverse and distinctive three-
dimensional structures (Juliano, 2002). While, cadherins and adherens junctions facilitate 
cell-cell interconnectivity, allowing formation of intercalated, epithelial sheets (Gumbiner, 
1996), adhesion to a supporting substrate is facilitated by different permutations of α and β 
integrin heterodimers (Gumbiner, 1996; van Der Flier and Sonnenberg, 2001). Consequently, 
integrin-mediated cell-ECM adhesion is implicated in the regulation of cell survival, 
migration, proliferation, differentiation and even tumour progression (Juliano, 2002; 
Brakebusch and Fӓssler, 2003; Brunton et al., 2004). Thus, ECM-attachment to a collagen- or 
fibronectin-rich interstitial matrix (ECM) is an essential requirement for tissue integrity and 
homeostasis in epithelial cells (Gumbiner, 1996).    
 
This importance of cell-ECM attachment during cell survival is demonstrated through 
adhesion-based signals (originating from cell-ECM interactions) supporting tumour 
progression by promoting anoikis resistance (Fanucchi and Veale, 2011) and autophagy 
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induction (Fung et al., 2008; Lock and Debnath, 2008; Chen and Debnath, 2010). Previous 
studies involving skeletal muscle cells often suggested a form of mTOR regulation via 
mechanotransduction-based events. Here, the ECM was shown to play a role in cell growth 
signals propagated through the mTOR signalling pathway, which occurred in a PI3K-
dependent manner (Baar and Esser, 1999; Hornberger, 2011). Three main observations lead 
to this conclusion. Firstly, mechanical stimulation induces signalling through the integrin-
triggered focal adhesion protein kinase, ILK (Legate et al., 2006; Hannigan et al., 2011). 
Secondly, mechanical stimulation in this manner also leads to the activation of both PI3K and 
PKB (Bolster et al., 2003; Hornberger et al., 2003). Thirdly, constitutive signalling through 
PI3K/PKB promotes skeletal muscle growth in a rapamycin-sensitive manner (Bodine et al., 
2001; Varma and Khandelwal, 2007). Thus, mechanically-derived stimuli could, in theory, 
activate mTORC1 through the PI3K/PKB signalling machinery. 
 
In confirmation of the above, the data presented in Chapter 4 provide evidence for the 
activation mTORC1 signalling in HOSCC cells in response to mechanically-derived 
extracellular-originating stimuli. Although p-PKB(Ser 473) were not measured here, it was 
observed that mechanical signals commonly increase both mTOR and p-RPS6(Ser 235/236) 
protein expression levels in HOSCC cells – indicating a novel, non-canonical mode of 
mTOR/mTORC1 regulation through adhesion to the physical environment. With regard to 
the route of signal transmission, the lack of a detectable protein-protein interaction between 
mTOR and both ILK and FAK in the WHCO series of cell lines highlights an indirect 
mechanism of signal transduction from mechanical stimulus to mTORC1. Thus, we strongly 
believe that since specific inhibition of the kinase ability of PI3K perturbs this 
mechanotransduction effect on mTORC1, these results demonstrate unequivocally that 
intracellular signal transduction of adhesion-based signals 1) modulate mTOR/mTORC1 
signalling, and 2) occurs in a PI3K-mediated manner in HOSCC cells.    
 
Combined, these observations provide a solid rationale to support our hypothesis that 
mechanical stimuli activate mTORC1 signalling through a mechanism involving the 
activation of ILK, thereby regulating autophagy induction and consequently supporting 
HOSCC cell survival. To provide further support for our contention, we illustrate these 
findings in Figure 5.1 and highlight the response of a substrate-dependant epithelial cellular 
system to this form of adhesion-based signal transduction. Under standard tissue culture 
condition, HOSCC’s maintain an enhanced rate of flux through the mTOR signalling 
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pathway (denoted by the elevated blue squares during State 1 “Homeostasis” in Figure 5.1, A 
versus B). Here, we demonstrated that soluble stimuli; such as growth factor, amino-acids and 
rapamycin treatment, impinge on this flux, therefore affecting homeostasis of HOSCC cells. 
Interestingly, autophagy seems to play an important survival role in HOSCC as we observed 
elevated expression of markers for autophagy induction potential (i.e. dephospho-mATG-13) 
under these conditions. Therefore, HOSCC cells tend to maintain an elevated basal rate of 
autophagy (represented as elevated red triangles). Conversely, pro-death signals mediated 
through apoptotic regulators, such as cleaved caspase-3, are completely down-regulated 
(indicated by purple circles touching the X-axis). 
 
Crucially, we demonstrated that mTOR/mTORC1 signalling may be increased by growth in 
the presence of fibronectin- or collagen-coated substrates (signified by the increase in blue 
squares over and above elevated signalling levels). This cell-substrate dependant increase in 
mTORC1 signalling may provide a rationale for the increase in autophagy observed when 
cell-substrate connections are abolished (denoted by State 2 “Transition” in Figure 5.1, B). 
Since we showed that a direct mTOR-ILK protein interaction does not account for this signal 
transduction, cell-substrate connections may signal to mTOR/mTORC1 through an integrin-
triggered medium, but one utilizing PI3K-mediated machinery to inhibit autophagy induction. 
Consequently, when these integrin-activating stimuli are lost, positive regulation of cellular 
concentrations of mTOR and mTORC1 signalling is diminished, allowing for the initiation of 
autophagy induction – as previously reported by Fung et al. (2008). Interestingly, we 
discovered that these autophagy induction signals precede pro-death signals in HOSCC cells 
(See Chapter 2 and Chapter 3 where autophagy induction increased while cleaved caspase-3 
was not detected under autophagy-promoting conditions; such as nutrient withdrawal for 24 
hours and PI3K-specific inhibition with LY294002). Together, this provides a rationale for 
autophagy to promote cell survival before cell death signals are properly initiated. 
 
In transformed epithelial phenotypes, exemplified by HOSCC, where anoikic-based pro-
death signals are delayed (Fanucchi and Veale, 2009; Fanucchi and Veale, 2011), this 
mechanism of autophagy induction may be exploited to enhance survival during 
dissemination before cell-ECM connections can be re-established. We illustrate this as 
apoptotic ‘pro-death’ signals (purple circles) do not out-compete autophagic pro-survival 
signals (red triangles) during State 3 “Pro-death Signals” in Figure 5.1, B. Supporting this 
contention is the tendency for HOSCC to display anoikis resistance, as shown by Fanucchi 
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and Veale, (2011). Therefore, the adhesion-based autophagy induction occurs through 
substrate-dependant regulation of the mTOR/mTORC1 signalling pathway, which is 
facilitated by the integrin-triggered focal adhesion protein kinase, ILK, positively regulating 
PI3K/PKB signalling and therefore mTOR/mTORC1 pathway. 
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A: Physiologically ‘normal’ epithelial cells         B: Trends observed within HOSCC cells 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Cellular response to changes in the state of cell-ECM adhesion. Comparison of the influence of essential signalling machinery on 
cell behaviour between a physiologically normal epithelial cell systems and the transformed HOSCC phenotype. The signalling 
response for mTOR/mTORC1 (blue squares), autophagy induction (red triangles) and apoptosis (purple circles) are described as a 
function of the state of cell adhesion, which transitions from cell-ECM attachment to cell-ECM detachment. 
mTOR Signalling Autophagy InductionAnoikis
Attachment Detachment
PCD Type-I PCD Type-II
                        1.                                       2.                       3.                     4.
               Homeostasis                       Transition         Pro-death        Full-blown
                                                                                       Signals           Apoptosis
State of Cell Adhesion
S
i
g
n
a
l
l
i
n
g
 
R
e
s
p
o
n
s
e
? 
mTOR Signalling Autophagy InductionAnoikis
                        1.                                       2.                        3.                     4.
               Homeostasis                       Transition          Pro-death        Full-blown
                                                                                         Signals          Apoptosis
Attachment Detachment
PCD Type-I PCD Type-II
?
?
ECM-derived
     stimuli
State of Cell Adhesion
S
i
g
n
a
l
l
i
n
g
 
R
e
s
p
o
n
s
e
123 
 
5.8. Conclusion 
Aberrant integrin-mediated adhesion and enhanced survival signalling are hallmarks of 
transformation associated with metastasis (Hanahan and Weinberg, 2011). These events 
oppose anoikic death programmes and induce autophagy; an evolutionary conserved cell 
survival mechanism, inappropriately (Fung et al., 2008; Lock and Debnath, 2008). Since 
detachment-induced autophagy indicates a form of adhesion-based regulation, ECM-
originating signals may be transmitted to the cellular machinery controlling autophagy 
induction – a form of regulation which is subsequently lost when epithelial cells become 
detached from a substrate. This type of control implicates crosstalk between an integrin-
triggered focal adhesion protein kinases (such as ILK) the mTOR signalling pathway, which 
is a critical regulator of autophagy induction (Foster and Fingar, 2010; Dobashi et al., 2011). 
Consequently, molecular analysis of the most significant cell adhesion, mTOR and autophagy 
signal transduction pathway intermediates constitutes an information-rich reporter system, 
enabling the examination of such crosstalk. 
 
Pivotal to this investigation was the use of a series of highly tumourigenic epithelial cell 
lines, with a propensity for metastasis, inappropriate survival signalling and anoikis evasion 
potential; human oesophageal squamous cell carcinoma (HOSCC) (Miller and Veale, 2001; 
Driver and Veale, 2006; Fanucchi and Veale, 2011). Up until now, very few studies have 
focussed on characterising the mTOR pathway as a molecular mechanism promoting 
progression of HOSCC. Only the work by Hou et al. (2007) and Hirashima et al. (2012) 
demonstrate that poorly- and well-differentiated ESCC cells of Chinese origin display ectopic 
mTOR expression and aberrant mTORC1 signalling, which is associated with the progression 
of solid epithelial tumours. In this study, we reveal that HOSCC cells parallel ESCC cells in 
this regard, providing a reasonable basis to suggest that aberrant mTOR/mTORC1 signalling 
plays a similar role in HOSCC of South African origin.  
 
Most importantly however, these data highlight that mTORC1-dependent autophagy 
induction is affected by the state of cellular attachment, which is advantageous for 
disseminating cells capable of evading anoikic cell death. Moreover, this type of regulation is 
not by way of a direct interaction with an integrin-triggered protein kinase, such as ILK, as 
first thought. Rather, ECM-modulation of mTOR acts through the PI3K signalling pathway. 
Therefore, these findings support our contention that the mTOR protein kinase is a target for 
adhesion-based signal transduction, which influences cell survival through mTORC1.  
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APPENDICES 
 
APPENDIX A 
 
1.1. Commonly Used Solutions 
 
1.1.1 Phosphate Buffered Saline (PBS) (1X) 
136.9 mM  Sodium Chloride 
2.680 mM  Potassium Chloride 
10.10 mM  Disodium Hydrogen Phosphate Dodecahydrate 
1.769 mM  Potassium Dihydrogen Phosphate 
Adjust to a pH between 7.2 – 7.3 
Make up to final volume with dH2O 
Autoclave to sterilize 
Store at 4 °C 
 
1.1.2 Tris Buffered Saline (TBS) (1X)  
50.00 mM  Tris-HCl (pH 7.8) 
147.0 mM  Sodium Chloride 
2.000 mM  Anhydrous Calcium Chloride 
Make up to final volume with dH2O 
Autoclave to sterilize. 
Store at 4 °C 
 
1.1.3 Tris Buffered Saline with Tween (TBS-T) 
50.00 mM  Tris-HCl (pH 7.8) 
147.0 mM  Sodium Chloride 
2.000 mM  Anhydrous Calcium Chloride 
0.100 %  Tween 
Make up to final volume with dH2O 
Store at 4 °C 
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1.1.4 10 % Sodium dodecyl Sulphate (SDS) 
 
10 %   SDS 
Make up to final volume with dH2O 
Heat to assist dissolution 
Adjust to pH 7.2 
Store at room temperature 
 
1.2. Tissue Culture 
 
1.2.1. DMEM/Hams F12 Medium Solution 
Mix DMEM/Hams F12 Medium Solutions in a 3:1 ratio 
Filter sterilize 
Store at 4 °C 
 
1.2.1.1. Dulbecco’s Modified Eagles Medium (DMEM) 
1.370 %   DMEM 
0.370 %   Sodium Bicarbonate 
2.000 %  Penicillin (500 U/ml)/Streptomycin (0.5 %) Solution  
 
 
1.2.1.2. Hams F12 Medium Solution 
1.070 %   Hams F12 Medium 
0.118 %   Sodium Bicarbonate 
2.000 %   Penicillin (500 U/ml)/Streptomycin (0.5 %) Solution 
 
1.2.2. Trypsin/Ethylenediaminetetra-acetic Acid (EDTA) 
Mix Trypsin Solution/EDTA in a 1:1 ratio 
Store at 4 °C 
 
1.2.2.1. Trypsin Solution 
0.010 %  Trypsin in PBS 
 
1.2.2.2. Ethylenediaminetetra-acetic Acid (EDTA) 
0.004 %   EDTA in PBS 
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1.3. Protein Extraction 
 
1.3.1. 2 % (v/v) Triton X-100 Protein Extraction Buffer 
50 mM  Tris-HCl (pH 7.2) 
150 mM   NaCl 
1 mM   Magnesium Chloride 
0.5 mM  Ethylene Glycol Tetraacetic Acid 
5 µl/ml   Phenyl-methyl-sulphonyl Fluoride (PMSF) 
10 µl/ml  Trasylol 
2.0 %   Triton-X-100 
Make up to 10 ml with dH2O 
 
1.3.2. Laemmli Double Lysis Buffer (2X) 
123.8 mM  Tris-HCl (pH 6.8) 
4.000 %  SDS 
20.00 %  Glycerol 
10.00 %  β-mercaptoethanol 
Make up to final volume with dH2O 
Store at 4 °C 
 
 
1.3.3. Laemmli Single Lysis Buffer (1X) 
 50 %   Laemmli Double Lysis Buffer (2X) 
50 %   dH2O 
Store at 4 °C 
 
 
1.4. Protein Estimation 
 
1.4.1. 95 % Ethanol 
95 %    Ethanol 
Make up to final volume with dH2O 
 
1.4.2. 7.5 % Trichloroacetic Acid (TCA) 
7.5 %   TCA 
Make up to final volume with dH2O 
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1.4.3. 0.25 % Coomassie Brilliant Blue Stain 
0.25 %   Coomassie Brilliant Blue Powder 
50.0 %   Methanol 
Dissolve, and then add: 
10.0 %   Glacial Acetic Acid 
Make up to final volume with dH2O 
 
1.4.4. Destain Solution 
12 %   Glacial Acetic Acid 
10 %   Methanol 
Make up to final volume with dH2O 
 
1.4.5. Elution Solution 
66 %   Methanol 
33 %   dH2O 
1.0 %   Concentrated Ammonia 
 
 
1.5. Sodium dodecyl Sulphate – Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
 
1.5.1. Sample Preparation 
 
1.5.1.1. Laemmli Lysis Buffer (1X) 
As previously described 
 
1.5.2. Buffers 
 
1.5.2.1. Running Buffer 
25.00 mM  Tris-HCl (pH 8.3) 
192.5 mM  Glycine 
3.740 mM  SDS 
Adjust solution to pH 8.3 using 5 N HCl 
Make up to final volume with dH2O 
Store at 4 °C 
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1.5.2.2. Separating Buffer 
18.12 g  Tris 
Adjust solution to pH 8.8 using 5 N HCl 
Make up to final volume with dH2O 
 
1.5.2.3. Stacking Buffer 
6.04 g  Tris 
Adjust solution to pH 6.8 using 5 N HCl 
Make up to final volume with dH2O 
 
1.5.3. Working Solutions 
 
1.5.3.1. Separating Gel 
375 mM  Tris-HCl (pH 6.8) 
10 - 12 %  Acrylamide 
0.100   %  N,N’–methylenebisacrylamide 
0.200   %  SDS 
Make up to final volume with dH2O 
Just prior to use add: 
1.000 %  Ammonium Persulphate Solution (APS) 
0.250  N’,N’,N’,N’–tetramethylethylene-diamene (TEMED) 
 
1.5.3.2. Stacking Gel 
125 mM  Tris-HCl (pH 6.8) 
5 – 8  %  Acrylamide 
0.100 %  N,N’–methylenebisacrylamide 
0.200 %  SDS 
Make up to final volume with dH2O 
Just prior to use add: 
1.000 %  Ammonium Persulphate Solution (APS) 
0.250 %  N’,N’,N’,N’–tetramethylethylene-diamene (TEMED) 
 
1.5.3.3. SDS Overlay 
400 µl of 50mg/ml SDS 
Make up to 10 ml with dH2O 
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1.5.3.4. Tracking Dye 
0.001 %  Bromophenol Blue 
50.00 %  Glycerol 
Make up to final volume with dH2O 
Store at – 4 °C 
 
1.5.3.5. 0.25 % Coomassie Brilliant Blue Stain 
As previously described (see Appendix A, Section 1.4.3) 
 
1.5.3.6. Destain Solution 
10 %  Acetic Acid 
10 %  Methanol 
Make up to final volume with dH2O 
 
1.6. Western Immunoblot Analysis 
 
1.6.1. Buffers 
 
1.6.1.1. Transfer Buffer 
25 mM  Tris-HCl (pH 8.3) 
20.0 %  Methanol 
1.41 %  Glycine 
Make up to final volume with dH2O 
 
1.6.1.2. TBS–for–Blotto Blocking Buffer 
50 mM  Tris-HCl (pH 7.8) 
2.0 mM  Anhydrous Calcium Chloride 
5.00 %  Non-fat Milk Powder 
0.01 %  Anti-foam 
0.05 %  TritonX-100 
Make up to final volume with dH2O 
 
1.6.1.3. 5 % Non-fat Milk Powder Blocking Solution 
5.0  %  Non-fat Milk Powder 
Make up to final volume with appropriate buffer 
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1.6.1.4. Phosphate Buffered Saline (PBS) (1X) 
As previously described (see Section 1.1.1) 
 
1.6.1.5. Tris Buffered Saline (PBS) (1X) 
As previously described (see Section 1.1.2)   
 
1.6.1.6. Tris Buffered Saline with Tween (1X) 
As previously described (see Section 1.1.3)   
 
1.6.2. SuperSignal® West Pico Chemiluminescent Substrate Kit  
Before use mix in a 1:1 ratio: 
50 %  Luminol Enhancer Solution 
50 %  Stable Peroxide Buffer 
 
1.6.3. Developer 
6.400 M  Methanol 
0.600 M  Anhydrous Sodium Sulphate 
80.0 mM  Hydroquinone (Quinol) 
0.45 mM  Anhydrous Sodium Carbonate 
34.0 mM  Potassium Bromide 
Make up to final volume with dH2O 
Store at room temperature in the dark 
 
1.6.4. Fixer 
0.8 M  Sodium Thiosulphate 
0.2 M  Sodium Metasulphite 
Make up to final volume with dH2O 
Store at room temperature in the dark 
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1.7. Co-Immunoprecipitation Analysis 
 
1.7.1. Radio-immunoprecipitation Assay (RIPA) Buffer 
50 mM   Tris-HCl (pH 7.5)  
150 mM   NaCl  
0.5 %   Deoxycholate  
0.5 %  Triton X-100  
0.05 %   SDS  
1 mM   PMSF/Aprotinin  
Make up to final volume with dH2O  
Store at 4 °C 
 
1.7.2. Phenylmethanesulphonylfluoride (PMSF) Stock Solution 
34.8 mg  PMSF 
Make up to 10 ml with Methanol 
 
1.7.3. PMSF/Aprotinin Solution 
0.1 mM  PMSF Stock Solution 
1.00 ml  Trasylol 
Make up to 100 ml with PBS (1X) 
 
1.7.4. Immunoprecipitation (IP) Buffer  
20 mM  Tris (pH 8.0) 
0.50 %  Nonidet P-40 (NP-40) 
0.90 %  Sodium Chloride 
Make up to final volume with dH2O 
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1.8. Specific Inhibition of PI3K with LY294002  
 
1.8.1. LY294002 Working Dilution 
20 µM   LY294002 in 100 % DMSO 
 
1.8.1.1. LY294002 Stock 
1 mg/ml 
Make up to final volume with 100 % DMSO 
 
1.9. Specific Inhibition of mTOR with Rapamycin 
 
1.9.1. Rapamycin Working Dilutions 
20 nM    Rapamycin in 100 % DMSO 
50 nM   Rapamycin in 100 % DMSO 
100 nM   Rapamycin in 100 % DMSO 
 
1.9.1.1. Rapamycin Stock 
1 mg/ml 
Make up to final volume with 100 % DMSO 
 
1.10. Specific Inhibition of p90RSK with BI-D1870 
 
1.10.1. BI-D1870 Working Dilution 
10 µM   BI-D1870 in 100 % DMSO 
 
1.10.1.1. BI-D1870 Stock 
1 mg/ml 
Make up to final volume with 100 % DMSO 
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1.11. Growth on Fibronectin 
 
1.11.1. Fibronectin Working Dilution 
10 µg/ml  Fibronectin in PBS 
 
1.11.1.1. Fibronectin Stock 
1 mg/ml 
Make up to final volume with PBS 
 
1.12. Growth on Collagen 
 
1.12.1. Collagen Working Dilution 
100 µg/ml  Collagen in 0.02 N Acetic Acid 
Made up to volume with dH2O 
 
1.12.1.1. Collagen Stock 
3 µg/µl   Rat Tail Collagen in 0.5 M Acetic Acid 
Made up to volume with dH2O 
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APPENDIX B 
 
2.1. Sample standard curve 
 
Figure B1: Sample standard curve for the estimation of protein concentration from HOSCC 
cells lysates. BSA standards of a known and varying concentration (1, 3, 6, 9, 12, 
16 and 20 μg/μl; x-axis), together with their respective absorbance values 
determined at 596 nm (y-axis), were used to create the standard curve. The 
equation of the curve was used to calculate the amount of unknown protein in 
HOSCC cell lysates. R
2
 is indicative of linear regression. 
 
2.2. Calculation of percent change (% ∆) in protein expression levels after 
semi-quantitative densitometric analysis 
 
Measures of relative difference may be expressed as unitless ratios. One approach to obtain 
percent change between two semi-quantitative measurements of % IOD is the difference 
between the final and initial value, divided by the initial value (Loyd, 2008). Therefore, 
percent change (% ∆) may be expressed as: 
 
∆	= 	
∆	%	
%		

 
 
∴ 	%	∆	= 	
%		 −	%		

%		

			% 
 
 
 
 
 
 
 
 
; where positive % ∆ = increase in protein 
                                         expression. 
 
; where negative % ∆ = decrease in protein   
                                          expression. 
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 2.3. Repeated western immunoblot analysis of mTOR and p
polypeptides, in response to growth on either fibronectin or collagen.
 
 
Figure B2: Repeated immunodetection of mTOR and p
growth on substrates coated with either fibronectin or 
indicative of mTOR (220 kDa) and p
detected in WHCO 3 cells (U, FN and CN), not detected in WHCO 5 cells (FN and 
CN), not detected in WHCO 6 cells (FN) and weakly in SNO cells (U and FN). 
Therefore, these western immunoblots were repeated. Initially, 15 μg of protein 
was loaded from each sample in order 
however this value was now doubled to 30 μg of protein from each sample. 
Consequently, appropriate polypeptide bands indicative of mTOR (220 kDa) and 
p-RPS6
(Ser 235/236)
 (36 kDa) were detected by immunoblot, relative
kDa) which was used to demonstrate equal protein loading of 
lysates.  
-RPS6
(Ser 235/236)
 in 
collagen
-RPS6
(Ser 235/236)
 (36 kDa) were weakly 
to detect mTOR and p
152 
-RPS6 
 
 
HOSCC cells after 
. Polypeptides 
-RPS6
(Ser 235/236)
, 
 to β-actin (46 
HOSCC cell 
153 
 
2.4. Commonly used antibodies and incubation conditions during western immunoblot analysis 
Table B1: Commonly used antibody dilutions and incubation times. 
Primary 
Antibody 
Transfer 
Time 
(hr) 
Dilution 
(Ab:Buffer) 
Incubation 
Time 
(hr) 
Buffer and 
Temperature 
Conditions* 
Secondary 
Antibody 
Dilution 
(Ab:Buffer) 
Incubation 
Time 
(hr) 
Buffer and 
Temperature 
Conditions* 
mTOR 3 1:1 000 2 
2.5 % BSA in 
TBS-T:TBS (1:1) 
at RT 
Goat anti-rabbit 
HRP-conjugate 
1:5 000 1 
TBS: TBS-T (1:1) 
at RT in the dark 
p-RPS6 
(Ser 235/236)
 
1.5 1:2 000 Overnight 
5 % BSA in TBS-
T at 4 °C 
Goat anti-rabbit 
HRP-conjugate 
1:2 000 1 
5 % milk powder 
in TBS-T PBS at 30 
°C in the dark 
mATG-
13 
1.5 1:1 750 Overnight 
1 % milk 
powder in TBS-T 
at 4 °C 
Goat anti-rabbit 
HRP-conjugate 
1:5 000 1 
5 % milk powder 
in TBS-T at 30 °C 
in the dark 
ILK 1.5 1:1 500 1 1 X PBS at RT 
Goat anti-rabbit 
HRP-conjugate 
1:30 000 1 
1 X PBS at 30 °C in 
the dark 
CC-3 1.5 1:500 Overnight 
2.5 % milk 
powder in TBS-T 
at 4 °C 
Goat anti-rabbit 
HRP-conjugate 
1:2 000 1 
5 % milk powder 
in TBS-T at 30 °C 
in the dark 
β-actin 1.5 1: 1000 2 1 XPBS at RT 
Goat anti-rabbit 
HRP-conjugate 
1:35 000 1 
1 X PBS at 30 °C in 
the dark 
FAK 2 1:500 2 1 X PBS at RT 
Goat anti-rabbit 
HRP-conjugate 
1:5 000 1 
1 X PBS at RT in 
the dark 
Raptor 2.5 1:500 2 
2.5 % BSA in 
TBS-T:TBS (1:1) 
at RT 
Goat anti-rabbit 
HRP-conjugate 
1:5 000 1 
TBS: TBS-T (1:1) 
at RT in the dark 
 
Key: The star (*) symbol indicate conditions performed at room temperature (RT). 
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2.5. PI3K pathway information for the WHCO series of cell lines obtained from Shaw Ph.D. Thesis (2011) 
 
Table B2: Summary of complimentary PI3K/PKB pathway information obtained from specific inhibition of PI3K with 
LY294002. 
 
Protein Cell Line 
 
WHCO1 WHCO3  WHCO 5  WHCO6  SNO  MCF-7 
 
↑/↓ H/M/L ↑/↓ H/M/L ↑/↓ H/M/L ↑/↓ H/M/L ↑/↓ H/M/L ↑/↓ H/M/L 
PTEN ↓ Low ↓ Low ↑ Med ↑ High ↓ Low ↓ Med 
p-PKB 
(Ser473)
 
↓ Low ↓ Low ↓ Low ↓ Low ↓ Low ↓ High 
 
Key: Low = 0 – 45 %; Medium (Med) = 46 – 75 %; High = 76 – 100 % (and above). Protein expression levels are based on the Hager et al., (2011) 
classification system for analyses of mTOR and p-RPS6 proteins (Materials and Methodology, Laser densitometry and analysis of relative protein 
expression). Change in relative marker set protein expression is designated by either positive (↑) or negative (↓) arrows. These data were obtained 
from the Ph.D. Thesis of Shaw (2011). 
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Appendix C 
 
3.1. Raw IOD and % IOD data obtained from semi-quantitative densitometric 
analysis 
 
Table C1: Levels of marker set protein expression during standard tissue culture 
conditions (Serum +).   
 
Protein Cell Line 
 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
 IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD % IOD 
mTOR 3294 88 1171 31 3310 88 4387 117 3971 106 3727 100 
p-RPS6 
(Ser 235/236)
 
2714 69 2226 56 4882 124 4894 124 362 9 3926 100 
mATG-13 1095 142 852 110 191 24 623 80 936 121 770 100 
ILK 3815 87 3772 86 4472 101 5638 128 5665 129 4385 100 
 
Table C2: Standard error for levels of marker set protein expression expressed as 
% IOD) during standard tissue culture conditions (Serum +). 
 
Protein Cell Line 
 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
mTOR 1.70 3.77 1.03 4.80 7.75 0.00 
p-RPS6 
(Ser 235/236)
 
41.21 41.35 15.91 17.50 3.41 0.00 
mATG-13 27.54 29.40 22.85 34.92 22.29 0.00 
ILK 3.41 3.41 23.45 2.24 5.07 0.00 
 
Table C3: Comparison of mTOR and mTORβ protein expression levels during 
standard tissue culture conditions (Serum +). 
 
Protein Cell Line 
 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 HEK-293 
 IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
mTOR 81 1.3 112 1.8 3430 53 3664 56 3226 50 5373 83 6445 100 
mTOR
β 
272 28 949 100 0.0 0.00 0.0 0.0 0.0 0.0 176 18 190 20 
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Table C4: Standard error for mTORβ protein expression (expressed as % IOD) 
during standard tissue culture conditions (Serum +). 
 
Protein Cell Line 
 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 HEK-293 
mTOR 0.01 0.59 5.22 0.63 7.83 1.70 0.00 
mTORβ 51.17 29.10 0.00 0.00 0.00 30.69 0.00 
 
Table C5: Marker set protein expression from the apoptotic cell (A/C) control.   
 
Protein 
Tissue Culture 
Condition 
Cell Line 
  WHCO6 
  IOD % IOD 
mTOR 
S+ 2159 100 
A/C 651 30 
p-RPS6 
(Ser 235/236)
 
S+ 7914 100 
A/C 0 0 
mATG-13 
S+ 5996 100 
A/C 1427 24 
ILK 
S+ 4629 100 
A/C 3586 77 
 
Table C6: Protein expression levels of marker set proteins after specific inhibition 
of PI3K with LY294002. 
 
Protein  Cell Line 
  WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
  IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD % IOD 
mTOR 
L- 1609 75 155 7 1366 63 2159 100 877 41 3232 150 
L+ 2212 102 499 23 2053 95 1806 84 1046 48 5445 252 
p-RPS6 
(Ser 235/236)
 
L- 453 6 196 2 3751 47 7914 100 3457 44 2755 35 
L+ 225 3 2397 30 856 11 3039 38 212 3 184 2 
mATG-13 
L- 5062 84 7513 125 4153 69 5996 100 7385 123 10277 171 
L+ 4918 82 6408 107 6453 108 5138 86 4792 80 3537 59 
ILK 
L- 3991 86 2541 55 2410 52 4629 100 7091 153 2667 58 
L+ 4151 90 2561 55 3284 71 3642 79 4895 106 3245 70 
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Table C7: Standard error of marker set protein expression (expressed as % IOD) 
specific inhibition of PI3K with LY294002. 
 
Protein Treatment Cell Line 
  WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
p-RPS6 
(Ser 235/236)
 
L- 0.92 0.22 1.32 0.00 0.00 0.00 
L+ 1.48 3.90 8.57 14.00 0.00 0.00 
mATG-13 L- 4.50 0.00 22.66 0.00 18.82 25.16 
L+ 1.34 34.45 13.58 3.59 8.63 19.07 
 
Table C8: Protein expression levels of marker set proteins during conditions of 
serum-free tissue culture (Serum -).   
 
Protein Cell Line 
  WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
  IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD % IOD 
mTOR 
S+ 3156 98 3546 110 4222 130 3237 100 3993 123 4146 128 
S- 4070 126 680 21 2272 70 1765 55 4492 139 2515 78 
p-RPS6 
(Ser 235/236) 
S+ 1818 36 4336 85 4528 89 5075 100 3032 60 3934 78 
S- 1176 23 35 1 3304 65 2050 40 2154 42 2957 58 
mATG-13 
S+ 523 38 3048 224 649 48 1359 100 1003 74 1374 101 
S- 747 55 631 46 353 26 1710 126 1010 74 3484 256 
ILK 
S+ 8103 108 5812 77 7323 98 7508 100 7448 99 6900 92 
S- 6582 88 4170 56 6221 83 6528 87 7583 101 5267 70 
 
Table C9: Standard error for protein expression levels expressed as % IOD) of 
marker set proteins during serum-free tissue culture (Serum -). 
 
Protein 
Tissue 
Culture 
Condition 
Cell Line 
  WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
mTOR 
S+ 8.36 18.21 17.01 0.00 7.24 0.84 
S- 20.73 19.33 14.07 17.28 6.27 2.63 
p-RPS6 
(Ser 235/236)
 
S+ 1.74 5.82 6.10 0.00 3.44 2.48 
S- 0.25 0.18 3.28 6.01 1.96 5.20 
mATG-13 
S+ 20.44 191.97 17.52 0.00 29.58 0.00 
S- 30.15 20.70 6.20 15.31 30.33 0.00 
ILK 
S+ 18.57 8.26 3.81 0.00 2.42 17.86 
S- 8.79 7.38 15.97 2.23 13.94 7.05 
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Table C10: Expression levels of marker set proteins after specific inhibition of mTOR 
with rapamycin. 
 
Protein 
Rapamycin 
Treatment 
Conditions 
Cell Line 
 
 WHCO6 SNO MCF-7 
 
Time 
(hr) 
Concentration 
(nM) 
IOD % IOD IOD % IOD IOD % IOD 
mTOR 
0 0 2167 100 1694 78 2852 132 
6 
20 2924 135 1376 63 2410 111 
50 3543 163 950 44 3173 146 
100 4298 198 1445 67 2983 138 
24 
20 1733 80 2141 99 2994 138 
50 2055 95 1227 57 2919 135 
100 2124 98 493 23 2641 122 
p-RPS6 
(Ser 235/236) 
0 0 9768 100 8331 85 8197 84 
6 
20 3853 39 3722 38 693 7.00 
50 2898 30 3119 32 115 1.00 
100 1864 19 2593 27 87 1.00 
24 
20 1405 14.0 100 1.00 195 2.00 
50 731 7.00 142 1.00 168 2.00 
100 189 2.00 324 3.00 320 3.00 
mATG-13 
0 0 601 100 934 155 151 25 
6 
20 393 65 1200 200 234 39 
50 154 26 1394 232 167 28 
100 717 119 787 131 260 43 
24 
20 1018 169 1109 184 161 27 
50 94 16 1309 218 117 19 
100 121 20 575 96 602 100 
ILK 
0 0 3279 100 3511 107 2734 83 
6 
20 2855 87 3883 118 4962 151 
50 2148 66 3653 111 3871 118 
100 1444 44 2936 90 4147 127 
24 
20 3143 96 2942 90 4145 126 
50 2812 86 4155 127 3421 104 
100 4173 127 3442 105 7672 234 
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Table C11: Standard error for mTOR protein expression expressed as % IOD) after 
specific inhibition of mTOR with rapamycin. 
 
Protein 
Rapamycin 
Treatment 
Conditions 
Cell Line 
 
Time 
(hr) 
Concentration 
(nM) 
WHCO6 SNO MCF-7 
mTOR 
0 0 0.00 7.23 0.00 
6 
20 4.23 22.77 0.00 
50 3.92 7.37 0.00 
100 9.62 9.58 0.00 
24 
20 1.20 6.84 0.00 
50 8.58 14.48 0.00 
100 9.05 7.60 0.00 
 
Table C12: Protein expression levels of marker set proteins after specific p90RSK 
inhibition with BI-D1870 
 
Protein Treatment Cell Line 
  WHCO5 WHCO6 SNO MCF-7 HEK-293 
  IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
mTOR 
U 970 54 1808 100 1595 88 1342 74 3699 205 
DMSO 1167 65 1850 102 1584 88 1489 82 2270 126 
BI 948 52 1301 72 1237 68 1509 83 2501 138 
p-RPS6 
(Ser 235/236)
 
U 3919 46 8439 100 59 58 64 64 5276 84 
DMSO 5997 71 75 75 67 67 50 49 6730 108 
BI 5712 67 65 65 85 85 50 50 2264 36 
 
Table C13: Standard error for key protein intermediates (expressed as % IOD) after 
specific p90RSK inhibition with BI-D1870 
 
Protein Treatment Cell Line 
  WHCO5 HEK-293 
mTOR 
U 11.21 47.79 
DMSO 2.59 21.70 
BI 23.48 55.43 
p-RPS6 
(Ser 235/236)
 
U 5.81 0.00 
DMSO 13.79 0.00 
BI 6.28 0.00 
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Table C14: Protein expression levels of marker set proteins after growth of HOSCC 
cells on fibronectin (FN) or collagen (CN).   
 
Protein Cell Line 
  WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
  IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
IOD 
% 
IOD 
mTOR 
U 541 37 91 6 902 61 1471 100 427 29 105 4 
FN 1032 70 125 8 110 7 1539 105 578 39 817 28 
CN 2251 153 148 10 159 11 81 5 1291 88 288 10 
p-RPS6 
(Ser 235/236)
 
U 9195 110 3726 45 3933 47 8353 100 6263 75 8194 98 
FN 8706 104 4189 50 1580 19 10584 127 11156 134 8423 101 
CN 9149 110 5034 60 1646 20 1761 21 10967 131 9118 109 
 
Table C15: Standard error for marker set proteins (expressed as % IOD) after growth 
of HOSCC cells on fibronectin (FN) or collagen (CN).   
 
Protein Cell Line 
  WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
mTOR 
U 8.46 0.48 13.43 0.00 0.71 1.19 
FN 18.45 0.67 0.71 7.86 8.87 9.26 
CN 16.31 0.58 0.31 0.86 6.98 3.27 
p-RPS6 
(Ser 235/236)
 
U 7.59 1.21 13.22 0.00 3.09 18.37 
FN 8.57 3.10 5.48 2.36 0.90 9.59 
CN 3.02 4.16 5.47 6.19 11.53 2.83 
 
Table C16: Protein expression levels for marker set proteins after combination 
treatment with fibronectin (FN) and PI3K-specific inhibition LY294002. 
 
Protein Treatment Cell Line 
  WHCO 5 WHCO6 SNO MCF-7 
  IOD % IOD IOD % IOD IOD 
% 
IOD 
IOD % IOD 
mTOR 
U 509 60 849 100 334 39 542 64 
FN 713 84 967 114 768 90 553 65 
L+ 687 81 129 15 962 113 536 63 
FN & L+ 526 62 202 24 489 58 367 43 
p-RPS6 
(Ser 235/236)
 
U 2346 71 3319 100 3551 107 2578 78 
FN 3564 107 3454 104 2588 78 3330 100 
L+ 1466 44 1644 50 2035 61 876 26 
FN & L+ 2134 64 1873 56 2564 77 1018 31 
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Table C17: Standard error of marker set protein expression (expressed as % IOD) 
after combination treatment with fibronectin (FN) and PI3K-specific 
inhibition LY294002. 
 
Protein Treatment Cell Line 
  WHCO  5 WHCO 6 SNO MCF-7 
mTOR 
U 0.32 0.00 9.36 13.61 
FN 8.91 35.38 23.19 12.18 
L+ 25.47 1.98 20.47 12.48 
FN & L+ 13.12 2.51 8.55 7.45 
p-RPS6 
(Ser 235/236)
 
U 2.95 0.00 15.80 7.38 
FN 15.62 3.77 11.13 13.75 
L+ 7.54 2.43 8.55 3.45 
FN & L+ 12.51 5.27 10.97 4.51 
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APPENDIX D 
 
4.1. Statistical analysis of protein expression levels obtained from semi-quantitative densitometry.    
 
Table D1: Student’s t-test analysis of the difference in protein expression between cells of the WHCO series and the MCF-7 
cell line obtained under standard tissue culture conditions (Serum +). 
 
i) WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
Protein Mean SD SEM Mean SD SEM Mean SD SEM Mean SD SEM Mean SD SEM Mean SD SEM 
mTOR 3294.5 727.5 420.0 1171.6 262.2 151.4 3310.9 121.0 69.9 4387.0 0.0 0.0 3971.2 1468.0 847.5 3727.5 899.9 519.6 
p-RPS6 
(Ser 
235/236) 
2714.4 2774.0 1961.5 2226.2 2686.4 1899.5 4882.0 84.5 59.7 4894.2 0.0 0.0 362.1 256.0 181.0 3926.5 764.9 540.8 
mATG-
13 
1095.4 1374.1 971.6 852.5 1097.1 775.7 52.853 31.4 22.2 623.5 0.0 0.0 936.0 1012.2 715.7 770.8 899.5 636.1 
ILK 3815.5 344.9 199.1 3772.3 2579.2 1489.1 4472.1 2215.8 1279.2 5638.7 0.0 0.0 5665.9 507.4 292.9 4385.8 130.2 75.1 
 
ii) WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
Protein 
t-
statistic 
p value 
t-
statistic 
p value 
t-
statistic 
p value 
t-
statistic 
p value 
t-
statistic 
p value 
t-
statistic 
p value 
mTOR -0.648 0.552 -4.723 0.009 -0.794 0.471 1.269 0.273 0.245 0.818 N.A. N.A. 
p-RPS6 
(Ser 
235/236) 
-0.596 0.612 -0.861 0.480 1.756 0.221 1.789 0.215 -6.249 0.0247 N.A. N.A. 
mATG-
13 
0.279 0.806 0.0814 0.943 -8.832 0.0126 -0.232 0.838 0.172 0.879 N.A. N.A. 
ILK 2.679 0.0553 -0.411 0.702 0.0673 0.950 16.660 < 0.001 4.232 0.0133 N.A. N.A. 
 
* Indicates significant difference (p < 0.05). 
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Table D2: Student’s t-test analysis comparing mTORβ protein expression under standard tissue culture conditions (Serum +). 
 
i) WHCO1 WHCO3 MCF-7 HEK-293 
Protein Mean SD SEM Mean SD SEM Mean SD SEM Mean SD SEM 
mTORβ 272.1 63.1 44.6 949.0 701.09 495.7 176.1 30.5 21.5 190.8 107.9 76.3 
 
ii) WHCO1 WHCO3 MCF-7 HEK-293 
Protein t-statistic p value t-statistic p value t-statistic p value t-statistic p value 
mTORβ 0.919 0.455 1.512 0.135 -0.185 0.435 N.A. N.A. 
 
* Indicates significant difference (p < 0.05). 
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Table D3: Paired t-test analysis on the difference in marker set protein expression during conditions of serum withdrawal 
for 24 hours (Serum -). 
 
i) mTOR WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
 S+ S- S+ S- S+ S- S+ S- S+ S- S+ S- 
Mean 3156.8 4070.3 3546.0 53.167 4222.7 2272.7 3237.4 1765.6 3993.0 4492.4 4146.4 2515.4 
SD 468.8 1445.4 4373.0 3.650 2102.5 788.7 0.0 1220.0 405.6 351.5 1582.2 1922.9 
SEM 270.6 834.5 2524.8 2.107 1213.8 455.3 0.0 704.3 234.2 202.9 913.5 1110.1 
 
ii) p-RPS6 
(Ser 235/236) 
WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
 S+ S- S+ S- S+ S- S+ S- S+ S- S+ S- 
Mean 1818.1 1176.3 4335.7 34.7 4527.5 3303.7 5075.0 2050.4 3031.7 2154.3 3933.6 2957.1 
SD 2670.0 1887.9 974.0 15.8 1056.2 288.7 0.0 394.3 1924.5 1836.8 157.6 678.0 
SEM 1541.5 1090.0 562.3 9.1 609.8 166.7 0.0 227.6 1111.1 1060.5 91.0 391.4 
 
iii) mATG-
13 
WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
 S+ S- S+ S- S+ S- S+ S- S- S+ S- S+ 
Mean 522.5 746.6 5048.1 630.7 649.0 352.9 1358.7 1709.8 1002.5 1010.4 6976.9 180.7 
SD 392.8 579.3 860.3 397.7 336.5 119.1 0.0 294.1 568.3 582.8 340.6 72.7 
SEM 277.7 409.6 608.3 281.2 237.9 84.2 0.0 207.9 401.9 412.1 240.8 51.4 
 
iv) ILK WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
 S+ S- S+ S- S+ S- S+ S- S+ S- S+ S- 
Mean 8102.7 6581.5 5812.3 4170.1 7322.9 6221.2 7507.8 6528.3 7448.4 7583.4 6899.9 5267.2 
SD 2768.0 1072.3 854.0 779.9 2945.9 1971.6 312.3 471.3 0.0 1764.2 3767.3 2898.4 
SEM 1598.1 619.1 493.0 450.2 1700.8 1138.3 180.3 272.1 0.0 1018.5 2175.0 1673.4 
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v) Table D3 continued 
Protein Cell Line 
 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
 
t-
statistic 
p value 
t-
statistic 
p value 
t-
statistic 
p value 
t- 
statistic 
P value 
t- 
statistic 
p value 
t- 
statistic 
p value 
mTOR -0.960 0.438 11.382 0.030 1.214 0.349 2.090 0.172 -7.159 0.0190 0.936 0.448 
p-RPS6 
(Ser 235/236) 
1.418 0.292 7.555 0.0171 2.626 0.120 13.284 0.005 5.307 0.0337 2.272 0.151 
mATG-13 -1.700 0.339 13.505 0.0471 1.925 0.305 -1.689 0.340 -0.766 0.584 23.252 0.0274 
ILK 1.425 0.290 13.883 0.005 0.753 0.530 6.234 0.024 -0.133 0.907 2.709 0.114 
 
* Indicates significant difference (p < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
166 
 
Table D4: Paired t-test analysis on the extent fibronectin (FN)- or collagen (CN)-coated substrates effect marker set protein 
expression. 
 
i) WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
mTOR U FN CN U FN CN U FN CN U FN CN U FN CN U FN CN 
Mean 541 1032 2970 91.2 124 147 902.3 109 158 1470 1538 80.6 427.1 578.4 1291.4 N.A. N.A. N.A. 
SD 528 1150 0.0 29.7 41.7 36.1 837.6 44.5 19.3 0.0 490.5 53.6 44.3 553.4 435.3 N.A. N.A. N.A. 
SEM 373 813 0.0 21.0 29.4 25.5 592.2 31.4 13.6 0.0 346.8 37.9 31.3 391.3 307.8 N.A. N.A. N.A. 
 
ii) WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
p-RPS6 
(Ser 
235/236) 
U FN CN U FN CN U FN CN U FN CN U FN CN U FN CN 
Mean 9195 8705 9148 3725.8 4188 5034 3933.0 1580 1645 8353.2 10584 1760 6263.2 11155 10967.2 8194 8423 9117 
SD 2689 3035 1071 427.1 1098 1473 4685.4 1943 1937 0.0 835.5 2193 1095.6 317.2 4086.7 6511 3399 1001 
SEM 1902 2146 757.5 302.0 776 1042 3313.1 1373 1370 0.0 590.8 1550 774.7 224.3 2889.7 4604 2403 708.0 
 
iii) WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
FN t-statistic p value t-statistic p value t-statistic p value t-statistic p value t-statistic p value t-statistic p value 
mTOR -1.115 0.466 -3.991 0.156 1.413 0.392 -0.197 0.876 -0.420 0.747 N.A. N.A. 
p-RPS6 2.005 0.295 -0.975 0.508 1.213 0.439 -3.776 0.165 -8.889 0.0357 -0.104 0.934 
 
iv) WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF-7 
CN t-statistic p value t-statistic p value t-statistic p value t-statistic p value t-statistic p value t-statistic p value 
mTOR -6.507 0.0485 -1.213 0.439 1.227 0.435 -6.507 0.0485 -1.213 0.439 1.227 0.435 
p-RPS6 0.0407 0.974 -1.768 0.328 1.177 0.448 0.0407 0.974 -1.768 0.328 1.177 0.448 
 
* Indicates significant difference (p < 0.05). 
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Table D5: Paired t-test analysis of mTOR and p-RPS6
(Ser 235/236)
 protein expression in response to combined Fibronectin (FN) 
stimulation and PI3K-specific inhibition with LY294002. 
 
I) WHCO5 WHCO6 SNO MCF-7 
mTOR U FN L+ 
FN & 
L+ 
U FN L+ 
FN & 
L+ 
U FN L+ 
FN & 
L+ 
U FN L+ 
FN & 
L+ 
Mean 509.0 712.8 188.9 270.6 849.2 967.4 128.5 201.6 333.9 767.8 961.7 488.6 542.3 552.8 535.6 366.7 
SD 10.9 302.8 102.3 82.7 0.0 1201.8 67.4 85.1 318.0 787.7 695.2 290.5 462.4 413.7 424.0 253.2 
SEM 7.7 214.1 72.3 58.4 0.0 849.8 47.6 60.1 159.0 393.8 347.6 145.2 266.9 238.9 244.8 146.1 
 
ii) WHCO5 WHCO6 SNO MCF-7 
p-RPS6 
(Ser 
235/236) 
U FN L+ 
FN & 
L+ 
U FN L+ 
FN & 
L+ 
U FN L+ 
FN & 
L+ 
U FN L+ 
FN & 
L+ 
Mean 2345.9 2432.2 1034.9 1439.5 3318.5 8073.8 1644.0 1872.9 2393.9 2587.5 1382.9 1741.4 2577.9 2293.3 613.8 698.2 
SD 391.9 2073.2 1000.5 1659.9 0.0 8010.4 322.0 699.2 2097.7 1477.2 1135.5 1456.3 979.4 1825.4 458.1 598.2 
SEM 226.2 1196.9 577.6 958.3 0.0 4624.8 185.9 403.7 1211.1 852.9 655.6 840.8 565.4 1053.9 264.4 345.3 
 
iii) WHCO5 WHCO6 SNO MCF-7 
 t-statistic p value t-statistic p value t-statistic p value t-statistic p value 
FN -0.919 0.527 -0.139 0.912 -1.181 0.323 -0.0826 0.942 
L+ 3.998 0.156 15.121 0.0420 -1.815 0.167 0.0493 0.965 
FN & L+ 3.601 0.172 10.759 0.0295 -0.662 0.555 1.402 0.296 
 
iv) WHCO5 WHCO6 SNO MCF-7 
 t-statistic p value t-statistic p value t-statistic p value t-statistic p value 
FN -0.0862 0.939 -1.028 0.412 -0.518 0.656 0.485 0.676 
L+ 2.808 0.107 9.004 0.0121 1.735 0.225 5.581 0.0306 
FN & L+ 1.080 0.393 3.581 0.0350 1.037 0.409 7.824 0.0159 
* Indicates significant difference (p < 0.05).
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Plagarism analysis by Turnitin Orginality Report Software   
 
Analysis Settings and Procedure: 
Turnitin software analyses a string of 20 words with a database comprising of scientific journal 
articles, peer-reviewed publications and internet-based sources for a specified degree of 
similarity. During this analysis, a string of twenty (20) words were selected and the overall 
similarity could not exceed 15 %.  
 
Sumbitted File: 
Ari_Nerwich_0604379w_Turn It In Document_Ari Nerwich_MSc_Sep 2012.docx by Ari Nerwich 
From MSc Dissertation 2012B (MCB Masters) 
Processed on 28-Sep-2012 12:31 PM SAST 
ID: 271156785 
Word Count: 24624 
 
The above submission included the following sections: abstract, introduction, results and 
discussion, but excluded figure legends and references in order to minimize the detection of 
false-positive hits. See next page for an example of the results using the Document Viewer. 
 
Findings: 
 
A. Similarity: 
 
Overall Similarity Index (OSI): 4% 
 
B. Similarity by Source: 
1. Internet Sources: 1 % 
2. Publications: 3 % 
3. Student Papers: 0 % 
 
A full report of this MSc is available through the following link: 
https://api.turnitin.com/dv?s=1&o=271156785&u=1012947287&student_user=1&lang=en_us&session-
id=5a45d4d0f2acfce7bb579eb37efa3aaa 
 
Outcome 
Acceptable level of source similarity was found in the submitted document (OSI = 4 %). Kindly 
see an example of the report, which can be found on the next page. 
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